Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

San Joaquin County
Emergency Medical Services Agency
Advanced Life Support Treatment Protocols
EMS Policy No. 5700

Katherine Shafer, M.D., EMS Medical Director
Version 1.9.1 - Effective: August 22, 2025
Replaced Version 1.9 – July 1, 2025

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 1 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

San Joaquin County Emergency Medical Services Agency EMS Policy No. 5700
Advanced Life Support Treatment Protocols, are:
Effective: August 22, 2025
Replaced: Version 1.9 – July 1, 2025
Medical Director:

____

EMS Administrator:

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 2 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Contents
Introduction.................................................................................................................................................. 7
How this protocol book is organized ................................................................................................... 7
Layout One .......................................................................................................................................... 7
Layout Two .......................................................................................................................................... 7
Layout Three ..................................................................................................................................... 13
Protocol Numbering ......................................................................................................................... 14
Routine Patient Care ............................................................................................................................... 15
Routine Patient Care (RPC-01)...................................................................................................... 16
Adult ........................................................................................................................................................... 23
Advanced Airway Management (AAIR-01) .................................................................................. 24
Airway Obstruction (AAIR-02) ........................................................................................................ 26
Mechanical Ventilation for Patients with Pulses(A-03) ............................................................... 28
CPAP via Ventilator-)(AAIR-04) ..................................................................................................... 30
Adult Cardiac............................................................................................................................................. 33
Atrial Fibrillation / Atrial Flutter (ACAR-01) ................................................................................... 34
Bradycardia (ACAR-02)................................................................................................................... 36
Chest Pain of Suspected Cardiac Origin (ACAR-03) ................................................................. 38
Medical Cardiac Arrest (ACAR-04)................................................................................................ 40
Return of Spontaneous Circulation (ACAR-05) ........................................................................... 46
Non Traumatic Shock (ACAR-06).................................................................................................. 48
Supraventricular Tachycardia (ACAR-07) .................................................................................... 50
Ventricular Assist Device (VAD) Failure (ACAR-08)................................................................... 52
Sustained Ventricular Tachycardia with a Pulse (ACAR-09)..................................................... 54
Adult Respiratory ...................................................................................................................................... 57
Acute Pulmonary Edema (ARSP-01) ............................................................................................ 58
Bronchospasms (ARSP-02)............................................................................................................ 60
Smoke Inhalation (ARSP-03) ......................................................................................................... 62
Adult Neurological .................................................................................................................................... 65
CVA/TIA/Stroke (ANRO-01) ........................................................................................................... 66
Hyperglycemia (ANRO-02) ............................................................................................................. 68
Hypoglycemia (ANRO-03) .............................................................................................................. 70
New Onset Altered Level of Consciousness Unknown Etiology(ANRO-04) ........................... 72
Seizures (ANRO-05) ........................................................................................................................ 74
Adult Environmental ................................................................................................................................. 77

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 3 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Allergic Reaction/Anaphylaxis (AENV-01).................................................................................... 78
Bites & Envenomation (AENV-02) ................................................................................................. 80
Hyperthermia (AENV-03) ................................................................................................................ 82
Hypothermia (AENV-04).................................................................................................................. 84
Adult Trauma............................................................................................................................................. 87
Trauma (ATRA-01)........................................................................................................................... 88
Injury Specific Guidelines ........................................................................................................................ 90
Trauma: Injury Specific Treatments .............................................................................................. 91
Traumatic Arrest (ATRA-02) ........................................................................................................... 94
Obstetrical ................................................................................................................................................. 99
Childbirth (AOBG-01)..................................................................................................................... 100
Eclampsia & Preeclampsia (AOBG-02) ...................................................................................... 102
Obstetrical Emergencies (AOBG-03) .......................................................................................... 104
Postpartum Care (AOBG-04) ....................................................................................................... 106
Adult Overdose ....................................................................................................................................... 109
Acute Dystonic Reactions (AODP-01) ........................................................................................ 110
Beta Blockers Overdose (AODP-02) ........................................................................................... 112
Calcium Channel Blocker Overdose (AODP-03)....................................................................... 114
Actue Drug Intoxication (AODP-04) ............................................................................................ 116
Cyclic Antidepressants Overdose (AODP-05) ........................................................................... 118
Opiate Overdose (AODP-06)........................................................................................................ 120
Organophosphates Exposure (AODP-07) .................................................................................. 122
Adult General .......................................................................................................................................... 125
Sepsis (AGEN-01) .......................................................................................................................... 126
Patients From Out Patient Offices (AGEN-02) .......................................................................... 128
Pain Management (AGEN-03) ..................................................................................................... 130
Nausea (AGEN-04) ........................................................................................................................ 132
Pediatric Airway Management ............................................................................................................. 135
Pediatric Advanced Airway Management (PAIR-01) ................................................................ 136
Pediatric Airway Obstruction (PAIR-02)...................................................................................... 138
Pediatric Cardiac .................................................................................................................................... 141
Neonatal Resuscitation (PCAR-01) ............................................................................................. 142
Pediatric Bradycardia (PCAR-02) ................................................................................................ 144
Pediatric Medical Cardiac Arrest (PCAR-03) ............................................................................. 146
Pediatric Non Traumatic Shock (PCAR-04) ............................................................................... 148
Pediatric Return of Spontaneous Circulation (PCAR-05) ........................................................ 150

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 4 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Supraventricular Tachycardia (PCAR-06) ................................................................. 152
Pediatric Ventricular Assist Device (VAD) Failure (PCAR-07) ................................................ 154
Pediatric Sustained Ventricular Tachycardia with a Pulse (PCAR-08) .................................. 156
Pediatric Respiratory ............................................................................................................................. 159
Pediatric Bronchospasms (PRSP-01) ......................................................................................... 160
Pediatric Croup (PRSP-02)........................................................................................................... 162
Pediatric Epiglottitis (PRSP-03) ................................................................................................... 164
Pediatric Smoke Inhalation (PRSP-04)....................................................................................... 166
Pediatric Neurologic ............................................................................................................................... 169
Pediatric Hyperglycemia (PNRO-01) .......................................................................................... 170
Pediatric Hypoglycemia (PNRO-02) ............................................................................................ 172
Pediatric New Onset A.L.O.C. Unknown Etiology (PNRO-03) ................................................ 174
Pediatric Seizures (PNRO-04) ..................................................................................................... 176
Pediatric Environmental ........................................................................................................................ 179
Pediatric Allergic Reaction/Anaphylaxis (PENV-01) ................................................................. 180
Pediatric Bites & Envenomation (PENV-02) .............................................................................. 182
Pediatric Hyperthermia (PENV-03).............................................................................................. 184
Pediatric Hypothermia (PENV-04) ............................................................................................... 186
Pediatric Trauma .................................................................................................................................... 189
Pediatric Trauma (PTRA-01) ........................................................................................................ 190
Injury Specific Guidelines ...................................................................................................................... 192
Trauma: Injury Specific Treatments ............................................................................................ 193
Pediatric Traumatic Arrest (PTRA-02) ........................................................................................ 196
Pediatric Overdose................................................................................................................................. 199
Pediatric Acute Dystonic Reactions (PODP-01)........................................................................ 200
Pediatric Beta Blockers Overdose (PODP-02) .......................................................................... 202
Pediatric Calcium Channel Blocker Overdose (PODP-03) ...................................................... 204
Pediatric Acute Drug Intoxication (PODP-04) ............................................................................ 206
Pediatric Cyclic Antidepressants Overdose (PODP-05) .......................................................... 208
Pediatric Opiate Overdose (PODP-06) ....................................................................................... 210
Pediatric Organophosphates Exposure (PODP-07) ................................................................. 212
Pediatric General.................................................................................................................................... 215
Pediatric Brief, Resolved, Unexplained, Event (PGEN-01) ..................................................... 216
Pediatric Nausea (PGEN-02) ....................................................................................................... 218
Pediatric Pain Management (PGEN-03) ..................................................................................... 220
Pediatric Patients from Out Patient Offices (PGEN-04) ........................................................... 222

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 5 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Sepsis (PGEN-05) .......................................................................................................................... 224
Interfacility Transport ............................................................................................................................. 227
Monitoring Mechanical Ventilators – ALS (IFT-01) ....................................................................... 228
Monitoring Potassium Chloride Infusions – ALS (IFT-02) ........................................................... 229
Monitoring Heparin Infusions – ALS (IFT-03) ................................................................................ 232
Monitoring Nitroglycerin Infusions – ALS (IFT-04) ........................................................................ 235
Sedation of Intubated Patients during ALS Interfacility Transfer (IFT-05) ................................ 239
Monitoring Magnesium Sulfate Infusions – ALS (IFT-06) ............................................................ 240
Abbreviations Glossary ......................................................................................................................... 242

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 6 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Introduction
San Joaquin County Emergency Medical Services Agency (SJCEMSA) EMS Policy No. 5700,
Advanced Life Support (ALS) Treatment Protocols are based on current emergency medicine
standards of care and is a significant change to the delivery of prehospital patient care in the
San Joaquin County EMS System. The medical direction in the protocols are presented in a
format designed for ease of use by prehospital personnel. This introduction section provides a
brief explanation of how the ALS protocols are structured and offers suggestions for how to use
this book most effectively.

How this protocol book is organized
There are three different style layouts in this book which are also color coded by section:
1. Layout 1:
A. Routine patient care (blue).
2. Layout 2: Left hand page and right hand page:
A. Adult airway management (purple).
B. Adult treatment protocols (gold).
C. Pediatric airway management (light blue).
D. Pediatric treatment protocols (pink).
3. Layout 3:
A. Interfacility transfer protocols (no color).

Layout One
Routine patient care (RPC-01), is formatted as a book with:
1. Definitions.
2. Step by step approach to:
A. Standard precautions.
B. Scene size up.
C. Circulation assessment.
D. Airway assessment.
E. Breathing assessment.
F. Level of consciousness assessment.
G. Considerations.
H. Objective findings.
I. Physical head to toe exam.
J. History taking.
3. Developing a general clinical impression.

Layout Two
Layout two contains all the treatments for:
A. Adult airway management (purple headers).
B. Adult patients (gold color headers).
C. Pediatric airway management (blue headers).
D. Pediatric patients (pink color headers).
The majority of protocols are formatted in a left side & right side layout (fig. 1) for ease of use.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 7 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Figure 1

Left side of treatment sections
The left page is designed to be a preparation resource as well as a quick reference guide,
unless it is a two-page flow chart such as in the cardiac arrest protocol (ACAR-04). They
contain:
1. A brief description of the protocol.
2. Critical definitions.
3. Documentation standards.
4. Objective findings:
A. Signs & symptoms,
B. Comorbidities & Home meds,
C. Differentials.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 8 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Protocol Example
At the top of each left side treatment protocol you will see a brief description (fig. 2) of the
protocol. In the example in figure two, it describes the differences between atrial fibrillation and
atrial flutter.

Figure 2
Critical definitions
Directly below the protocol brief is the critical definition section (fig. 3). These definitions will be
used to select which treatment regimen the patient should receive based on an assessment of
the patient symptom levels (e.g. asymptomatic, mildly symptomatic, and grossly symptomatic).
It is important to note that not all definitions are the same, and vary from protocol to protocol to
provide the most appropriate treatment and follow best medical practice in the prehospital
setting.

Figure 3
Documentation standards
Each protocol also has a set of documentation standards (fig. 4), which outlines the minimum
information that is required to be included in the patient care record. The section starts off with
vital signs, and includes how often they need to be taken and documented. For most protocols it
is every five (5) minutes for unstable or critical patients, and every fifteen (15) minutes for stable
patients. However, in some protocols, such as return of spontaneous circulation (ACAR-05) vital
signs are required to be taken and documented every three (3) minutes.
Below vital signs you will see a statement that reads, “If performed, before and after
interventions or if condition changes.” This means if you perform an assessment such as
cardiac monitoring or physical assessment it is required to document those findings before and
after any intervention and if the patient presentation changes. Since patients often only require
treatment based on one of the symptom levels (asymptomatic, mildly symptomatic, etc.), it is
only necessary to document assessment findings that pertain to the patient’s symptom levels. It
is however important to include pertinent negatives in the patient care report to demonstrate
why a particular assessment or treatment was not needed. For example, a pertinent negative for
a patient with heart rate of 52 who did not require administration of atropine could be that, they
are currently on beta-blockers and do not have complaints related to their cardiovascular
system.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 9 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Figure 4
Objective findings
The last section (fig. 5) on the left page is the objective findings section. It starts with a list of
possible signs and symptoms that the patient may have, but the list is not all-inclusive. For
example, a grossly symptomatic atrial fibrillation may not always have cyanosis to their fingers.
The next column includes comorbidities that a patient may have as well as home medications
they may be taking. The last column in the objective section is possible differentials. This
column can often be used as a list of things to rule out or assess for, prior to intervention.

Figure 5

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 10 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Right side of treatment sections
The right side page of the treatment sections are designed to not only be a preparation tool but
a quick reference guide. Drug doses or critical procedures will be listed on the right hand page
unless it is a two-page flow chart such as in the cardiac arrest protocol (ACAR-04). The right
side page includes:
1. Treatments by critical definition:
A. Asymptomatic.
B. Mildly symptomatic.
C. Grossly symptomatic.
2. Considerations.
3. Base Hospital Orders.
4. Drug dose charts.
A. Dopamine.
B. Epi infusion.
5. Assessment charts.
A. Glasgow coma scale.
B. Apgar scale.
C. Cincinnati pre hospital stroke screen (CPSS).
D. Rapid Arterial Occlusion Evaluation (RACE).
Treatments by critical definition
Each protocol has variations of treatment regimens based on how sick or critical the patient
presents. These presentations are defined in the critical definition section on the left hand page
(fig. 3).

Figure 6
Most protocols follow the asymptomatic, mildly symptomatic, grossly symptomatic style of
separation and outline what treatments should be done without a base order based on how the
patient fits into the critical definition listed on the left page. For example, in figure six (6) a mildly

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 11 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

symptomatic patient should have intravenous access but intraosseous access is not approved,
and an asymptomatic patient should not have any vascular access.
Additionally, it should be noted that oxygen therapy is based on pulse oximetry and work of
breathing unless otherwise noted.
Considerations
This section (fig.7) is designed to give general advice on each protocol. Addtionally, this column
may include specific advice about a disease process or information on what to look out for as
the patient condition changes.

Figure 7

Base Hospital Orders
At the bottom of the right hand page each section (in red) contains requirements for Base
Hospital Orders (fig. 8). The typical requirement states, “Consult Base Hospital if additional
orders are needed or patient has an atypical presentation.” However, many of the Base Hospital
Orders are very specific about what can be requested (fig. 9).

Figure 8

Figure 9
In some cases, SJCEMSA Policy specifically allows paramedics to perform a procedure or
provide medication only upon receipt of a Base Hospital Physician (BHP) order. In these cases,
MICNs are allowed to relay orders from the BHP. The paramedic shall document the
Physician’s name on the patient care report.
MICNs shall adhere to SJCEMSA Policies when offering advice, guidance, and direction to ALS
and BLS field personnel.
Base Hospital Physicians may order a deviation from any of the approved SJCEMSA treatment
policies, as long as they remain within the paramedic scope of practice. These types of orders
may not be relayed by the MICN. Each order from the BHP that deviates from policy must be
documented on a Base Hospital Report Form, the prehospital patient care report, and be
submitted to the SJCEMSA for review.
In order to facilitate the best possible delivery of prehospital emergency medical care, attending
paramedics have the right to speak directly to a Base Hospital Physician during any call.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 12 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Layout Three
The final layout is the interfacility transfer (IFT) section. The section provides medical direction
for patient care and treatment specific to interfacility transfers. Protocols address the minimum
and maximum medication dosages, ventilator settings, and additional information regarding
approved medications and procedures.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 13 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Protocol Numbering
All protocols have a six-character alphanumeric identifier that is a combination of age, section
abbreviation and number in sequence (Fig 10). The first letter of the identifier is either “A” or “P,”
which signifies adult or pediatric. The next three (3) letters are abbreviations of the section
followed by a two (2) digit number of the protocols in alphabetical order in that section. For
example, ARSP-02, means Adult-Respiratory number two.
Figure 10

AGE

Section
Abbreviation

Airway

01-04

(AIR)
Cardiac

01-03

(CAR)
Respiratory

Adult or Pediatric

Number

(RSP)
Neurologic
(NRO)
Environmental
(ENV)
Trauma

01-03

01-05

01-04

01-02

(TRA)
Obstetrical
(OBG)
Overdose / Poisoning
(ODP)
General

01-04

01-07

01-04

(GEN)

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 14 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Routine Patient Care

Version 1.9 EMS Policy No. 5700 ALS Treatment Protocols Effective July 1, 2025
Page 15 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Routine Patient Care

RPC-01

Routine Patient Care (RPC-01)
This protocol applies to all patients. The patient assessment primary survey is to identify and
correct immediate life threats. The secondary survey is the systematic assessment and
complaint focused, relevant physical examination of the patient. The secondary survey may
be done concurrently with the patient history and should be performed after the Primary
Survey and the initiation of Routine Medical Care. The purpose of the secondary survey is to
identify problems, which though not immediately life or limb threatening, could increase
patient morbidity and mortality. Exposure of the patient for examination may be reduced or
modified as indicated due to environmental factors.
Definitions:
1. Standard Precautions- means the application of body substance isolation precautions
including the use of appropriate personal protective equipment (PPE) shall apply to all
patients receiving care, regardless of their diagnosis or presumed infectious status. Body
substance isolation precautions apply to 1) blood; 2) all bodily fluids, secretions, and
excretions except sweat, regardless of whether or not they contain visible blood; 3) non
intact skin; and 4) mucous membranes. Standard precautions are designed to reduce the
risk of transmission of microorganisms from both recognized and unrecognized sources of
infection in the prehospital setting.
2. Adult Patient- means a patient 13 years of age or older, or taller than a weight-based
assessment tape (146.5 cm).
3. Weight-based assessment tape Pediatric Emergency Tape- means a pediatric lengthbased resuscitation tape used to determine drug doses, fluid volumes, defibrillation
settings, and equipment sizes. The tape is designed to estimate a child’s weight based on
length (head to heel). The tape should also include information about vital signs.
4. Pediatric Patient- means a patient that is twelve (12) years of age or younger and is not
taller than a weight-based assessment tape (146.5 cm).
Note: If in doubt concerning whether to treat a patient as an adult or pediatric (i.e., obese
child) treat as pediatric.
5. Neonate/newborn- means a pediatric patient from birth to one month of age.
6. Infant means a pediatric patient from one month to one year of age.
7. Child- means a pediatric patient from one year to twelve years of age.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients every 3
minutes for ROSC patients:
A. BP.
B. Respirations.
C. Pulse.
2. Physical assessment.
3. All additional Documentation Standards outlined in each protocol.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 16 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Routine Patient Care

RPC-01

Routine Patient Care
Treatment
1. Use Standard Precautions:
A. Application of body substance isolation precautions including the use of appropriate
personal protective equipment (PPE) shall apply to all patients receiving care.
B. Body substance isolation precautions apply to:
i.
Blood.
ii.
All bodily fluids, secretions, and excretions except sweat, regardless of whether or
not they contain visible blood.
iii.
Non intact skin.
iv.
Mucous membranes.
2. Perform a complete patient assessment including:
A. Primary Survey.
B. Secondary Survey.
3. Initiate specific treatments in accordance with San Joaquin County Emergency Medical
Services Agency Treatment protocols including, when appropriate:
A. Monitor vital signs:
i.
Initial set.
ii.
Repeat every 5 minutes for unstable patients.
iii.
Repeat every 10 minutes for stable patients.
B. Initiate spinal precautions, if indicated.
C. Administer oxygen.
D. Control hemorrhage.
E. Cardiac monitor.
F. Administer IV access as indicated (may use saline lock when appropriate).
G. Obtain blood glucose level, as indicated
4. Transport.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 17 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Routine Patient Care

RPC-01

Routine Patient Care
Patient Assessment Primary Survey
Scene Size Up:
1. Recognize hazards, ensure safety of scene and secure a safe area for treatment.
2. Apply universal body substance isolation precautions.
3. Recognize hazards to patient and protect patient from further injury.
4. Identify the number of patients and initiate ICS/MCI operations if warranted:
A. Ensure an ALS ambulance response and order additional resources.
B. Consider initiating S.T.A.R.T. triage.
5. Observe position of patient(s).
6. Determine mechanism of injury.
7. Plan strategy to protect evidence at potential crime scene.
General Impressions:
1. Check for life threatening conditions.
2. Introduce self to patient, and determine chief complaint or mechanism of injury
Circulation:
1. Check for pulse. If no pulse, start CPR, See protocol ACAR-04.
2. Defibrillate as necessary.
3. Control life-threatening hemorrhage with direct pressure and use a tourniquet as
appropriate.
4. Palpate radial pulse.
A. Determine absence or presence.
B. Assess general quality (strong/weak).
C. Identify rate (slow, normal, or fast).
D. Assess regularity (regular/irregular).
5. Assess skin for signs (capillary refill, cyanosis, mottling, etc.).
6. Reassess mental status for signs of hypo-perfusion/SHOCK.
7. Treat hypo-perfusion
8. Obtain ECG and continually monitor cardiac rhythm as appropriate.
Airway:
1. Ensure open airway; if airway is obstructed refer to protocol AAIR-02 or PAIR-02.
2. Ensuring an adequate airway supersedes spinal immobilization.
3. Protect spine from unnecessary movement in patients at risk for spinal injury.
4. Look and listen for evidence of upper airway problems and potential obstructions:
A. Vomit.
B. Bleeding.
C. Loose, missing teeth or dentures.
D. Facial trauma.
5. Utilize any appropriate adjuncts OPA/NPA as indicated to maintain airway.
Breathing:
1. Look, listen, and feel in order to assess ventilation and oxygenation.
2. Expose chest, if necessary, and observe for chest wall movement.
3. Determine approximate rate and depth and assess character and quality.
4. Reassess mental status.
5. Intervene for inadequate ventilation with:
A. BVM device, airway adjunct and supplemental oxygen.
6. Assess for other life threatening respiratory problems and treat as needed.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 18 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Routine Patient Care

RPC-01

Routine Patient Care
Patient Assessment Primary Survey
Level of consciousness:
1. Information Needed:
A. Surroundings: for example syringes, blood glucose monitoring supplies, insulin.
B. Changes in mental status: Baseline status, onset and progression of altered state,
symptoms prior to altered state such as headache, seizures, confusion, trauma and
last time known well.
C. Medical History: Diabetes, epilepsy, substance abuse, mental health, medications,
allergies.
D. Identify and document neurological deficits and consider possible stroke, overdose/
intoxication.
2. Considerations:
A. Potential treatable causes (hypoglycemia, stroke, neurological injury, syncope,
overdose, and sepsis) and refer to appropriate protocol.
B. Consider indications for spinal motion restriction.
3. Objective Findings:
A. Level of consciousness (AVPU) and neurological assessment.
B. Signs of trauma.
C. Breath odor.
D. Pupil size and reactivity.
E. Needle track marks.
F. Medical information tags, bracelets, or medallions.
4. Determine Glasgow Coma Scale (GCS) Score.
Expose, Examine & Evaluate:
1. In situations with suspected life-threatening mechanism of injury, complete a Rapid
Trauma Assessment.
2. Expose head, trunk and extremities.
3. Examine Head to Toe for DCAP-BTLS:
A. Deformity.
B. Contusion/Crepitus.
C. Abrasion.
D. Puncture.
E. Bruising/Bleeding.
F. Tenderness.
G. Laceration.
H. Swelling.
Obtain base line vital signs:
1. Pulse.
2. Respirations.
3. BP.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 19 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Routine Patient Care

RPC-01

Routine Patient Care
Patient Assessment Secondary Survey
History:
1. A patient’s history should optimally be obtained from the patient directly. If language,
culture, age, disability barriers or patient condition interferes with obtaining the history,
consult with family members, significant others or scene bystanders. Check for
advanced directives such as a DNR order, Medic-Alert bracelet and prescription
bottles as appropriate. Be aware of the patient’s environment and issues such as
domestic violence, possible human trafficking victim, child or elder abuse or neglect
and report concerns. The following information should be obtained during the history:
A. Allergies.
B. Medications.
C. Past medical history relevant to the chief complaint.
D. Have patient prioritize his or her chief complaint if complaining of multiple
problems.
E. Last time known well (clock time).
F. Ascertain recent medical history such as hospital admissions, surgeries, etc.
G. Mechanism of injury if appropriate.
H. In addition, obtain history relevant to specific patient complaints.
Head and Face:
1. Observe and palpate skull (anterior and posterior) and face for DCAP-BTLS.
2. Check eyes for equality, responsiveness of pupils, movement and size of pupils,
foreign bodies, discoloration, contact lenses or prosthetic eyes.
3. Check nose and ears for foreign bodies, fluid or blood.
4. Recheck mouth for potential airway obstructions (swelling, dentures, bleeding, loose
or avulsed teeth, vomit, absent or present gag reflex) and odors, altered voice or
speech patterns and evidence of dehydration.
Neck:
1. Observe and palpate for DCAP-BTLS, jugular vein distension, use of neck muscles for
breathing, tracheal tugging, tracheal shift, stoma and medical information medallions.
Chest:
1. Observe and palpate for DCAP-BTLS, scars, implanted devices such as pacemakers
and indwelling IV/arterial catheters, medication patches, chest wall movement,
asymmetry and accessory muscle use in breathing.
2. Have patient take a deep breath if possible and observe and palpate for signs of
discomfort, asymmetry and air leak from any wound.
3. Assess lung sounds and heart tones as appropriate.
Abdomen:
1. Observe and palpate for DCAP-BTLS, scars and distention.
2. Palpation should occur in all four quadrants taking special note of tenderness, masses
and rigidity.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 20 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Routine Patient Care

RPC-01

Routine Patient Care
Patient Assessment Secondary Survey Continued
Pelvis/Genital-Urinary:
1. Generally, a patient’s genital area should not be exposed and examined unless the
assessment of this body region is required due to the patient’s condition, such as
trauma to the region, active labor or suspected/known bleeding. When possible have
an EMT or paramedic of the same gender as the patient, perform evaluations of the
pelvis/genital area.
2. Observe and palpate for DCAP-BTLS, asymmetry, sacral edema and as indicated for
other abnormalities.
3. Palpate and gently compress lateral pelvic rims and symphysis pubis for tenderness,
crepitus or instability.
4. Palpate for bilateral femoral masses, if warranted.
Shoulder and Upper Extremities:
1. Observe and palpate for DCAP-BTLS, asymmetry, skin color, capillary refill, edema,
medical information bracelet, and equality of distal pulses.
2. Assess sensory and motor function as indicated.
Lower Extremities:
1. Observe and palpate for DCAP-BTLS, asymmetry, skin color, capillary refill, edema
and equality of distal pulses.
2. Assess sensory and motor function as indicated.
Back:
1. Observe and palpate for DCAP-BTLS, asymmetry and sacral edema.
Precautions and Comments:
1. Observation and palpation can be done while gathering a patient’s history.
2. A systematic approach will enable the rescuer to be rapid and thorough and not miss
subtle findings that may become life threatening.
3. Minimize scene times, especially with trauma patients and pediatrics, by
packaging/preparing the patient for immediate transport upon ambulance or air
ambulance arrival (spinal stabilization, pediatric immobilization device, ensuring rapid
ingress/egress for BLS personnel and equipment.)
4. The secondary survey should ONLY be interrupted if the patient experiences airway,
breathing or circulation deterioration requiring immediate intervention. Complete the
examination before treating other identified non-life threatening problems.
5. Reassessment of vital signs and other observations are necessary, particularly in
critical or rapidly changing patients. Vital signs should be taken approximately every 5
minutes. Changes and trends observed in the field are essential data to be
documented and communicated to the transport personnel or receiving facility.
6. As stated in the Primary Survey DCAP-BTLS is a mnemonic that stands for:
A. Deformity.
B. Contusion/Crepitus.
C. Abrasion.
D. Puncture.
E. Bruising/Bleeding.
F. Tenderness.
G. Laceration.
H. Swelling.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 21 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 22 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway Management

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 23 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

AAIR-01

Advanced Airway Management (AAIR-01)
Definitions:
1. Oral Tracheal Intubation (OTI) Attempt - Means the introduction of an Endotracheal
Tube Inducer (ETTI) or endotracheal tube past the patient’s teeth.
2. Difficult Airway - Means an airway that has been predicted to be difficult based on
assessment of the patient or upon an attempt to visualize the cords and the patient has a
Cormack-Lehane (CL) grade of three (3) or four (4).
Cormack and Lehane Classification Grades of Difficult Laryngoscopy
Grade I

Most of glottis is seen

Grade II

Only posterior portion of glottis can be seen

Grade III

Only epiglottis may be seen (none of glottis seen)

Grade IV

Neither epiglottis nor glottis can be seen

Grade I

Grade I I

Grade III

Grade IV

3. “Successful OTI Attempt” - Means a verified placement and securing of the
endotracheal tube into the patient’s trachea.
Documentation Standards:
Oral tracheal intubation confirmation:
Supraglottic airway confirmation:
1. Visualization of tube through cords.
1. Capnography value and waveform.
2. Condensation in ETT.
2. Bilateral lung sounds.
3. Capnography value and waveform.
3. Minimal epigastric sounds.
4. Positive chest rise.
4. Bilateral lung sounds.
Every 5 minutes and on gross patient
5. Negative epigastric sounds.
movement:
6. Positive chest rise.
1. Capnography value and waveform.
Every 5 minutes and on gross patient
2. Bilateral lung sounds.
movement:
3. Minimal epigastric sounds.
1. Capnography value and waveform.
4. Positive chest rise.
2. Bilateral lung sounds.
At transfer of care:
3. Negative epigastric sounds.
1. Capnography value and waveform.
4. Positive chest rise.
2. Bilateral lung sounds.
At transfer of care:
1. Capnography value and waveform.
3. Minimal epigastric sounds.
2. Bilateral lung sounds.
4. Positive chest rise.
5. Name of receiving paramedic or ED
3. Negative epigastric sounds.
physician.
4. Positive chest rise.
5. Name of receiving paramedic or ED
physician.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 24 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

Advanced Airway Management

AAIR-01

Indications and procedure for Oral Tracheal Intubation
1. Inability of the patient to protect their airway (coma, decreased level of consciousness
with loss of gag reflex).
2. Inability to adequately ventilate or oxygenate the patient using an OPA and BVM device.
3. Cardiac arrest. Adhere to sequence as specified in EMS Protocol ACAR-04.
4. Respiratory arrest.
DO NOT perform if gag is present.
1. Initiate BLS airway as needed before attempting advanced airway.
2. Prepare equipment and position patient with the intent to provide an airway via either an
endotracheal tube or via a supraglottic airway.
3. Upon a determination that the patient has a Cormack-Lehane grade of one (1) or two (2),
attempt to insert an endotracheal tube as described in EMS Policy No. 2545 –
Endotracheal Intubation – Adult. If patient has a Cormack-Lehane grade of (3) reposition
the head and revisualize. If still a Cormack-Lehane grade of (3) see below.
4. A stylet or endotracheal tube inducer (ETTI) SHALL BE USED ON ALL ATTEMPTS.
5. No more than two (2) attempts per patient with pre-oxygenation and continuous oximetry
monitoring prior to each attempt.
6. After two (2) unsuccessful attempts at endotracheal intubation, insert a supraglottic
airway.
7. Each attempt should last no longer than thirty (30) seconds. If during any attempt patient
SpO2 falls below 90%, immediately cease and ventilate to increase saturation.
8. Ventilate with 100% oxygen for one (1) minute prior to attempting to intubate.
9. Monitor pulse oximetry continuously.
Indications and procedure for Supraglottic Airway Device
1. Cormack-Lehane grade of 3 or 4 on oral tracheal visualization.
2. Physical or physiological impediments to the successful insertion of an endotracheal tube.
3. After two unsuccessful attempts to insert an endotracheal tube.
4. Use a laryngoscope to facilitate placement.
Note:
1. Remove and replace the I-Gel Airway if resistance is met upon initial insertion.
2. After two (2) unsuccessful attempts, place a BLS airway and transport to the closest
receiving hospital.
INDICATIONS FOR NEEDLE CRICOTHYROTOMY
1. Complete airway obstruction not relieved by airway adjuncts, positioning and direct
laryngoscopy to remove obstruction. See protocol AAIR-02.
Considerations
1. DO NOT delay transport to establish an advanced airway in patients except in the case of
complete airway obstruction, as evidenced by a complete inability to ventilate the patient
using an Oral Pharyngeal Airway (OPA) and BVM device.
2. If unable to establish an airway due to complete airway obstruction not relieved using an
OPA and BVM maneuvers, use direct laryngoscopy to visualize airway if patient is
unconscious and remove foreign body with Magill’s forceps. See protocol AAIR-02, and
transport to closest receiving hospital.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 25 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

AAIR-02

Airway Obstruction (AAIR-02)
Definitions:
1. Partial Airway Obstruction- Difficulty breathing but still able to ventilate.
2. Severe Airway Obstruction- Poor air exchange increased breathing difficulty, silent
cough, cyanosis, and/or inability to speak or breathe.
3. Adult Patient- Means a patient 13 years of age or older, or taller than a weight-based
assessment tape (146.5 cm.)
Documentation Standards:
1. Every 10 minutes for stable patients, every 5 minutes for unstable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. Complete physical assessment.

Objective Findings:
Signs & Symptoms
1. Holding neck (universal
choking sign).
2. Silent cough.
3. Stridor.
4. Inability to speak.
5. Drooling.

Comorbidities
1. Nothing by mouth, (NPO
orders).
2. CVA.
3. Brain injury.
4. Choking episode.
5. Coughing while eating.
6. Dementia.

Differentials
1. Epiglottitis.
2. Esophageal obstruction.
3. Subglottic stenosis.
4. Vocal cord dysfunction.
5. Retro pharyngeal
abscess.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 26 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

AAIR-02

Airway Obstruction (AAIR-02)
Treatment- Partial Obstruction
1. Cardiac monitor.
2. Monitor SpO2, if <94%, 1-15 LPM, O2, NC or NRB, titrate to 94%.
3. Suction as needed.
4. Encourage patient to cough.

Treatment - Severe Obstruction
If awake and alert:
1. Perform abdominal thrusts.
2. Remove foreign body.
3. Cardiac monitor.
4. Monitor SpO2.
If unconscious:
1. Place patient on ground and initiate chest thrusts.
2. Remove foreign body with direct laryngoscopy and Magill forceps.
3. Assist ventilations with BVM.
4. Cardiac monitor.
5. Monitor SpO2.
If unable to remove foreign body:
1. Attempt endotracheal intubation.
If unable to intubate and unable to ventilate adequately with BVM:
1. Perform needle cricothyrotomy.
Considerations
1. Avoid sedating medication.
2. Make early receiving hospital notification for unresolved obstruction.
3. Keep patient calm.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 27 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

AAIR-03

Mechanical Ventilation for Patients with Pulses(A-03)
Definitions:
The purpose of this protocol is to authorize paramedics to use and monitor mechanical
ventilators during prehospital transport for ROSC patients and respiratory arrest patients
with a pulse that are greater than 50 kg.
Documentation Standards:
1. Every 5 minutes for unstable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. Complete physical assessment.
3. Ventilator settings listed below every 5 minutes.
Ventilator Settings
Modes
Values
SIMV- (Synchronized Intermittent
Ventilator Settings:
Mechanical Ventilation) is a type of
VT- (Tidal Volume)
volume control mode of ventilation. With 400-450ml
this mode, the ventilator will deliver a
FiO2- (Fraction of Inspired Oxygen)
mandatory (set) number of breaths with
70-100%
a set volume while at the same time
RR- (Ventilation Rate) “BPM” on Zoll Z Vent.
allowing spontaneous breaths.
16/m
PEEP- (Positive End Expiratory Pressure)
AC- (Assist Control) Not currently
5-8 cm of H2O
approved for prehospital use. A mode PIP- **(Peak Inspiratory Pressure)
of mechanical respiration in which all
40 cm of H2O
breaths are mandatory and are machine I:E- ** (Inspiratory to Expiratory Ratio)
triggered, and machine cycled; a
1:3
minimum breathing rate is set but the
PS- (Pressure Support)
patient can trigger breaths at a faster
10cm of H2O
pace.
PS- (Pressure Support) Provides
ventilation based on a preset pressure.
VS- (Volume Support) Provides
Ventilation based on a preset volume.
CPAP- (Continuous Positive Airway
Pressure) See AAIR-04.
BL- (Bilevel) Not currently approved
for pre hospital use. Non-invasive
ventilation used to support breathing
administered through a face mask, nasal
mask, or a helmet.

Alarms:
PIP- **Peak Inspiratory Pressure
High:30 cm of H2O
Low:10 cm of H2O
VT- **Tidal Volume
High:625ml
Low:225ml
RR- **(Ventilation Rate) “BPM” on Zoll Z Vent.
High:26
Low:8
**Not currently approved for adjustment in
this protocol.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 28 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

AAIR-03

Mechanical Ventilation for Patients with Pulses -02)
Procedure
1. Turn on ventilator and complete system self-check.
2. Connect patient to mechanical ventilator using appropriate ventilator circuit.
3. SpO2 must be used to continuously monitor the patient’s oxygen saturation.
4. Treat the patient according to appropriate treatment policy (i.e. pulmonary edema).
Initial Ventilator Settings
50 to 75Kg
>75kg
5. Mode: SIMV (V);
5. Mode: SIMV (V);
6. RR: 16;
6. RR: 16;
7. Tidal Volume: 400ml
7. Tidal Volume: 450ml
8. PEEP: 5cm of H20;
8. PEEP: 5cm of H20;
9. FiO2: 100%;
9. FiO2: 100%;
10. Pressure Support: 10;
10. Pressure Support: 10;
11. Trigger Level -2.0;
11. Trigger Level -2.0;
12. I:E Ratio: 1:3.0.
12. I:E Ratio: 1:3.0.
13. Patient must be placed on continuous capnography and capnography monitoring during
mechanical ventilation.
14. High or Low EtCO2- During transport, adjust BPM to keep EtCO2 between 35-45.
a. To decrease EtCO2: increase RR by 2 every 2 min to a max of 24 RR.
b. To increase EtCO2: decrease RR by 2 every 2 min to a min of 8 RR.
IF transport time is greater than 20 min:
1. If arrest is secondary to CHF and lung sounds have rales or pink sputum is in the ETT
and SpO2 remains below 90%:
c. Increase PEEP to 8 cm of H2O.
2. FiO2- Titrate Oxygen with the objective to use as little O2 as possible to maintain SpO2
92-98%,
d. Decreased by 10% every 5 minutes to no less than 70% If patient is
unable to maintain SpO2 above 94%: Immediately increase FiO2 to 100%.
Troubleshooting
DOPE- When in doubt return to BVM Ventilations!!!
1. Dislodgment;
2. Obstruction;
3. Pulmonary embolism / tension pneumothorax;
4. Equipment;
**If unable to clear any alarm with 4 or less actions or button pushes, return to BVM
ventilations!!
Sedation of Intubated Patients
1. If below Inclusion and Exclusion criteria are met: midazolam 2-5mg IV/IO, may repeat
once in 10 min.
Inclusion Criteria
Exclusion Criteria
1. EtCO2 greater than 30mmHg;
1. Pulse <50 or >160bmp;
2. SpO2 greater than 88%;
2. SBP <100 or >200;
3. Pt showing purposeful movement, or signs of
agitation such as over breathing the ventilator,
or increased HR.
Base hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 29 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

AAIR-04

CPAP via Ventilator-02)(AAIR-04)
Definitions:
The goal of CPAP is to improve ventilation and oxygenation in an effort to avoid
intubation in patients who present with severe respiratory distress.
A. Assessment/Treatment Indicators: CPAP is authorized for use in patients who are age
eight (8) or older with one of the following:
1. Congestive Heart Failure (CHF) with acute pulmonary edema;
2. Near drowning/submersion;
3. Other causes of severe respiratory distress, excluding trauma.
B. Contraindications:
1. Respiratory or cardiac arrest;
2. Failing respirations;
3. Inability to maintain airway;
4. Severely depressed level of consciousness (LOC);
5. Systolic blood pressure < 90mmHg;
6. Signs and symptoms of pneumothorax;
7. Major trauma, especially head injury or suspected chest injury;
8. Facial anomalies or inability to obtain a mask seal.
C. Relative Contraindications:
1. Decreased LOC;
2. Claustrophobia;
3. Unable to tolerate mask.
Documentation Standards:
4. Every 5 minutes for unstable patients:
A. BP;
B. Respirations;
C. Pulse;
D. SpO2.
5. Complete physical assessment.
Objective Findings:
Signs & Symptoms
Equipment Needed Differentials
1. Peripheral pitting edema.
1. CPAP
1. Congestive Heart
2. Dyspnea that worsens with activity or
(pressure
Failure (CHF) with
when lying down.
generator and
acute pulmonary
3. Wheezing or gasping for breath.
circuit set with
edema.
4. Cold, clammy skin.
ability to deliver 2. Near
5. Anxiety, restlessness.
7.5 cm to 10 cm
drowning/submersion.
6. A cough that produces frothy sputum
of H20 pressure 3. Other causes of
that may be tinged with blood.
with appropriate
severe respiratory
7. Blue-tinged lips.
sized facemask
distress, excluding
8. A rapid, irregular heartbeat
and straps).
trauma.
(palpitations).
2. Nebulizer, if
9. Difficulty breathing with exertion.
required for
10. Swelling in lower extremities.
bronchodilator
administration.
3. Oxygen source.
4. Cardiac
monitor.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 30 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway

AAIR-04

CPAP via Ventilator AAIR-02)
1.
2.
3.
4.
5.
6.
7.
8.
9.

Position the patient in a seated position with legs dependent.
Apply cardiac monitor and assess vital signs.
SpO2 must be used to continuously monitor the patient’s oxygen saturation.
Treat the patient according to appropriate treatment policy (i.e. pulmonary edema).
Set up the CPAP system following manufacturer directions.
Explain the procedure to the patient.
It is important to reassure the patient throughout the procedure.
Verify that oxygen is flowing to the mask and then apply mask.
Initial Ventilator Settings:
a. Mode: CPAP
b. BPM: 12 or default;
c. PEEP: 5cm of H20;
d. FiO2: 100%;
e. Pressure Support: 0;
f. Trigger Level -2.0;
g. I:E Ratio: 1:3.0.
10. Continuously monitor patient for improvement or failure to improve.
11. The patient should improve in the first five minutes with CPAP, evidenced by decreased
heart rate and blood pressure, decreased respiratory rate and an increased SpO2.
12. If the patient does not improve or becomes worse with CPAP, remove the CPAP device
and assist ventilations with BVM as needed.
13. Notify the receiving hospital of the type of CPAP device that is being used.
Troubleshooting
If time constraints allow
1. Trouble Triggering Breath: If patient is A/Ox4 and able to breath on their own and
appears to be struggling to trigger a breath: Decrease trigger level to -1.0, and
increase pressure support to 5cm of H2O.
2. Condition Not Improving:
a. If after 5 min condition is not improving PEEP may be: increased in increments
of 2cm of H2O every 5 minutes to max of 10cm of H2O.
b. If after 3 min condition is not improving or patient expresses a need for more air
pressure or shows signs of air hunger: increase pressure support (PS) by 5
every 3 minutes to a max of 10.
3. Extended Transport Time: If transport is greater than 20 minutes and patient is
tolerating CPAP and shortness of breath is improving and SpO2 is above 94%: FiO2
can be decreased by 10% every 5 minutes to no less than 70%. If patient is unable
to maintain SpO2 above 94%: Immediately increase FiO2 to 100%.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 31 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Airway
This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 32 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 33 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-01

Atrial Fibrillation / Atrial Flutter (ACAR-01)
Atrial Fib: The rhythm is irregularly irregular. Atrial rate can be 350 to 600 but as a rule cannot
be counted. Ventricular rate can be between 160 and 180. QRS complex is usually normal.
Some patients may alternate between atrial fibrillation and atrial flutter.
Atrial Flutter: Atrial rhythm should be regular and can appear to have a “saw tooth” pattern.
Ventricular rhythm may be regular or irregular if variable block is present. Ventricular rate 140
to 160, but may be slower. QRS complex usually normal and may follow every second, third
or fourth flutter wave. Some patients may alternate between atrial fibrillation and atrial flutter.
Definitions:
1. Asymptomatic- Patient has no complaints related to heart rate.
2. Mildly symptomatic- Patient is symptomatic and hemodynamically stable. May have
palpitations, fatigue or near syncope.
3. Grossly symptomatic- Patient is symptomatic and NOT hemodynamically stable. Must
have ALOC, chest pain, or hypotension.
Documentation standards:
1. Every 5 minutes for unstable patients,
3. Physical assessment.
every 15 minutes for stable patients:
4. Skin signs.
A. BP.
5. Duration of symptoms.
B. Respirations.
6. Frequency of symptoms.
C. Pulse.
7. Precipitating factors (e.g., exertion,
D. SpO2
sleep, caffeine, alcohol use).
2. Obtain
A. 12 Lead ECG.
B. Pain scale PRN
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Elevated pulse.
1. A-Fib or A-Flutter.
1. SVT.
2. JVD.
2. Myocardial infarction.
2. AMI.
3. Cyanosis to lips or fingers.
3. Hypertension.
3. Sepsis.
4. Pulmonary or peripheral
4. Coronary artery bypass
4. Electrical abnormality.
edema.
grafting (CABG).
5. Holiday heart
5. Thready pulse.
5. Recent heavy drinking.
syndrome.
6. Weight loss.
6. Thyroid storm.
7. Wolf Parkinson White.
Home Meds:
1. Blood thinners.
2. Rate-controlling agents:
A. Antiarrhythmic.
B. Beta blockers
C. Calcium channel
blockers.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 34 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-01

Atrial Fibrillation / Atrial Flutter
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. 12 lead ECG.
Treatment #1- Asymptomatic:
DO NOT start IV/IO solely for presence of A-Fib/A-Flutter if patient is asymptomatic.
Treatment #2- Mildly Symptomatic:
1. IV, NS, TKO.
2. May consider IVF bolus If no fluid restrictions and lung sounds are without crackles and/or
rales:
500ml, NS Fluid, may repeat max 1L.
Treatment #3- Grossly Symptomatic:
1. IV/IO.
2. NS 500ml rapid IVF bolus to SBP >90, may repeat, max 1L.
3. If remains hypotensive with rapid ventricular response, BHO for synchronized
cardioversion.
Considerations:
1. Patients are rarely hemodynamically unstable from A-Fib or A-Flutter unless rapid HR with
RVR.
2. Field synchronized cardioversion should be avoided if patient is stable enough to make it
to ED.
3. It is imperative to rule out other causes, such as sepsis, ALOC or low BP.

Base Hospital Orders
1. Synchronized cardioversion 100J.
2. Additional NS beyond 1L.
3. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 35 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-02

Bradycardia (ACAR-02)
Bradycardia is characterized by a decrease in the in heart rate. This can be caused by a
multitude of problems ranging from a decrease in atrial depolarization due to slowing of the
sinus node or AV blocks. It may be secondary to sinus node disease, increased
parasympathetic tone or drug effects (e.g., digitalis, propranolol or verapamil.) The rhythm is
regular or slightly irregular with the heart rate below 60 beats per minute.
Definitions:
1. Asymptomatic- Patient has no complaints related to heart rate.
2. Mildly symptomatic- Patient is symptomatic and hemodynamically stable.
3. Grossly symptomatic- Patient is symptomatic and NOT hemodynamically stable. (Must
have ALOC, chest pain or hypotension related to a slow heart rate).
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2
2. Obtain:
A. 12 lead ECG.
B. Blood glucose level, if diabetic.
C. Pain scale PRN.
D. Physical assessment.
E. Skin signs, including capillary refill time.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Syncope.
1. Damage to heart tissues
1. High degree heart block.
2. Dizziness or
from heart disease or
2. Decompensated shock.
lightheadedness.
heart attack.
3. Right side MI.
3. Fatigue.
2. Congenital heart defect.
4. Digoxin toxicity.
4. Shortness of breath.
3. Infection of heart tissue
5. Beta blocker overdose.
5. Chest pains.
(myocarditis).
6. Increased vagal tone.
6. Confusion or memory
4. A complication of heart
7. Intracranial hemorrhage.
problems.
surgery.
8. Athletic with normally low
7. Easily tiring during
5. Imbalance of chemicals in
heart rate.
physical activity.
the blood, such as
9. Lyme disease.
potassium or calcium.
10. Calcium channel blocker
6. Medications, including
OD/Toxicity.
some drugs for other
11. Hyperkalemia.
heart rhythm disorders,
high BP and psychosis.
Home Meds:
1. Beta blockers.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 36 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-02

Bradycardia
1. Cardiac monitor.
2. 12 Lead ECG.
3. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
Treatment #1- Asymptomatic:
DO NOT start IV/IO solely for HR <60 if patient is asymptomatic.
Treatment #2- Mildly Symptomatic:
1. IV, NS, TKO.
Treatment #3- Grossly Symptomatic:
1. IV/IO.
2. Fluid bolus for hypotension, if no fluid restrictions and lung sounds are without crackles
and/or rales.
NS 500ml IV bolus, may repeat bolus, max 1L.
3. Atropine 0.5 mg IV/IO, every 5 minutes, max of 3 mg.
If no response to first 1.5mg atropine or complete heart block:
1. Midazolam 1-2mg IV/IO.
2. Transcutaneous pacing.
If no response to atropine or pacing:
1. Dopamine 10mcg/kg/min via dial-a-flow, titrate to SBP >90.
OR
2. Epinephrine 10mcg 1:100,000 IV/IO, every 3-5 minutes, titrate to SBP >90.
Considerations:
1. Patients are rarely symptomatic from heart rates of 50 to 60 BPM. Other causes should be
ruled out prior to pacing or atropine.
To make epinephrine 1:100,000:
1. Mix 9ml NS with 1ml of epinephrine 1:10,000.

Base Hospital Orders
1. For renal failure and history suggestive of hyperkalemia:
A. Calcium chloride 500mg 10%, IV/IO.
B. Sodium bicarbonate 1 mEq/kg, IV/IO.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
Dopamine
Mix 400mg in 250ml,NS or D5W, using a 60gtts drip set, (60 drops/min = 60 ml/hr)
Weight (kg) gtts/min=10mcg/kg/min
Weight (kg) gtts/min=10mcg/kg/min
35-45 15 gtts/min
85-90 35 gtts/min
45-55 20 gtts/min
95-105 40 gtts/min
60-70 25 gtts/min
110 &up 45 gtts/min
75-80 30 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 37 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-03

Chest Pain of Suspected Cardiac Origin

(ACAR-03

)

Characterized by: substernal chest pain; chest or epigastric discomfort; heaviness;
squeezing; burning or tightness; pain radiating or isolated to jaw, shoulders, arms or back;
nausea; diaphoresis; dizziness; dyspnea; anxiety; or back pain. Patient may have history of
coronary artery disease.
Definitions:
1. STEMI- ST segment elevation myocardial infarction.
2. SRC- STEMI Receiving Center
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2
2. Obtain:
A. 12 lead ECG.
B. Blood glucose level, if diabetic.
C. Pain scale PRN.
D. Physical assessment.
E. Lung sounds.
3. If aspirin withheld, why?
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Description of pain
1. Other cardiac problems.
1. Muscular skeletal chest
(OPQRST):
2. Hypertension.
pain.
A. Onset: acute or
3. Diabetes.
2. Pericarditis.
progressive.
4. Stroke.
3. Stable angina.
B. Provocation: better
5. Family history of MI/CAD. 4. Pulmonary embolism.
with rest or NTG.
6. Drug use (e.g. Cocaine,
5. Pericardial effusion.
C. Quality: dull or
Meth).
6. Gastroenteritis.
pressure.
7. GERD.
D. Radiation: shoulder or Home Meds:
8. Pancreatitis.
back.
1. Aspirin: Has the patient
9. Aortic Dissection.
E. Severity variable on a
taken an aspirin today?
scale of 1-10.
Does the patient usually
F. Time: last known well
take aspirin? Has the
time.
patient been advised by
2. Nausea.
their private medical
3. Vomiting.
doctor to take one (1)
4. Diaphoresis.
aspirin per day?
5. Dyspnea.
2. Nitroglycerin: Have they
6. Dizziness.
taken it?
7. Palpations.
8. Indigestion.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 38 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-03

Chest Pain of Suspected Cardiac Origin
Treatment:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, 1-15 LPM, O2, NC or NRB, titrate to 94%.
3. 12 Lead ECG.
4. Blood glucose level, if diabetic.
5. IV, NS, TKO.
6. NTG 0.4mg, SL if SBP >100 every 5 minutes x3 doses.
7. ASA 324mg PO, if patient is able to swallow.
If chest pain persists after 3 NTG, and SBP >100:
8. Morphine 2mg IV/IO, every 5 minutes. Max of 10 mg.
If chest pain persists after 3 NTG, and SBP <100:
9. Fentanyl 1 mcg/kg slow IV/IO, every 5 minutes, max single dose 100 mcg, max total dose
2 mcg/kg.
STEMI Alert Process if 12 lead reads:
LP12 (***ACUTE MI SUSPECTED***)
LP15 (***MEETS ST ELEVATION MI CRITERIA***)
Zoll E Series (** ** ** ** * ACUTE MI * ** ** ** **)
Zoll X Series (*** STEMI ***)
1. Contact SRC as early as possible and Transmit 12 Lead to SRC.
2. Transport as to SRC.
3. Scene time should be less than ten (10) minutes.
Nitroglycerin:
1. No NTG if computerized interpretation of 12 lead states Inferior MI or elevation of greater
than 2 mm in 2 or more contiguous inferior leads (II, III, or aVF).
2. No NTG if patient has had Viagra in past 24 hours or Cialis in past 36 hours.
Morphine:
1. No MS if computerized interpretation of 12 lead states Inferior MI or elevation of greater
than 2 mm in 2 or more contiguous inferior leads (II, III, or aVF). Administer fentanyl 1
mcg/kg slow IV/IO, every 5 minutes, max single dose 100 mcg, max total dose 2 mcg/kg.
Aspirin:
1. HOLD ASPIRIN IF DISSECTION IS SUSPECTED.
2. May give Aspirin 324mg PO if patient reports taking “baby”/daily 81mg Aspirin.
Considerations:
1. It is no longer recommended to place patient on oxygen unless SpO2 is less than 94% or
patient appears short of breath.
2. DO NOT initiate an IO if patient is conscious and stable.
3. If SBP below 90 at any point infuse NS 500ml IV/IO bolus, may repeat x3, to max of
1500mL if no crackles and/or rales present.
4. If 12 lead ECG does not indicate “Acute MI Suspected” and patient is showing signs and
symptoms of STEMI to including:
a. 2 mm ST elevation in two or more contiguous leads.
5. Notify approved STEMI center and transmit 12 Lead ECG to receiving ED for physician
interpretation.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
2. If patient remains hypotensive after fluid bolus - discuss additional fluid vs. dopamine.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 39 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-04

Medical Cardiac Arrest (ACAR-04)
The goal of cardiac resuscitation is to preserve cerebral and coronary function through
meticulous attention to procedure and achieving return of spontaneous circulation (ROSC).
Definitions:
1. POI- Passive oxygen insufflation.
2. High quality CPR- use TEAM approach:
A. 100 to 120 compressions per minute.
B. Compress at least 2 inches.
C. Allow complete recoil.
D. Minimize interruptions.
E. Rotate compressors every 2 minutes.
F. Pre-charge monitor for defibrillation while CPR is in progress.
3. Contraindications for this protocol:
A. Traumatic arrest - see protocol ATRA-02.
B. VAD- see protocol ACAR-08.
4. Transport notes on this protocol:
A. Follow instructions on Page 40 for adult patients in medical cardiac arrest secondary
to drowning.
B. Complete airway obstruction or known prior respiratory arrest- Follow treatments in
protocol, but transport immediately.
Documentation Standards:
1. Every 5 minutes:
A. Respirations.
B. Pulse.
2. Obtain:
A. Cardiac rhythm strip.
B. SpO2.
C. Capnography.
D. Blood glucose level.
E. Physical assessment.
F. Pupils.
G. Lung sounds.

Objective Findings:
Signs & Symptoms
1. Quickly assess for obvious
signs of death:
A. Decapitation.
B. Decomposition.
C. Burnt beyond
recognition.
D. Lividity.
E. Rigor mortis.
2. No pulse.
3. No respiration.

3.

Circumstances surrounding the arrest:
A. Estimated down time.
B. Onset (witnessed or unwitnessed).
C. Preceding symptoms.
D. Bystander CPR.
E. Medications.
F. Environmental factors (hypothermia,
inhalation, and asphyxiation).

Comorbidities
1. Angina.
2. Myocardial infarction.
3. COPD.
4. Emphysema.
5. Hypertension.

Differentials
1. Respiratory arrest leading
cardiac arrest.
2. Drowning.
3. Hypothermia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 40 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-04

Medical Cardiac Arrest
Reversible causes should be addressed for all medical cardiac arrest patients.
Treatments- treat reversible causes upon identification.
Reversible Causes:
1. Hypovolemia- (history suggesting volume depletion)
Start 2nd, IV/IO, 2L, bolus, IV/IO.
2. Hypoxia- (SpO2 <94%)
Maintain ventilations at 8-10 minutes, with 100% O2, BVM & OPA. Intubate if CL of 1 OR
2, Supraglottic airway if CL 3 and greater.
3. Hydrogen ion- (acidosis, long down time, dialysis pt.) 1mEq/kg, sodium bicarbonate,
IV/IO.
4. Hypoglycemia- (<70 mg/dL)
10ml/kg, dextrose 10%, IV/IO OR 25Gms, dextrose 50%, IV/IO.
5. Hypocalcemia- (down time >60 min, dialysis pt.) 500mg, calcium chloride 10%, IV/IO.
6. Hyperkalemia- (down time >60 min, dialysis pt.) 1mEq/kg sodium bicarbonate, IV/IO.
7. Hypothermia- (body temp below 34°C) Active rewarming with warm IV/IO fluids, start 2nd,
IV if possible, hot packs to neck and groin.
8. Tension Pneumothorax- (absent lung sounds on affected side) Needle decompression.
9. Tamponade, Cardiac
Start 2nd, IV, 2L, bolus, IV/IO, NS, bolus.
10. Toxins
See protocol AODP-01 to 07.
11. Torsade’s de Pointes
Magnesium Sulfate 2 g, IV/IO over 5 min.
Termination of Resuscitative (TOR) Efforts
1. Must have:
A. No shocks delivered.
B. Been unwitnessed.
C. Persistent asystole or PEA.
D. ETCO2 <20mmHg.
E. 30 minutes of treatment.
If patient meets above criteria, a TOR can be done with an MICN. If any of the above is not
met, base hospital physician approval is required.

Base Hospital Orders
1. Termination of resuscitative efforts after 30 minutes if any shocks were delivered.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 41 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-04

Medical Cardiac Arrest
Ventricular Fibrillation (VF) / Pulseless Ventricular Tachycardia (pVT)
2
MIN

If ROSC at rhythm
check go to
protocol ACAR-05.

1. 200 compressions.
2. 15LPM O2 NRB & OPA.
3. IV/IO, NS, WO.

Rhythm Check # 1
VF/pVT

2
MIN

1. Shock 200 joules.
2. 200 compressions.
Rhythm Check #2
2
MIN

VF/pVT

Always consider
reversible causes
and treat when
identified

1. Shock 200 joules.
2. 200 compressions.
3. 1mg/kg lidocaine, IV/IO,
every 5min, max of 3mg/kg.

Rhythm Check #3
2
MIN

1. Shock 200 joules.
2. 200 compressions.
3. 1mg epi, IV/IO, every 4 min.

VF/pVT

1.
2.
3.
4.

Ventilate with BVM at 30:2 compressions to ventilations.
Intubate, CL 1 & 2.
Supraglottic airway, CL 3 & 4.
After advance airway is placed, ventilate every 5-6 seconds, with continuous
compressions.
5. Return to rhythm Check #2.
All joules- are in biphasic, use of monophasic equivalent dose if equipped
to do so is appropriate. Follow manufacturer’s recommendations for single
shocks.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 42 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-04

Medical Cardiac Arrest
Asystole / Pulseless Electrical Activity
If ROSC at rhythm
check go to
protocol ACAR-05.

1. 200 compressions.
2. 15LPM O2 NRB & OPA.
3. IV/IO, NS, WO.

2
MIN

Rhythm Check #1
Asystole/ PEA
2
MIN
1. 200 compressions.
2. 1mg epi, IV/IO, every 4 min.
Rhythm Check #2
Asystole/ PEA

Always consider
reversible causes
and treat when
identified.

2
MIN

1. 200 compressions.

Rhythm Check #3
Asystole/ PEA

1. 200 compressions.
2. 1mg epi, IV/IO, every 4 min.

2
MIN

1. Ventilate with BVM at 30:2 compressions to
ventilations.
2. Intubate, CL 1 & 2.
3. Supraglottic airway, CL 3 & 4.
4. After advance airway is placed, ventilate every 56 seconds, with continuous compressions.
5. Return to rhythm Check #2.

All joules- are in biphasic, use of monophasic equivalent dose if equipped
to do so is appropriate. Follow manufacturer’s recommendations for single
shocks.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 43 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-04

Pulseless Ventricular Tachycardia/Ventricular Fibrillation

(ACAR-

04)

1. Start CPR at 100-120 compressions per minute with cycles of 200 compressions.
2. OPA/NPA and initiate passive oxygen insufflation with O2 @ 15LPM via NRB if no
contraindications for 8 minutes before assisting ventilations with BVM.
3. Place on cardiac monitor – SpO2 and ETCO2.
4. Defibrillate as soon as possible @ 200 joules (or manufacturer’s recommendation), repeat
at pulse check every 2 minutes if in VF/VT.
5. Establish IV/IO.
6. Initiate NS 500ml IVF bolus, max of 2L.
7. If VT/VF after 2 defibrillations, lidocaine 1mg/kg via IV/IO. May repeat every 5 minutes if
VF/VT persists, max total dose of 3mg/kg.
8. Epinephrine 1mg 1:10,000 IV/IO, every 4 minutes. To be initiated after 3 cycles of CPR.
9. Establish advanced airway (ETT or SGA) after 8 minutes of passive oxygen insufflation
10. Continue cycles of 2 minutes of CPR, followed by shock of VF/VT, and epinephrine 1mg
every 4 minutes, for 15 minutes then transport.
11. If ROSC is achieved, initiate transport and continue transport even if ROSC is lost.
12. Patients in persistent/refractory VT/VF at 15 minutes should be transported. If within 15
minutes of SRC, transport to SRC, otherwise transport to closest facility.
13. Patients in refractory VT/VF administer magnesium sulfate 2 g IV/IO over 5 minutes.
Exceptions:
If cardiac arrest is due to suspected drowning or respiratory arrest (i.e. airway obstruction,
status asthmaticus), immediately initiate positive pressure ventilation with BVM and 100%
oxygen at 30:2 ration of compressions to ventilations. After advanced airway is placed,
ventilate once every 5-6 seconds with continuous compressions. Do not perform passive
oxygen insufflation.
Considerations:
1. The goal is high quality compressions with early defibrillation.
2. If IV is not established after first attempt, DO NOT delay vascular access with IV
attempts. Go directly to IO.
3. Monitor capnography with BVM & OPA.
4. Always consider reversible causes and treat when identified.
5. Oral tracheal intubation should be used as the definitive airway for CL scores of 1&2.
6. VAD see protocol ACAR-08.
7. DO NOT initiate therapeutic hypothermia.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 44 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-04

Asystole/PEA (ACAR-04)
1. Start CPR at 100 – 120 compressions per minute with cycles of 200 compressions
2. OPA/NPA and initiate passive oxygen insufflation with O2 @ 15LPM via NRB if no
contraindications for 8 minutes before assisting ventilations with BVM at 30:2
compressions to ventilations.
3. Place on cardiac monitor, SpO2 and ETCO2.
4. Establish IV/IO.
5. Early epinephrine 1mg IV/IO, every 4 minutes.
6. Initiate fluid bolus NS 500ml, max of 2L.
7. If ROSC is achieved, initiate transport and continue transport even if ROSC is lost.
8. If cardiac arrest witnessed by EMS providers or if patient is in a public place, initiate
transport to closest facility at 15 minutes.
9. Establish advanced airway (ETT or SGA) after 8 minutes of passive oxygen insufflation.
10. AT 30 MINUTES proceed to determination of death protocol with base hospital contact.
Exceptions:
If cardiac arrest is due to suspected drowning or respiratory arrest (i.e. airway obstruction,
status asthmaticus), immediately initiate supported respirations with BVM. Do not perform
passive oxygen insufflation.
Considerations:
1. The goal is high quality compressions and EARLY epinephrine.
2. If IV is not established after first attempt, DO NOT delay vascular access with IV attempts.
Go directly to IO.
3. Monitor capnography with BVM & OPA.
4. Always consider reversible causes and treat when identified.
5. Oral tracheal intubation should be used as the definitive airway for CL scores of 1 & 2.
6. VAD see protocol ACAR-08.
7. DO NOT initiate therapeutic hypothermia.

Base Hospital Orders
1. Termination of resuscitative efforts after 30 minutes if any shocks were delivered.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 45 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-05

Return of Spontaneous Circulation (ACAR-05)
The presence of a palpable pulse and/or BP for at least 30 seconds after cardiac arrest.
Definitions:
1. Medical Cardiac Arrest- Cardiac arrest not caused by trauma.
2. Traumatic Arrest- Cardiac arrest secondary to trauma.
3. STEMI Receiving Facility (SRC)- Facility approved by SJCEMSA to receive patients with
ST elevation myocardial infarctions.
Documentation Standards:
1. Every TWO MINUTES (2) minutes:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
E. EtCO2.
2. Obtain:
A. 12 Lead ECG.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment.
E. Lung sounds.
F. Capillary Refill.
Objective Findings:
Signs & Symptoms
1. Breathing.
2. Coughing.
3. Movement.
4. Palpable pulse.
5. Measurable BP.

Comorbidities
1. Chest pain.
2. Shortness of breath.
3. Recent travel with
complaint of leg pain prior
to arrest.

Differentials
1. Myocardial infarction.
2. Pulmonary embolism.
3. Aortic dissection.
4. Hypovolemia.
5. Septic shock.
6. Acute blood loss.
7. Hyperkalemia.
8. Intracranial hemorrhage.
9. H’s & T’s.
a. Hypovolemia.
b. Hypoxia.
c. Hydrogen ion
acidosis.
d. Hyper/Hypoglycemia.
e. Hyper/Hypokalemia.
f. Hyper/Hypothermia.
g. Tension
pneumothorax.
h. Tamponade cardiac.
i. Toxins.
j. Thrombosis,
pulmonary or cardiac.
k. Torsade’s De
Pointes.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 46 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-05

Return of Spontaneous Circulation
1.
2.
3.
4.
5.
6.
7.
8.
9.

Cardiac monitor.
Monitor SpO2, if <94%, 1-15 LPM O2 via NC/NRB/BVM, titrate to 94%.
Monitor EtCO2 with BVM and OPA or advanced airway.
12 Lead ECG. Transmit to receiving emergency department.
If not performed during arrest, IV/IO, NS, TKO.
NS 500ml IVF bolus, repeat PRN to maintain SBP> 90, max 2L.
If not given during arrest, lidocaine 1mg/kg IV/IO ONLY if VF/VT present during arrest.
If low HR, see bradycardia protocol ACAR-02.
Closely monitor SBP, if decreasing, initiate early vasopressors:
A. Dopamine 10mcg/kg/min, via dial-a-flow, titrate to SBP>110 OR,
B. Epinephrine 10mcg, 1:100,000, IV/IO, every 2 minutes, titrate to SBP >110.

To make 1:100,000 epinephrine:
1. Mix 9ml NS with 1ml of epinephrine 1:10,000.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
2. If V-Tach persists lidocaine 0.5mg/kg IV/IO, every 5 minutes, max cumulative dose of
3mg/kg.
Dopamine
Mix 400mg in 250ml, NS or D5W, using a 60ggts drip set, (60 drops/min = 60 ml/hr)
Weight (kg) gtts/min=10mcg/kg/min Weight (kg)
gtts/min=10mcg/kg/min
35-45 15 gtts/min
85-90
35 gtts/min
45-55 20 gtts/min
95-105
40 gtts/min
60-70 25 gtts/min
110 &up
45 gtts/min
75-80 30 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 47 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-06

Non Traumatic Shock (ACAR-06)
Shock is a syndrome which is characterized by inadequate tissue perfusion. Shock can have
a variety of underlying causes including hypovolemia, sepsis, cardiogenic, and anaphylaxis.
Definitions:
1. Asymptomatic- Patient has no complaints.
2. Mildly Symptomatic- Patient has tachycardia with low blood pressure and no change in
level of consciousness.
3. Grossly Symptomatic- Patient is symptomatic and NOT hemodynamically stable. (Must
have ALOC, significant chest pain or hypotension or delayed capillary refill).
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. Obtain:
A. 12 Lead ECG.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment.
E. Capillary refill.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Compensated shock: this 1. GI bleeding.
1. Myocardial infarction.
often missed stage of
2. Vomiting.
2. Sepsis.
shock is characterized by 3. Diarrhea.
3. Pulmonary embolism.
normal to slightly
4. Allergic reaction.
4. Acute blood loss.
decreased BP and
5. Sepsis.
5. GI bleed.
tachycardia.
6. Anti-hypertensive O.D.
6. Intracranial hemorrhage.
2. Decompensated shock:
7. Fever.
7. Aortic dissection.
hypotension and
8. Recent surgery.
tachycardia.
3. Irreversible shock:
hypotension and
bradycardia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 48 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-06

Non Traumatic Shock
1. Cardiac monitor.
2. Monitor SpO2, if < 94%, 1-15 LPM via NC or NRB, titrate to 94%.
3. 12 Lead ECG.
Treatment #1- Mildly Symptomatic
4. IV, NS, TKO.
5. NS 500ml IVF bolus, to BP of 90 systolic, max of 2L.
If patient has fluid restrictions (CHF, ESRD, HD) or lung sounds with crackles and/or rales.
6. NS 250ml IVF bolus, to SBP >90, max of 1L. Reassess lung sounds and SpO2 between
boluses.
Treatment #2- Grossly Symptomatic without fluid restrictions:
1. IV/IO, NS, TKO.
2. NS 500ml rapid IVF bolus, to SBP >90, max of 2L.
If after rapid bolus 2L NS, SBP remains <90, proceed to addition of vasopressors.
Treatment #3 – Grossly symptomatic with fluid restrictions
If patient has fluid restrictions (CHF, ESRD, HD) or lung sounds with crackles and/or rales
AND SpO2 >94%:
1. Rapid IVF bolus of NS 250ml, to SBP >90, max of 1L. Reassess lung sounds and SpO2
between boluses.
2. If patient develops crackles and/or rales, SpO2 drops or does not respond to fluid bolus,
proceed to additional of vasopressors.
3. Dopamine 10mcg/kg/min, via dial-a-flow OR,
4. Epinephrine 10mcg of 1:100,000, IV/IO, every 3-5 minutes, titrate to SBP >90.
Considerations:
1. Patients that appear to be mildly symptomatic can be in the compensatory stage of shock,
ANTICIPATE DETERIORATION.
2. Consider CPAP if lung sounds are not clear and patient has signs of respiratory distress in
addition to vasopressors.

To make epinephrine 1:100,000:
1. Mix 9ml NS with 1ml of epinephrine 1:10,000.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
Dopamine
Mix 400mg in 250ml,NS or D5W, using a 60gtts drip set, (60 drops/min = 60 ml/hr)
Weight (kg) gtts/min=10mcg/kg/min
Weight (kg) gtts/min=10mcg/kg/min
35-45 15 gtts/min
85-90 35 gtts/min
45-55 20 gtts/min
95-105 40 gtts/min
60-70 25 gtts/min
110 &up 45 gtts/min
75-80 30 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 49 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-07

Supraventricular Tachycardia (ACAR-07)
Supraventricular tachycardia (SVT), also called paroxysmal supraventricular tachycardia, is
defined as an abnormally fast heartbeat.
Definitions:
1. Asymptomatic- Patient has no complaints related to heart rate.
2. Mildly symptomatic- Patient is symptomatic but hemodynamically stable.
3. Grossly Symptomatic- Patient is symptomatic and NOT hemodynamically stable. (Must
have ALOC, chest pain or hypotension related to a SVT).
4. All Joules- are in biphasic, use of equivalent monophasic dose if equipped to do so is
appropriate. Follow manufacturer’s recommendations for single shocks.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse and quality.
D. SpO2.
2. Obtain:
A. 12 lead ECG.
B. Blood glucose level if diabetic.
C. Pain scale PRN.
D. Physical assessment.
E. Skin signs, including capillary refill time.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
1. A fluttering in chest.
2. Rapid heartbeat
(palpitations).
3. Shortness of breath.
4. Lightheadedness or
dizziness.
5. Sweating.
6. A pounding sensation in
the neck.
7. Fainting (syncope) or
near fainting.

Comorbidities
1. SVT.
2. Stimulant drug use.
3. Illicit drug use.
4. Cardiac ablation.
Home Meds:
1. Beta blockers.
2. Calcium channel
blockers.

Differentials
1. Atrial fibrillation.
2. Atrial flutter.
3. Dehydration.
4. Sepsis.
5. Beta blocker withdrawal.
6. Wolf Parkinson White
Syndrome.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 50 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-07

Supraventricular Tachycardia
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. 12 lead ECG.
Treatment #1 Asymptomatic:
DO NOT start IV solely for HR >150, if patient is asymptomatic.
Treatment #2- Mildly Symptomatic:
1. IV, AC or higher if possible, NS, TKO.
2. Perform Valsalva’s maneuver.
3. NS 500ml IVF bolus, to SBP >90.
If no response to fluid bolus:
4. Adenosine 6 mg rapid IVP. If no response after 2 minutes give adenosine 12mg rapid IVP,
If no response after 2 min may repeat adenosine 12mg rapid IVP once.
5. If no response after 3 doses of adenosine, if not already, begin transport.
Treatment #3- Grossly Symptomatic:
1. NS 500ml rapid IVF bolus.
2. If IV readily obtained, give adenosine 12 mg rapid IVP.
If no response or unable to readily establish IV:
1. Synchronized cardioversion 100J.
2. If no response, synchronized cardioversion 200J.
3. If IV/IO established, may give midazolam 2mg IV/IO immediately prior to synchronized
cardioversion. Do not delay synchronized cardioversion in unstable patient.
4. If no response to synchronized cardioversion, begin transport and make base hospital
contact.
Considerations:
1. Patients are rarely symptomatic from heart rates of 150 to 160 BPM. Other causes should
be ruled out prior to adenosine or synchronized cardioversion.

Base Hospital Orders
1. Additional synchronized cardioversions.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 51 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-08

Ventricular Assist Device (VAD) Failure

(ACAR-08)

The following are key points to remember from this American Heart Association Scientific
Statement about cardiopulmonary resuscitation (CPR) in adults and children with mechanical
circulatory support (MCS).
Definitions:
1. LVAD- Left Ventricular Assist Device.
2. RVAD- Right Ventricular Assist device.
3. BiVAD- Biventricular Assist Device.
4. Pulsatile- Will have pulsing or rhythmic sound, possible palpable radial pulse and CO2
will read accurately.
5. Continuous Flow- Most commonly located in patient’s thorax and will have no peripheral
pulses. Utilize monitor generated Mean Arterial Pressure (MAP) to assess perfusion, CO2
will read accurately.
6. HeartMate II- The most commonly implanted device. This device is a continuous flow
device and patients will not have a palpable pulse.
7. HeartWare- Older version but still common. This device is a continuous flow device and
patients will not have a palpable pulse.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. MAP (BP is not accurate in these patients).
B. Respirations.
C. Pulse.
D. SpO2.
2. Obtain:
A. 12 lead ECG.
B. EtCO2 if using and advanced airway or BVM and OPA.
C. Blood glucose if diabetic.
D. Pain scale PRN.
E. Physical assessment.
F. Capillary refill.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 52 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-08

Ventricular Assist Device (VAD) Failure
Treatment
1. Cardiac monitor.
2. Monitor SpO2, if < 94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Monitor MAP.
4. Monitor EtCO2 if using and advanced airway or BVM.
5. 12 lead ECG.
6. Assess the device to see if it is working:
A. Gather information regarding the type of device, the implantation hospital, and/or the
VAD Coordinator contact telephone number.
B. Telephone number may be available by a tag on the device, on the refrigerator, or on
a medical alert bracelet.
C. If a caregiver is present, utilize his/her knowledge.
D. Listen to their directions regarding VAD device management until you are able to
contact the VAD Coordinator. The VAD Coordinator can help you decide the best
course of action regarding assessment of the equipment. NOTE: Only the base
hospital is legally allowed to give orders regarding patient care.
7. If the patient has a continuous flow VAD (non-pulsatile / pulseless), auscultate the left
upper quadrant of the patient’s abdomen for the “hum” of the VAD, which can help direct
the appropriate actions.
8. A pulsatile VAD will make an audible sound without auscultation. Pulsatile VADs are
usually older devices which pump blood via pulsatile mechanism, generating a peripheral
pulse.
9. Determine if the device has power:
A. If the device has power, you will see a green light on the HeartMate II, the most
commonly implanted device.
B. On the HeartWare device, the display will tell you the Liters per Minute (LPM) of blood
flow.
10. Check the VAD for secure connections and that the batteries are charged and functional.
If VAD is definitively confirmed by a trained person and there are no signs of life, no MAP and
no pulse:
11. Start CPR see protocol ACAR-04.
Considerations
1. While pulse oximetry can be used in patients with a VAD, the results may not be accurate
because of the lack of pulsatile flow.
2. A CO2 value of <20mmHg in an unresponsive, correctly intubated, pulseless patient with
a VAD would seem to be a reasonable indicator of poor systemic perfusion and should
prompt rescuers to initiate chest compressions.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 53 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-09

Sustained Ventricular Tachycardia with a Pulse

(ACAR-09)

A regular or slightly irregular rhythm, heart rate 100 to 200 and wide >0.12 seconds QRS
complex.
Definitions:
1. Sustained Ventricular Tachycardia- Wide complex QRS rhythm >100BPM lasting longer
than 30 seconds.
2. Asymptomatic- Patient has no complaints related to heart rate.
3. Mildly Symptomatic- Patient is symptomatic (CP, SOB, weakness, lightheadedness) and
hemodynamically stable.
4. Grossly Symptomatic- Patient is symptomatic and hemodynamically unstable (ALOC,
significant chest pain, delayed capillary refill or hypotension).
5. All Joules- Are in biphasic, use of equivalent monophasic dose if equipped to do so is
appropriate. Follow manufacturer’s recommendations for single shocks.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. Obtain:
A. 12 lead ECG.
B. Pain scale PRN.
C. Physical assessment.
D. Skin signs, including capillary refill time.
E. Blood glucose level, if diabetic.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Dizziness.
1. Cardiac arrest.
1. Atrial fibrillation.
2. Shortness of breath.
2. Syncope.
2. Aberrant conduction.
3. Lightheadedness.
3. Palpitations.
4. Feeling as if your heart is
4. Heart disease.
racing (palpitations).
5. Prior synchronized
5. Chest pain (angina).
cardioversion.
6. Loss of consciousness or
6. Implanted defibrillator.
fainting.
7. Family history of early
sudden death.
Home Meds:
1. NTG.
2. ASA.
3. Beta blockers.
4. Calcium channel blockers.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 54 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Cardiac

ACAR-09

Sustained Ventricular Tachycardia with a Pulse
1.
2.
3.
4.

Cardiac monitor.
Monitor SpO2, if < 94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
12 lead ECG.
IV, NS, TKO.

Treatment #1- Asymptomatic:
1. NS 500mL IVF bolus.
Treatment #2- Mildly Symptomatic:
1. Lidocaine 1mg/kg IVP.
2. Give lidocaine 0.5mg/kg IV if persists after 5 minutes. May repeat 0.5 mg/kg x2, every 5
minutes.
Treatment #3- Grossly Symptomatic:
1. Transport to SRC.
2. NS 500ml rapid IVF bolus, titrate to SBP >90, max of 2L. To be done in conjunction with
synchronized cardioversion.
3. Synchronized cardioversion 100J. If no response, repeat, increasing by 50J, max of 3 shocks.
4. Give lidocaine 1mg/kg IV/IO bolus after synchronized cardioversion.
5. If no response to synchronized cardioversion, give lidocaine 1mg/kg IV/IO, may repeat
0.5mg/kg x 2, every 5 minutes.
6. If IV/IO established, may give midazolam 2mg IV immediately prior to synchronized
cardioversion. Do not delay synchronized cardioversion in an unstable patient.

Considerations:
1. If ECG appears polymorphic (Torsades De Pointes)
magnesium sulfate 2g, IV/IO, infusion in 250ml NS, over 20 minutes.
2. For suspected TCA overdose see protocol AODP-05.

Base Hospital Orders
1. Additional synchronized cardioversions.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 55 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 56 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Respiratory

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 57 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Respiratory

ARSP-01

Acute Pulmonary Edema (ARSP-01)
Pulmonary edema is a condition caused by excess fluid in the lungs. Fluid collection in the
numerous air sacs within the lungs cause difficulty breathing.
Definitions:
1. Acute Pulmonary Edema- Means an acute onset of respiratory difficulty with SBP >120
and rales or occasional wheezes. May have a history of cardiac disease.
2. Mild SOB with Pulmonary Edema- Patient complains of SOB with mild work of breathing
(speaking full sentences with difficulty) auscultated rales and no complaints of chest pain.
3. Moderate SOB with Pulmonary Edema- Patient has moderate work of breathing
(speaking 3-5 word sentences) possible complaints of chest pain and has rales on
auscultation.
4. Severe SOB with Pulmonary Edema- Patient has severe work of breathing (speaking 13 word sentences) ALOC or chest pain, with rales on auscultation and or pink frothy
sputum production.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
E. ETCO2
2. Obtain:
A. 12 lead ECG.
B. Blood glucose level on diabetic patients.
C. Pain scale PRN.
D. Physical assessment.
E. Lung sounds.
F. Skin signs including capillary refill.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
11. Peripheral pitting edema. 1. Congestive heart failure.
1. Pneumonia.
12. Dyspnea that worsens
2. Atrial fibrillation.
2. Smoke inhalation.
with activity or when lying 3. Myocardial infarction.
3. Altitude sickness.
down.
4. Coronary artery disease.
4. Pulmonary embolism.
13. Wheezing or gasping for
5. COPD.
5. Flash pulmonary edema.
breath.
6. Emphysema.
6. Mitral valve regurgitation.
14. Cold, clammy skin.
7. Previous intubations
7. Sepsis.
15. Anxiety, restlessness.
secondary to CHF.
8. ARDS.
16. A cough that produces
8. Conditions related to
9. Anaphylaxis.
frothy sputum that may
valve failure.
10. Acute bronchospasms.
be tinged with blood.
9. End stage renal diseases.
17. Blue-tinged lips.
(ESRD)
18. A rapid, irregular
10. Hemodialysis.
heartbeat (palpitations).
19. Difficulty breathing with
Home Meds:
exertion.
1. Lasix.
20. Swelling in lower
2. ASA.
extremities.
3. Beta blockers.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 58 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Respiratory

ARSP-01

Acute Pulmonary Edema
1. Cardiac monitor.
2. Monitor SpO2, if < 94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. 12 Lead ECG.
Treatment #1- Mild SOB with pulmonary edema:
1. Transport in position of comfort.
Treatment #2- Moderate SOB with pulmonary edema:
1. Establish IV, NS, TKO.
2. If suspected cardiac origin and SBP >100, NTG 0.4mg, every 3 minutes PRN.
Treatment #3- Severe SOB with pulmonary edema:
1. Establish IV/IO, NS, TKO.
2. CPAP or PPV ventilation if ALOC.
3. If suspected cardiac origin and SBP >100, NTG 0.4mg SL, every 3 minutes PRN.
4. If pulmonary edema present and SBP <100, make base hospital contact during transport
for possible vasopressor use.

Considerations
1. With severe SOB, DO NOT delay CPAP or PPV ventilation if ALOC.
2. Consider withholding bronchodilators if patient has wheezing breath sounds and no
history of reactive airway disease, consider acute CHF.
3. May treat nausea according to protocol AGEN-04.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
For SBP < 90,
2. Dopamine 10mcg/kg/min, via dial-a-flow OR,
3. Epinephrine 10mcg, 1:100,000, IV/IO, every 3-5 minutes, titrate to SBP >90.
To make 1:100,000 epinephrine:
1. Mix 9ml NS with 1ml of epinephrine 1:10,000.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 59 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Respiratory

ARSP-02

Bronchospasms (ARSP-02)
Bronchospasm occurs when the airways (bronchial tubes) go into spasm and contract. This
makes it hard to breathe and causes wheezing (a high-pitched whistling sound).
Bronchospasm can also cause frequent coughing without wheezing. Bronchospasm is often
due to irritation, inflammation, or allergic reaction of the airways. People with asthma get
bronchospasm. However, not everyone with bronchospasm has asthma.
Definitions:
1. Mild Respiratory Distress- Means mild wheezing, shortness of breath and/or cough, and
ability to speak full sentences.
2. Moderate Respiratory Distress- Means spontaneous adequate breathing with significant
wheezing/SOB accompanied by any of the following signs: accessory muscle use, nasal
flaring, grunting, and/or inability to speak full sentences.
3. Severe Respiratory Distress- Means ineffective respirations and/or inadequate tidal
volume, which may be accompanied by any of the following signs: accessory muscle use,
cyanosis, inability to speak, gasping respirations, and/or decreased level of
consciousness.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG for severe distress or chest pain.
B. Blood glucose level, if diabetic.
C. Pain scale PRN.
D. Physical assessment including skin signs.
E. Lung sounds. (if giving treatment, lung sounds before and after intervention should be
noted)
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Respirations <10 or >30
1. Asthma.
1. Smoke inhalation.
per minute.
2. COPD.
2. Allergic reaction.
2. Rhythm (abnormal
3. Emphysema.
3. Anaphylaxis.
pattern, shallow).
4. Chemical exposure.
4. Congestive heart failure.
3. Effort (labored).
5. Smoking.
5. Spontaneous
4. Lung sounds (wheezing,
6. Previous intubation.
pneumothorax.
stridor).
6. Pulmonary embolism.
5. Cough.
Home Meds:
7. Vocal cord dysfunction.
6. Fever.
1. Albuterol.
8. Pneumonia.
7. Sputum production.
2. Atrovent.
9. Plural effusion.
8. Rash.
3. Steroids.
9. Urticaria.
4. Home Neb.
10. Restlessness.
5. Home O2.
6. Antihistamines.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 60 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Respiratory

ARSP-02

Bronchospasms
1. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
Treatment #1- Mild Bronchospasm:
1. Albuterol 2.5 mg/3ml NS & atrovent 0.5mg/2.5ml via nebulizer with 4-6 LPM O2 x1.
Treatment #2- Moderate Bronchospasm:
1. Albuterol 2.5 mg/3ml NS & atrovent 0.5mg/2.5ml via nebulizer with 4-6 LPM O2 x1.
2. Cardiac monitor.
3. Repeat albuterol 2.5 mg/3 ml NS every 5 minutes as needed.
4. IV, NS, TKO.
Treatment #3- Severe Bronchospasm:
1. Consider CPAP.
2. Albuterol 2.5 mg/3ml NS & atrovent 0.5mg/2.5ml via mask nebulizer or in-line with CPAP
x1.
3. Cardiac monitor.
4. Repeat albuterol 2.5mg/3ml NS as needed.
5. 12 lead ECG.
6. IV, NS, TKO.
If no response after initial albuterol or worsening respiratory status.
7. Magnesium sulfate 2g IV/IO in 250 NS, infusion over 20 minutes. DO NOT administer if
patient has known kidney disease or on dialysis.
If not responding to magnesium sulfate
8. Administer epinephrine 1:1,000 0.3mg IM.
Treatment #4- Respiratory Failure from severe bronchospasm
1. Assist ventilations with BVM 100% oxygen and initiate an inline nebulizer treatment with
albuterol 2.5mg/3ml NS & atrovent 0.5mg/2.5ml NS.
2. Begin continuous inline albuterol nebulizer therapy until patient status has improved and
wheezing has resolved.
3. Cardiac monitor.
4. Administer epinephrine 1:1,000 0.3mg IM, repeat every 5 minutes as needed.
5. Consider magnesium sulfate 2g IV/IO, in 250ml NS, infusion over 20 minutes.
6. Obtain 12 lead ECG.
7. Only place advanced airway when patient is without gag reflex or unable to ventilate.
Considerations
1. Suction as needed.
2. Titrate oxygen to SpO2 of 92% for patients with a history of COPD.
3. Upper airway obstruction; Relieve obstruction by positioning, suction, abdominal thrusts,
or direct removal with Magill forceps.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 61 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Respiratory

ARSP-03

Smoke Inhalation (ARSP-03)
Smoke inhalation is the leading cause of death due to fires. It produces injury through several
mechanisms, including thermal injury to the upper airway, irritation or chemical injury to the
airways from soot, asphyxiation, and toxicity from carbon monoxide (CO) and other gases such
as cyanide.
Definitions:
1. Asymptomatic- Known significant exposure to smoke with no complaints or asymptomatic.
2. Mildly Symptomatic- Known significant exposure to smoke, with signs and symptoms,
such as weakness or mild shortness of breath.
3. Grossly Symptomatic- Known significant exposure to smoke, with serious signs and
symptoms, such as ALOC, severe shortness of breath, unconscious.
4. Carbon Monoxide- Is a colorless, odorless, and tasteless poisonous gas that can be fatal
when inhaled. CO inhibits the blood’s capacity to carry oxygen. CO can be produced when
burning any fuel. CO is a byproduct of incomplete combustion.
5. Smoke Inhalation- Should be suspected in patients rescued from closed-space fires or
exposed to significant amounts of smoke.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Blood glucose level, if diabetic.
C. Pain scale PRN.
D. Physical assessment.
E. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Similar to flu with no fever.
1. Exposure to smoke
1. Anaphylaxis.
2. Dizziness.
from fire.
2. ARDS.
3. Severe headaches.
2. Exposure to gas and/
3. Chemical exposure.
4. Nausea.
chemicals.
4. Pulmonary edema.
5. Sleepiness.
6. Fatigue/weakness.
7. Disorientation/confusion.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 62 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Respiratory

ARSP-03

Smoke Inhalation
1. Monitor SpO2.
Treatment #1- Mildly symptomatic:
1. If SpO2 <94%, O2 1-6 LPM via NC, titrate to 94%.
2. Cardiac monitor.
3. IV, NS, TKO.
4. Consider nebulized saline.
5. If CO poisoning suspected, administer 15 LPM O2 via NRB regardless of SpO2.
6. Treat wheezes according to protocol ARSP-02.
Treatment #2- Grossly symptomatic:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Cardiac monitor.
3. IV, NS, TKO.
4. Consider nebulized saline.
5. If CO poisoning suspected, administer 15 LPM O2 via NRB regardless of SpO2.
6. Treat wheezes according to protocol ARSP-02.
7. Consider CPAP if patient develops pulmonary edema.
8. For SBP <90 without evidence of fluid overload, NS 500ml IVF bolus, titrate SBP >90, max
2L.
9. Treat seizure according to protocol ANRO-05.
10. Treat dysrhythmias according to protocol ACAR-01 to 09.
11. If unmanageable airway involvement, transport to closest hospital.
Considerations:
1. Completely remove victim’s clothing prior to transport.
2. Evaluate patient for facial burns, hoarseness, black sputum, and soot in the nose or mouth.
3. Pulse oximetry values may be unreliable in smoke inhalation patients.
4. Anticipate deterioration.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 63 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 64 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 65 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-01

CVA/TIA/Stroke (ANRO-01)
To identify and treat patients suffering from stokes and TIA’s, and provide early notification to
Primary Stroke Center (PSC).
Definitions:
1. CVA- Cerebral Vascular Accident.
2. TIA- Transient Ischemic Attack. Patient with stroke-like symptoms that are improving
since onset.
3. RACE- Rapid Arterial Occlusion Evaluation.
4. CPSS- Cincinnati Prehospital Stroke Scale.
5. LKWT- Last Known Well Time (Clock time).
6. AC- Antecubital Fossa.
7. EJ- External Jugular.
8. PSC- Primary Stroke Center.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. Cardiac monitor.
B. 12 lead ECG.
C. Blood glucose level.
D. Pain scale PRN.
E. LAST KNOWN WELL TIME (LKWT) written as time of day (clock time), not as hours
or minutes prior to arrival.
F. Physical assessment.
G. Pupils.
H. Stroke scale (Cincinnati Prehospital Stroke Scale & RACE stroke score if indicated).
Objective Findings:
Signs & Symptoms
History
Differentials & Stroke Mimics
1. ALOC.
1. Previous CVA/TIA.
1. ALOC.
2. Weakness/Paralysis.
2. Previous trauma.
2. ETOH / Drug use.
3. Balance/Vertigo/Dizziness. 3. Previous cardiac surgery. 3. Hypo / Hyperglycemia.
4. Vision changes.
4. HTN.
4. Hypoxia.
5. Aphasia/Dysarthria.
5. Diabetes.
5. Hypercarbia.
6. Syncope.
6. Coronary artery disease. 6. Trauma.
7. Headache.
7. Atrial fibrillation.
7. Metabolic disorders.
8. Nausea and vomiting.
8. Medication (i.e. blood
8. Inter cranial hemorrhage.
9. Hyper /Hypotension.
thinners).
9. Dizziness
10. Seizures.
9. DNR orders / code
10. Syncope.
status.
11. Blurred vision.
PSC Alert Process
Upon recognition of RACE score greater than 5:
1. Initiate transport as soon as feasible.
2. Notify PSC via radio or phone of findings:
A. CPSS.
B. RACE score.
C. Blood glucose level.
D. LKWT (Clock time).
E. Pertinent history.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 66 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-01

CVA/TIA
1.
2.
3.
4.
5.
6.
7.
8.

Cardiac monitor
Monitor SpO2, if <94% 1-15 LPM via NC or NRB, titrate to 94%.
12 lead ECG.
Blood glucose level, if <70 mg/dL, see Protocol ANRO-03.
If SBP <90, NS 500ml IVF bolus, titrate to SBP >90, max of 2L.
Perform CPSS.
Perform RACE scale on all patients with POSITIVE CPSS.
PROVIDE STROKE ALERT and transport to stroke center, if patient has a positive CPSS
exam with symptoms <24 hours.
9. If patient has a positive CPSS exam with symptoms >24 hours, transport to PSC
WITHOUT stroke alert.
10. RACE score less than 5; IV, NS, TKO where available.
11. RACE score greater than 5; IV, AC or higher, (EJ after two failed attempts) NS, TKO.
Considerations
1. Accurate LKWT is vital to treatment in the hospital.
2. Limit IV attempts.
3. Look out for atypical presentations and stroke mimics.
4. Provide stroke alert to receiving hospital center as soon as possible.
5. Scene time should be kept to LESS THAN 15 MINUTES.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
Cincinnati Prehospital Stoke Screen
Normal
Abnormal
Facial Droop
Arm Drift
Speech

Both sides of face move equally
Can hold arms out equally
Uses correct words, no slurring

ITEM
FACIAL PALSY
ARM MOTOR
FUNCTION
LEG MOTOR
FUNCTION
HEAD AND
GAZE
DEVIATION
APHASIA
(EVALUATE IN RIGHT
SIDED WEAKNESS)

AGNOSIA
(EVALUATE IN LEFT
SIDED WEAKNESS)

One side of face does not move as well
One arms moves down
Uses incorrect words or slurred speech

RACE Stroke Scale
INSTRUCTION
ABSENT= (Symmetrical movement)
Ask the patient to show
MILD= (Slightly asymmetrical)
their teeth
MODERATE/SEVERE= (Completely asymmetrical)
Extending the arm of the
NORMAL/MILD= (Limb held up for more than 10 seconds)
patient 90 degrees if
MODERATE= (Limb held up for less than 10 seconds)
sitting or 45 degrees if
supine.
SEVERE= (Patient unable to raise arm against gravity)
NORMAL/MILD= (Limb upheld more than 10 seconds)
extending the leg of the
patient 30 degrees if
MODERATE= (Limb upheld less than 10 seconds)
supine
SEVERE= (Patient unable to raise leg against gravity)
ABSENT= (Eye movements to both side are possible)
observe eyes and
cephalic deviation to one
side
Ask the patient to "close
your eyes" and "make a
fist"
Assess for recognition
deficit: Does patient
recognize effected side?
"Whose arm is this?" Can
the patient lift both arms
and clap?

PRESENT= (Eyes deviation to one side observed)
NORMAL= (Performs bot tasks correctly)
MODERATE= (Performs one task correctly)
SEVERE= (Unable to perform either task)
NORMAL= (Recognizes arm and impairment)
MODERATE= (Unable to recognize arm or impairment)
SEVERE= (Unable to recognize arm and impairment)

Score
0
1
2
0
1
2
0
1
2
0
1
0
1
2
0
1
2

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 67 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-02

Hyperglycemia (ANRO-02)
An excess of glucose in the bloodstream, often associated with diabetes mellitus.
Definitions:
1. Asymptomatic- No symptoms or complaints related to blood glucose level.
2. Mildly Symptomatic- Showing symptoms of hyperglycemia such as polyuria, polydipsia,
tachypnea.
3. Grossly Symptomatic- ALOC, confusion, tachypnea.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. Cardiac monitor.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment.
E. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Frequent urination.
1. Insulin dependent
1. CVA.
2. Increased thirst.
diabetes.
2. ETOH intoxication.
3. Blurred vision.
2. Non-insulin dependent
3. Overdose.
4. Fatigue.
diabetes.
4. Shock.
5. Headache.
3. Excessive thirst.
5. Sepsis.
6. Fruity-smelling breath.
6. DKA.
7. Nausea and vomiting.
Home Meds:
7. HHNK.
8. Shortness of breath.
1. Insulin.
9. Tachypnea (especially in
2. Glucophage.
the absence of a SOB
3. Metformin.
complaint).
4. Januvia.
10. Dry mouth.
11. Weakness.
12. Confusion.
13. Coma.
14. Abdominal pain.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 68 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-02

Hyperglycemia
1. Monitor SpO2.
2. Blood glucose level.
Treatment #1- Asymptomatic:
1. If blood glucose level >300 mg/dL, DO NOT initiate IV solely for high blood glucose.
2. Notify receiving nurse.
Treatment #2- Mildly Symptomatic:
1. If SpO2 <94%, O2 1-6 LPM via NC, titrate to 94%.
2. If blood glucose level >300 mg/dL, consider IV, NS, TKO.
3. Notify receiving nurse.
Treatment #3- Grossly Symptomatic:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. If blood glucose level >300 mg/dL, establish IV/IO.
3. Cardiac monitor.
4. NS 500ml IVF bolus if no evidence of fluid overload (CHF, ESRD, HD). May repeat x 1,
max of 1L.
5. Obtain repeat blood glucose after fluid bolus.
6. Notify receiving nurse.
Considerations
1. If ALOC, perform stroke screen. Go to protocol ANRO-01, if positive.
2. If having any chest discomfort perform a 12 ECG lead. If STEMI go to protocol ACAR-03.
3. It is imperative to rule out other causes of ALOC.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 69 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-03

Hypoglycemia (ANRO-03)
Hypoglycemia is a condition caused by a very low level of blood glucose, your body's main
energy source.
Definitions:
1. Asymptomatic - No symptoms or complaints related to blood glucose level. A/Ox4, GCS
15.
2. Mildly Symptomatic - Showing symptoms of hypoglycemia such as confusion, abnormal
behavior or poor skin signs.
3. Grossly Symptomatic - Loss of consciousness or unconscious, seizure activity.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. An irregular heart rhythm. 1. Insulin dependent
1. CVA.
2. Fatigue.
diabetes.
2. ETOH intoxication.
3. Pale skin.
2. Non-insulin dependent
3. Overdose.
4. Shakiness.
diabetes.
4. Shock.
5. Anxiety.
3. Malnutrition.
5. Sepsis.
6. Sweating.
4. Chronic renal disease.
6. Adrenal Insufficiency.
7. Hunger.
5. Vomiting.
7. Insulin OD.
8. Irritability.
8. Malfunction Insulin pump.
9. Confusion.
10. Abnormal behavior.
Home Meds:
11. Visual disturbances.
1. Insulin.
12. Blurred vision.
2. Glucophage.
13. Seizures.
3. Metformin.
14. Loss of consciousness.
4. Januvia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 70 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-03

Hypoglycemia
1. Monitor SpO2.
2. Blood glucose level.
Treatment #1- Asymptomatic:
1. If blood glucose level <70 mg/dl with diabetes history, administer oral glucose.
2. If blood glucose level <70 mg/dl with NO diabetes history and NO symptoms DO NOT
initiate IV or give dextrose solely for blood glucose level <70 mg/dL.
3. Notify receiving nurse.
Treatment #2- Mildly symptomatic with blood glucose level <70 mg/dL:
1. If SpO2 <94%, 1-6 LPM O2 via NC, titrate to 94%.
2. IV, NS, TKO.
3. Administer 25g of dextrose 50% IV, titrate to blood glucose above 70 mg/dL or 100ml of
dextrose 10% IV, titrate to blood glucose >70 mg/dL.
4. Recheck blood glucose.
5. Notify receiving nurse.
Treatment #3- Grossly symptomatic with blood glucose level <70 mg/dL:
1. Cardiac monitor.
2. If SpO2 <94%, 1-15 LPM O2 via NC or NRB, titrate to 94%.
3. IV/IO, NS, TKO.
4. Administer 25g of dextrose 50%, IV/IO, titrate to blood glucose level >70 mg/dL or 100ml
of dextrose 10% IV/IO, titrate to blood glucose level >70 mg/dl.
5. Recheck blood glucose level.
6. If dextrose 10% administered and blood glucose level remains <70 mg/dL and patient is
still grossly symptomatic, administer 25g of D50%.
7. Notify receiving nurse.
Considerations
1. If ALOC continues after dextrose is given, perform stroke screen. Go to protocol ANRO01, if positive.
2. If having any chest discomfort, consider a 12 ECG. If STEMI go to protocol ACAR-03.
3. Always assess for the presence of an insulin pump, and have patient turn off pump if
hypoglycemic.
IF PATIENT IS OBTUNDED WITH POOR IV ACCESS:
1. Place semi-prone position.
2. Place glucose gel onto the end of a tongue depressor.
3. Spread glucose gel on the inside of the lower cheek (buccal area).
4. Promote maximal absorption of glucose product by massaging the outer lower cheek.
5. Continue this practice until the patient becomes able to control their airway.
6. Suction as necessary.

Base Hospital Orders
1. Consult Base Hospital if additional orders as needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 71 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-04

New Onset Altered Level of Consciousness Unknown
Etiology
(ANRO-04)

A mildly depressed level of consciousness or alertness is described as listless. Someone in
this state can be aroused with little difficulty. People who are obtunded have a more
depressed level of consciousness and cannot be fully aroused. Those who are not able to be
aroused from a sleep-like state are said to be stuporous.
Definitions:
1. Stroke Screen- Cincinnati Prehospital Stroke Scale.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment including skin signs and capillary refill.
E. Stroke screen.
F. GCS.
Objective Findings:
Signs & Symptoms
1. Evidence of trauma.
2. Fever.
3. Cough.
4. Fatigue.
5. Shakiness.
6. Skin color changes.
7. Snoring respirations.

Comorbidities
1. Recent fall.
2. Recent infections.
3. Change in medications.
4. Stopped medications.
5. Accidental overdose.
6. ETOH abuse.
7. Liver disease.
Home Meds
1. Blood thinners.
2. Lactulose.
3. Narcotics.
4. Parkinson medications.

Differentials
1. Alcohol intoxication.
2. Epilepsy.
3. Hypo/Hyperglycemia.
4. Over/Underdose of
medications.
5. Trauma.
6. Sepsis.
7. Shock.
8. Behavioral.
9. CVA/TIA.
10. Hypoxia.
11. Meningitis/encephalitis.
12. Encephalopathy.
13. Hyponatremia.
14. Alzheimer’s.
15. Parkinson’s.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 72 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-04

New Onset Altered Level of Consciousness Unknown
Etiology
Treatment:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Monitor CO2 if history of asthma/COPD or using an advanced airway or BVM.
4. Check blood glucose level, if <70 mg/dL, see protocol ANRO-03.
5. Obtain 12 lead ECG. If STEMI see protocol ACAR-03.
6. Perform stroke screen, if positive, see protocol ANRO-01.
If presenting with serious signs and symptoms that do not fit into any other protocol:
7. IV, NS, TKO.
8. If no evidence of fluid overload, treat hypotension or tachycardia with NS 500ml IVF bolus.
May repeat PRN, max 2L. Reassess lung sounds and SpO2 before each additional bolus.
Considerations
DO NOT initiate an IV for the presence ALOC alone, consider other causes:
1. Alcohol- Maintain airway as needed. If SBP <90 systolic, see protocol ACAR-06.
2. Epilepsy- If postictal, maintain airway as needed. If seizing, see protocol ANRO-05.
3. Insulin- If blood glucose level >70 mg/dL, see protocol ANRO-02. If blood glucose level
<70 mg/dL, see protocol ANRO-03.
4. Overdose/ Underdose - See overdose protocols AODP-01 to 07. If no reversible causes
and serious signs and symptoms, consider IV/IO.
5. Trauma- See protocol ATRA-01.
6. Infection- See protocol AGEN-01.
7. Psychosis- This should be considered only after all other potential causes are ruled out.
8. Shock- See protocol ACAR-06.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
EYE
4 Alert
3 Verbal
2 Tactile
1 None

Verbal
5 Oriented
4 Confused
3 Inappropriate words
2 Incomprehensible speech
1 None

Motor
6 Spontaneous
5 Follows Commands
4 Localizes
3 Decorticate Posturing
2 Decerebrate Posturing
1 None

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 73 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-05

Seizures (ANRO-05)
A seizure is a sudden, uncontrolled electrical disturbance in the brain. It can cause changes
in your behavior, movements, feelings, and in levels of consciousness. In the prehospital
setting, our goal is the management of generalized seizure activity that may affect respiratory
drive or airway patency.
Definitions:
1. Tonic Seizures- Tonic seizures cause stiffening of your muscles. These seizures usually
affect muscles in your back, arms, and legs and may cause you to fall to the ground.
2. Clonic Seizures- Clonic seizures are associated with repeated or rhythmic, jerking
muscle movements. These seizures usually affect the neck, face, and arms.
3. Tonic-Clonic Seizures- Tonic-Clonic seizures, previously known as grand mal seizures,
are the most dramatic type of epileptic seizure and can cause an abrupt loss of
consciousness, body stiffening, and shaking, and sometimes loss of bladder control or
biting of the patient’s tongue.
4. Recurrent Seizure- Witnessed by prehospital personnel to be seizing for >2 minutes or
patient has two (2) seizures without regaining consciousness.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment including skin signs and capillary refill.
E. Pupils.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Evidence of trauma.
1. CVA.
1. Recent infection.
2. Febrile state.
2. Meningitis / Encephalitis.
2. Fever.
3. Current seizure activity. 3. Trauma.
3. Intracranial hemorrhage.
4. Medical information
4. Electrolyte imbalance.
4. Environment (heat/cold).
tags, bracelets, or
5. Alcohol withdrawal.
5. Epilepsy.
medallions.
6. VT/VF.
6. Drug use / ETOH Abuse.
7. Overdose.
8. Metabolic acidosis.
Home Meds:
9. Hyperthermia.
1. Acetazolamide(Acetazolam). 10. Hypoxia.
2. Carbamazepine (Tegretol).
3. Clobazam (Frisium).
4. Clonazepam (Rivotril).
5. Diazepam (Valium).
6. Ethosuximide (Zarontin).
7. Gabapentin (Neurontin).
8. Lamotrigine (Lamictal).
9. INH (Kuniazid).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 74 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Neurological

ANRO-05

Seizures
1.
2.
3.
4.
5.
6.

Cardiac monitor.
O2 1-15 LPM via NC or NRB, titrate to 94%.
Check blood glucose.
IV, NS, TKO.
For suspected hyperthermia, See protocol AENV-03.
If patient actively seizing, administer midazolam 5mg IV/IM/IO. May repeat in 5 minutes if
seizure activity continues. Max dose 10mg.
7. Intranasal route is not preferred; however, if IV/IM/IO is not possible, may give midazolam
5mg IN (2.5mg each nares.) May repeat in 10 minutes if seizure activity continues. Max
dose 10mg.

Considerations:
1. Protect patient from further injury e.g. move furniture and ensure safe area for treatment.
2. Spinal stabilization as indicated.
3. DO NOT forcibly restrain patient during seizure activity.
4. If narcotic overdose is suspected, refer to protocol AODP-06.
5. If eclampsia suspected, refer to protocol AOBG-02.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
2. Make base contact for additional medication if seizures continue after maximum dose of
midazolam.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 75 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 76 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 77 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-01

Allergic Reaction/Anaphylaxis (AENV-01)
Allergic reactions occur when your immune system reacts to a foreign substance ranging
from mild to severe.
Anaphylaxis is a severe, potentially life-threatening allergic reaction occurring within seconds
or minutes of exposure.
Definitions:
1. Mild- Hives, rash to arms or legs, itching, anxiety.
2. Moderate- Hives, rash to torso, bronchospasm, nausea.
3. Severe- Respiratory distress, wheezing, chest tightness, difficulty swallowing, altered
mental status.
4. Anaphylactic shock- Signs of hemodynamic instability, tachycardia, ALOC, hypotension,
syncope.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment.
E. Skin assessment.
F. Lung sounds before and after treatment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Sneezing.
1. Known allergy.
1. Bronchospasms.
2. Itching of the nose, eyes
2. Asthma.
2. Gastroenteritis.
or roof of the mouth.
3. Eczema.
3. Runny, stuffy nose.
4. Swelling of the lips,
Home Meds:
tongue, face or throat.
1. Epi-pen.
5. Hives.
2. Diphenhydramine.
6. Edema at the sting site.
7. Cough, chest tightness,
wheezing or shortness of
breath.
8. Loss of consciousness.
9. A drop in BP.
10. Urticaria.
11. Lightheadedness.
12. A rapid, weak pulse.
13. Nausea and vomiting.
14. Abdominal pain.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 78 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-01

Allergic Reaction/Anaphylaxis
1. Monitor SpO2, if <94%, O2, 1-15 LPM, NC or NRB, titrate to 94%.
2. If wheezing albuterol 5mg/6ml NS nebulized, PRN.
Treatment #1- Mild reaction:
1. Diphenhydramine 50mg PO.
Treatment #2- Moderate reaction:
1. IV, NS, TKO.
2. Diphenhydramine 50mg PO/IV/IM.
Treatment #3- Severe reaction:
1. Cardiac monitor.
2. IV/IO, NS, TKO.
3. Epinephrine 0.3mg 1:1,000 IM in lateral thigh.
4. Diphenhydramine 50mg IM/IV/IO.
5. Consider CPAP for respiratory distress.
Treatment #4- Anaphylactic shock:
1. Cardiac monitor.
2. Establish large bore IV/IO, NS.
3. Epinephrine 0.3mg 1:1,000 IM, lateral thigh. Repeat x1 in 5 minutes, if symptoms not
significantly improved.
4. Diphenhydramine 50mg IM/IV/IO.
5. Consider CPAP for respiratory distress.
6. If SBP <90, without fluid overload (CHF, ESRD, HD), NS 500ml rapid IVF bolus, titrate to
SBP >90, max 2L.
If after 2L NS, SBP <90
7. Dopamine 10mcg/kg/min via dial-a-flow OR epinephrine 10mcg 1:100,000 IV/IO, every 35 minutes, titrate to SBP >90.
If patient becomes:
8. Unresponsive with pulses:
A. Epinephrine drip infusion of 5mcg/min IV/IO.
9. Unresponsive with no pulses:
B. Adult cardiac arrest protocol ACAR-04.
Considerations:
1. Attempt to identify allergen if it can be done SAFELY.
2. Remove allergen, if possible.
3. If patient has received an EpiPen prior to arrival and is asymptomatic administer
diphenhydramine 50mg PO. If patient is mildly symptomatic, administer diphenhydramine
50mg IM/IV.
4. Consider 12 Lead ECG for any patient with possible cardiac history.
To make epinephrine 1:100,000:
1. Mix 9ml NS with, 1ml of epinephrine 1:10,000.
To make epinephrine Infusion with concentration of epinephrine 4mcg/ml:
1. Add 1mg of epinephrine 1:1,000 to 250ml NS.
Dosage = mcg/min, 60gtts/1ml drip set 5 mcg= 75 drops/min
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 79 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-02

Bites & Envenomation (AENV-02)
Common poisonous spiders to the Central Valley are the Brown Widow (brown with orange
hourglass on belly), Black Widow (black with red hourglass on body) spiders, and the Brown
Recluse spider. The only known, indigenous poisonous snake in the Central Valley is the
Rattlesnake.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Pain scale PRN.
C. Physical assessment.
D. Lung sounds.
E. Skin signs and capillary refill.
Objective Findings:
Signs & Symptoms
1. Abrasions.
2. Punctures.
3. Swelling and edema.
4. Pain to site.

Comorbidities
1. Working on or around
woodpiles or agriculture
storage.
2. Hiking.

Differentials
1. Abscess.
2. Cellulitis.
3. Necrosis.
4. Necrotizing fasciitis.
5. Allergic reaction.
6. Anaphylaxis.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 80 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-02

Bites & Envenomation
1. Ensure personal safety.
2. Clean and dress wound as appropriate.
3. Remove rings, watches, or other constricting items.
Treatment #1- Animal bite / Human bite:
1. For possible fracture, see protocol ATRA-01.
2. For complaint of pain, apply ice packs. If pain continues, provide pain management per
protocol AGEN-03.
Treatment #2- Insect bite or sting:
1. Scrape away stinger if appropriate.
2. DO NOT squeeze venom sac.
3. If allergic reaction or anaphylaxis, see protocol AENV-01.
4. For complaint of pain, apply ice packs. If pain continues, provide pain management per
protocol AGEN-03.
5. Consider cardiac monitor.
6. Consider monitoring SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
Treatment #3- Snake bite:
1. AVOID excessive movement of extremity.
2. Circle erythema at puncture site with ink pen and note time.
3. Monitor distal pulses.
4. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
5. For complaint of pain, DO NOT apply ice packs. Provide pain management per protocol
AGEN-03.
6. Consider cardiac monitor.
Considerations:
1. Do not apply constricting band or tourniquet.
2. Do not incise snakebites.
3. If dead or captured, have animal control transport snake for identification.
4. If safe, package insect or spider for transport and positive identification.
5. All bites (dog, cat, human, etc.) need to be transported for further evaluation at a hospital
for further cleansing and potential antibiotic therapy.
6. Time since envenomation is important as anaphylaxis rarely occurs more than 60 minutes
after inoculation.
7. Chemical ice packs should never be in direct contact with patient’s skin. Chemical ice
pack should be wrapped in towel or other fabric material.

Base Hospital Orders
1. For known and confirmed black widow bite: calcium chloride 8mg/kg, IV/IO, MAX 500mg.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 81 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-03

Hyperthermia (AENV-03)
Hyperthermia is a condition caused by your body overheating, usually as a result of
prolonged exposure to or physical exertion in high temperatures. This most serious form of
heat injury, heatstroke, can occur if your body temperature rises to 104° F (40° C) or higher.
The condition is most common in the summer months.
Definitions:
1. Mildly Symptomatic- Signs or heat cramps and heat exhaustion.
2. Grossly Symptomatic- Signs of heatstroke including ALOC or unconsciousness.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Blood glucose level.
C. Pain scale PRN.
D. Physical assessment with skin signs.
E. Lung sounds.
F. Temperature.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Headache.
Note: Persons at greatest risk 1. Always rule out other
2. Chest pain.
of hyperthermia are:
causes of ALOC.
3. Cramps.
1. The elderly.
2. Drug Induced
4. Nausea.
2. Athletes.
hyperthermia.
5. Weakness.
3. Persons on medications,
3. Malignant hyperthermia.
6. Abnormal temperature.
which impair the body’s
4. Rhabdomyolysis.
Heat cramps and heat
ability to regulate heat.
5. Sepsis.
exhaustion:
6. Serotonin syndrome.
1. Temperature normal to
slightly elevated.
2. Mental status alert to
slightly confused.
3. Skin signs diaphoresis,
warm or hot to touch.
4. Muscle cramps and
weakness.
Heat stroke:
1. High core temperature
usually above 104 F.
2. Altered mental status.
3. Skin hot to touch and
flushed.
4. Possible seizure activity.
5. Low BP.
6. Tachycardia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 82 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-03

Hyperthermia
1. Move patient to cool environment.
2. Remove excess clothing.
Treatment #1- Mildly symptomatic:
1. Spray or sprinkle patient’s face with cool (not cold) water and use fan to evaporate.
2. Apply ice packs to palms of hands and soles of feet.
3. If able to swallow safely, cool water PO.
4. Consider IV, NS, TKO.
5. NS 500ml IVF bolus, IV. Hold fluids if evidence of fluid overload.
Treatment #2- Grossly symptomatic:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Obtain blood glucose level.
4. Ice packs to palms of hands and soles of feet.
5. IV/IO, NS, TKO.
6. NS 500ml IVF bolus, IV, max 2L.
7. If seizing, see seizure protocol ANRO-05.
Considerations:
1. Chemical ice packs should never be in direct contact with patient’s skin. Ice pack should
be wrapped in towel or other fabric material.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 83 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-04

Hypothermia (AENV-04)
Hypothermia is a medical emergency that occurs when your body loses heat faster than it can
produce heat, causing dangerously low body temperatures. Normal body temperature is
around 98.6° F (37° C). Hypothermia occurs as your body temperature falls below 95° F (35°
C).
Definitions:
1. Mildly symptomatic- Signs and symptoms of hypothermia.
2. Grossly symptomatic- Signs and symptoms of hypothermia with ALOC, loss of
consciousness or hypotension.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Patient’s body temperature.
every 10 minutes for stable patients
4. Length of exposure.
A. BP.
5. Air temperature, water temperature.
B. Respirations.
6. Was patient wet or dry.
C. Pulse.
7. Time of mental status changes.
D. SpO2.
2. If performed, before and after intervention
or if condition changes:
A. 12 Lead ECG.
B. Blood glucose level.
C. Pain scale.
D. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Shivering.
1. Trauma.
1. Rule out other causes for
2. Slurred speech or
2. Alcohol consumption.
ALOC.
mumbling.
3. Pre-existing medical
2. Myxedema (severe
3. Slow, shallow breathing.
problems.
hypothyroid).
4. Weak pulse.
3. Sepsis.
5. Lack of coordination.
4. Environmental exposure.
6. Drowsiness.
5. Adrenal Insufficiency.
7. Confusion or memory
loss.
8. Loss of consciousness.
9. Altered mental status.
10. Evidence of local cold
injury-blanching, red or
wax looking skin
especially ears, nose and
fingers, burning or
numbness in affected
areas.
11. Stuporous or comatose.
12. Dilated pupils.
13. Hypotensive or pulseless.
14. Slowed or absent
respirations.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 84 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Environmental

AENV-04

Hypothermia
1. Move patient to warm environment.
2. Remove clothing if wet and cover with warm blankets.
3. Apply heat packs to groin and axilla.
Treatment #1- Mildly symptomatic:
1. Consider IV, NS, TKO.
2. Consider WARM NS 500ml IVF bolus. May repeat x1, max 1L.
Treatment #2- Grossly symptomatic:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Obtain blood glucose level, if <70 mg/dL, see protocol ANRO-03.
4. Consider 12 lead ECG.
5. IV/IO, NS, TKO.
6. WARM NS 500ml IVF bolus IV/IO, if not fluid overloaded. May repeat as needed, max 2L.
Considerations:
1. Do not attempt to thaw out frost bitten areas or apply heat packs to frostbite sites.
2. Chemical heat packs should never be in direct contact with patient’s skin. Heat pack
should be wrapped in towel or other fabric material.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 85 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 86 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 87 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-01

Trauma (ATRA-01)
Trauma can either be blunt or penetrating, open or closed, or any combination of all.
Definitions:
1. Blunt Trauma- Traumatic injury caused by a blunt object or surface.
2. Penetrating- Traumatic injury caused when an object enters the body.
3. Open- Traumatic injury with a break in the skin.
4. Closed- Traumatic injury without a break in the skin.
5. TBSA- Total Burn Surface Area.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Blood glucose level, if diabetic.
C. Pain scale PRN.
D. Medications such as blood thinners.
E. Baseline GCS and GCS after treatment.
F. Physical assessment including skin signs and capillary refill
G. Lung sounds.
H. Complete/Head to toe exam.
Objective Findings:
1. Mechanism of injury.
2. Medical history e.g. cardiovascular problems, diabetes, or seizure disorder
3. Check for DCAP-BTLS (Deformity, Contusion/Crepitus, Abrasion, Puncture, Bleeding,
Tenderness, Laceration, Swelling).
4. Glasgow coma score.
5. Neurological impairment or focal deficit e.g. paralysis, weakness.
6. Eyes/vision e.g. pupil inequality and reactivity, eye tracking, impaired vision/double
vision, stars.
7. Check for paradoxical chest wall movement (flail chest), rib cage, and sternal instability.
8. Check for pelvic instability, abdominal rigidity and guarding. Check for range of motion,
distal pulses, sensation, skin color, and associated injuries.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 88 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-01

Trauma
1.
2.
3.
4.

Place in spinal motion restriction if indicated.
See injury specific guidelines.
If bleeding, see injury specific guidelines.
If using a BVM ventilate at 24 breaths per min.

Treatment #1- Symptomatic:
1. Monitor SpO2, if <94%, 1-15 LPM via NC or NRB, titrate to 94%.
2. Consider treating for pain. See protocol AGEN-03.
If loss of consciousness:
3. Obtain blood glucose level. If <70 mg/dL, see protocol ANRO-03.
4. Consider stroke screen. If positive, see protocol ANRO-01.
If chest pain:
5. Cardiac monitor.
6. Consider 12 lead ECG. If medical emergency caused traumatic event or blunt trauma to
chest.
Treatment #2- Grossly symptomatic or signs or shock:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Consider treating for pain. See protocol AGEN-03.
If loss of consciousness or ALOC:
4. Obtain blood glucose level. If <70 mg/dL, see protocol ANRO-03.
5. Consider stroke screen. If positive, see protocol ANRO-01.
If chest injury:
6. Consider 12 lead ECG. Obtain if concern for medical emergency caused traumatic event
or blunt trauma to chest.
7. Large bore IV x2, NS, TKO.
8. If SBP <90, NS 500ml rapid IVF bolus. Titrate to SBP >90, max of 1L.
If after 1 L of NS, SBP<90
9. Epinephrine 10mcg 1:100,000 IV/IO every 3 min, titrate to SBP> 90.
*For blunt or penetrating trauma to the torso 2 gm TXA IV/IO, over 1 minute or infusion in
100ml NS over 10 min.
Considerations:
1. If brain injury is suspected, elevate the head of the patient as long as no signs of shock
are present.
2. Head injured patients that require intubation (No gag reflex and cannot protect own airway
AAIR-01) if time allows, pre-medicate head injured patients with fentanyl 2 mcg/kg IVP/IO
prior to intubation.
3. Transport patient in position of comfort if not in spinal precautions. Place pregnant
patients in left lateral recumbent position.
4. If concern for spinal cord injury, patient should be laid flat. If patient is without thoracic or
lumbar tenderness, may be placed in semi-fowler position no greater than 30 degrees.
5. All patients with a period of unconsciousness should be transported to an emergency
department for evaluation.
6. If patient meets Trauma Triage Criteria, transport to approved trauma center.
7. Scene time should be LESS THAN 10 MINUTES
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 89 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-01

Injury Specific Guidelines

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 90 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-01

Trauma: Injury Specific Treatments
Treatment for Bleeding Control
1. Direct pressure.
2. If unable to control with direct pressure alone, use
hemostatic dressing on wound and pack wound if
applicable.
3. Elevate extremity.
4. If bleeding is still not controlled, apply tourniquet.
Treatment for Eye Injury
1. Apply dressing as appropriate.
2. Loosely cover affected and unaffected eye.
Treatment for Tooth Injury
1. Keep avulsed teeth in saline soaked gauze.
OR
2. Commercial tooth saver kit.
3. Transport tooth with patient.
Treatment for Mandible Fracture
1. Splint with cravat or bandage.
Treatment for Impaled Object
1. Stabilize with large bulky dressings.
2. Leave in place.

Treatment for Flail Chest
1. Stabilize chest with large bulky dressing.
Treatment for Open Chest Wound
1. Cover wound with loose dressing, DO NOT seal.
Sucking chest wounds:
2. Immediately cover with gloved hand.
3. Cover with occlusive dressing taped on three sides
OR
4. Use commercially available chest seal.
Treatment for Tension Pneumothorax
1. Perform needle decompression:
A. 2nd or 3rd Intercostal space at midclavicular line.

Treatment Considerations
1. Secure tourniquets as high
on arm or leg as possible.
2. Note time of placement.
3. Do not apply bulky dressing
to wounds as they can hide
bleeding.
Treatment Considerations
1. DO NOT attempt to re-insert
eye.
Treatment Considerations
1. DO NOT attempt to re-insert
teeth.
2. DO NOT attempt to remove
partially avulsed teeth.
Treatment Considerations
1. Monitor airway for
compromise or difficulty
breathing.
Treatment Considerations
1. Removal of impaled objects
should only be considered if
object interferes with CPR or
airway cannot be managed.
2. Consider base contact for
consult.
Treatment Considerations
1. Observe for tension
pneumothorax.
Treatment Considerations
1. Continuously monitor patient
for tension pneumothorax.
2. Attempt to “burp” the wound
by removing occlusive
dressing, allowing air to
escape and then recovering
the wound, prior to needle
decompression.
Treatment Considerations
1. Tension pneumothorax
occurs when a patient has:
A. Absent or decreased
lung sounds.
B. Difficulty breathing.
C. Hypotension.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 91 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-01

Trauma: Injury Specific Treatments
Treatment for Cardiac Tamponade
1. Cardiac monitor.
2. 12 Lead ECG.
3. If SBP <90, NS 500ml rapid IVF bolus. Titrate to SBP
>90, max of 1L.
Treatment for Cardiac Contusion
1. Cardiac monitor for dysrhythmias.
A. V-Tach- see protocol ACAR-09.
2. Obtain 12 lead ECG.
Treatment for Evisceration of Organs
1. Cover eviscerated organs with saline soaked gauze.

Treatment for Genital Injuries
1. Cover genitalia with saline soaked gauze.

Treatment for extremity Injuries
1. Check for range of motion, distal pulses, sensation, skin
color, and associated injuries.
2. Elevate extremity.
3. Apply cold packs to reduce pain and decrease soft
tissue swelling.
4. Splint injured extremity in position found unless
precluded by extrication consideration, no palpable
pulses, or patient discomfort.
Treatment for Mid Shaft Femur Fracture
1. Apply traction splint.
Treatment for Extremity Amputation
1. Place or cover amputated part with dry sterile dressing.
2. Place in sealed plastic bag or wrap with plastic.
3. Place dressed and wrapped part on top of ice or cold
pack.
Treatment for Soft Tissue Injuries without serious bleeding
1. Cover open wounds with sterile dressings.

Treatment Considerations

Treatment Considerations
1. Consider 12 lead with blunt
chest trauma.
Treatment Considerations
1. Frequently assess gauze for
dryness and add additional
saline if needed.
2. DO NOT attempt to reinsert
organs.
Treatment Considerations
1. If necessary, apply direct
pressure to control bleeding.
2. Treat amputation as
extremity amputation.
Treatment Considerations
1. Pad all splinted extremities
and recheck distal pulses
and neurological function
every 5 minutes.
2. Do not apply traction or
attempt to reduce an open
extremity fracture.
Treatment Considerations
1. Closed mid shaft only.
Treatment Considerations
1. If patient condition allows
transport amputated part
with patient.
Treatment Considerations

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 92 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-01

Trauma: Injury Specific Treatments
Treatment for Burns
1. Remove clothing from burned area if possible without
removing skin.
2. Calculate TBSA using rule of nines.
3. Patients with respiratory distress see protocol ARSP-01
to 03.
4. Consider treating for pain. See protocol AGEN-03.
If <20% TBSA:
5. Estimate depth of burn (full thickness, partial thickness,
surface burn).
6. Cover with sterile dressing soaked with sterile water.
If >20% TBSA:
7. Cover with dry sterile burn sheet or cleanest dry sheet.
8. Place patient on dry sterile burn sheet for transport.
9. IV x2, NS, WO, titrate to Parkland Formula.
Chemical:
1. Follow appropriate decontamination or hazmat
procedures.
2. Brush off dry powders.
3. Remove contaminated clothing.
4. Irrigate with copious amounts of water.
Thermal and electrical:
1. Stop the burning process.
2. Cool with water for up to thirty (30) minutes, DO NOT
DELAY transport to approved trauma center.
3. Remove jewelry and non-adhered clothing.
4. Cover burn.

Treatment Considerations
1. Always attempt to identify
type and source of burn:
A. Chemical.
B. Electrical.
C. Steam.
D. Smoke.
E. Open flame.
Parkland Formula
4 ml x %TBSA x body weight
(kg) = Total for 24 hours.
50% given in first eight hours;
50% given in next 16 hours.
Chemical:
1. DO NOT attempt to remove
tar or other adhered
material.
2. If possible, bring chemical
Safety Data Sheet (S DS)
with patient to hospital.
Thermal and electrical:
1. Avoid prolonged cool water
usage due to risk for
hypothermia and local cold
injury.
2. DO NOT use ice water or
apply ice or ice packs to
patient.
3. DO NOT break blisters.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 93 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-02

Traumatic Arrest (ATRA-02)
Loss of cardiac and pulmonary function due to traumatic event.
Definitions:
1. High quality CPR - Use TEAM approach:
A. 100 to 120 compressions per minute.
B. 30:2 ratio compression to ventilation ratio.
C. Compress at least 2 inches.
D. Allow complete recoil.
E. Minimize interruptions.
F. Rotate compressors every 2 minutes.
G. Pre-charge monitor for defibrillation while CPR is in progress.
Documentation Standards:
1. Every 5 minutes:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
1. Capnography.
2. Blood glucose.
3. Physical assessment.
Objective Findings:
Obtain patient history and document the following:
1. Estimated down time.
2. Quickly assess for obvious signs of death:
A. Decapitation.
B. Decomposition.
C. Burnt beyond recognition.
D. Lividity.
E. Rigor mortis.
3. Circumstances surrounding the arrest:
A. Onset (witnessed or unwitnessed).
B. Preceding symptoms.
C. Bystander CPR.
D. Medications.
E. Environmental factors (hypothermia, inhalation, and asphyxiation).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 94 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-02

Traumatic Arrest
•

Is there obvious signs of death
per EMS Policy No. 5103, or,

•

Unwitnessed arrest by First
Responder with estimated
transport time of more than 20
minutes to the approved trauma
center,
AND
ECG rhythm is PEA less than 40
bpm or asystole.

NO

INITIATE IMMEDIATE TRANSPORT
to approved trauma center.

YES
CEASE EFFORTS

Treatment- Treat reversible causes upon identification
Reversible Causes:
1. Hypovolemia- (History suggesting volume depletion) NS 2L IVF bolus, start 2nd IV.
2. Hypoxia- (SpO2 <94%) Maintain ventilation at 24/min, with 100% O2, BVM & OPA.
Intubate if CL of 1 or 2, supraglottic airway if CL >3.
3. Hydrogen Ion- (Acidosis, crush patient, long down time, dialysis patient) Sodium
Bicarbonate 1mEq/kg IV/IO.
4. Hypoglycemia- (Blood glucose level <70 mg/dL) Dextrose 10% 10ml/kg IV/IO or
Dextrose 50% 25g IV/IO.
5. Hypocalcemia- (Long down time, crush injury, dialysis patient) Calcium Chloride 500mg
10% IV/IO.
6. Hyperkalemia- (Long down time, crush injury, dialysis patient) Sodium Bicarbonate
1mEq/kg IV/IO.
7. Hypothermia- (Body temp below 34°C) Active rewarming with warm IV/IO fluids, start
IV if possible, hot packs to neck and groin.
8. Tension Pneumothorax- (Absent lung sounds on affected side) Needle
decompression.
9. Tamponade, Cardiac- If SBP <90, lung sounds are clear and no fluid restrictions exist:
NS 2L IVF Bolus, start 2nd IV.
10. Toxins- See protocol AODP-01 to 07.
11. Thrombosis, Pulmonary & Coronary12. Torsade’s De Pointes- Magnesium Sulfate 2g IV/IO.
Considerations:
1. The goal is high quality CPR.
2. DO NOT delay vascular access with IV attempts. Go directly to IO if IV is not established
after first attempt.
3. Monitor capnography with BVM & OPA.
4. Oral tracheal intubation should be used as the definitive airway for CL scores of 1 & 2.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 95 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-02

Traumatic Arrest
Algorithm - Immediate Transport

To approved Trauma Center.
Perform ALL treatment enroute.

2 Min

Transport

1. 200 compressions.
2. OPA & BVM at 24/min
3. Bilateral needle decompression
unless isolated head injury.
4. IO/IV, NS, max 2L.
5. 2G TXA IV/IO over 1 min or infusion
in 100ml NS over 10 min.
6. Consider advanced airway.

Rhythm check #1

Shock
200Joules.

Asystole/PEA
1. 200 compressions.
2. Epi, 1mg IV/IO, once.

ROSC

See ROSC
protocol
ACAR-05.

2 Min

V-Fib/V-Tach

Rhythm check #2
V-Fib/V-Tach

1. 200 compressions.

ROSC

See ROSC
protocol
ACAR-05.

2 Min

Shock
200Joules.

Asystole/PEA

1. 200 compressions.
2. Lidocaine 1mg/kg
IV/IO, No Repeat.

Return to Rhythm check #1
Always consider
reversible causes
and treat when
identified.

2 Min

All Joules- are in Biphasic, Use of equivalent
Monophasic dose if equipped to do so is appropriate.
Follow manufacturer’s recommendations for single
shocks.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 96 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Trauma

ATRA-02

Traumatic Arrest
Treatment - Immediate Transport
If patient meets criteria for Immediate Transport, begin transport to approved Trauma Center.
Perform ALL treatment enroute. (0 min of CPR):
1. Start CPR at 100-120 compressions per minute.
2. Insert OPA.
3. Ventilate with BVM at 24 per minute.
4. Perform bilateral needle decompression unless isolated head injury.
5. IV/IO, NS, X2, WO, max 2 L,
6. 2G TXA, IV/IO over 1 min or infusion in 100ml NS over 10 min.
7. Consider advanced airways.
If after 200 compressions, (2 min of CPR):
1. ROSC- Initiate transport if not already transporting, see ROSC protocol ACAR-05.
2. Asystole/PEAA. Continue CPR.
B. Epinephrine 1mg, 1:10,000 IV/IO, once.
3. VFib/VTachA. Continue CPR.
B. Epinephrine 1mg, 1:10,000 IV/IO, once.
C. Shock at 200 joules (or manufacturer’s recommendation).
If after additional 200 compressions, (4 min of CPR):
1. ROSC- Initiate transport if not already transporting, see ROSC protocol ACAR-05.
2. Asystole/PEAA. Continue CPR
3. VFib/VTachA. Shock at 200 joules (or manufacturer’s recommendation).
B. Continue CPR.
Always consider
C. Lidocaine 1mg/kg IV/IO, once. No repeat.
reversible causes
and treat when
identified.

Considerations:
When mechanism of injury does not correlate with clinical condition, suggesting a nontraumatic cause of cardiac arrest, standard resuscitation measures should be followed. See
ACAR-04, p. 36.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9 EMS Policy No. 5700 ALS Treatment Protocols Effective July 1, 2025
Page 97 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 98 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Obstetrical

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 99 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-01

Childbirth (AOBG-01)
Childbirth, the process of delivering a baby and the placenta, membranes, and umbilical cord.
During the first stage of labor, the cervix dilates fully. The first stage of labor is divided into two
phases: the latent phase and the active phase. In the latent phase, contractions become
progressively more coordinated and the cervix dilates. The latent phase averages about 8
hours for a nullipara (a woman having her first baby) and 5 hours for a multipara (a woman
having a subsequent baby). In the active phase, the presenting part of the baby descends into
the mid pelvis. The active phase averages about 5 hours for a nullipara and 2 hours for a
multipara. In the second stage (which is called expulsion), the baby moves out through the
cervix and vagina to be born. Expulsion generally lasts 2 hours for a nullipara and 1 hour for a
multipara. The third stage of labor begins with the delivery of the baby and ends when the
placenta and membranes are expelled.
Definitions:
1. Imminent delivery- Means regular contractions, bloody show, low back pain, feels like
bearing down, crowning.
2. Breech presentation- Means presentation of buttocks or both feet.
3. Limb presentation- Means presentation of a single extremity.
4. Nuchal cord- Condition where the umbilical cord is around the baby’s neck during delivery.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Last menstrual period and possibility of
every 15 minutes for stable patients:
pregnancy.
A. BP.
4. Weeks of pregnancy, estimated due date,
B. Respirations.
any anticipated problems (e.g. preC. Pulse.
eclampsia, lack of prenatal care, expected
2. If performed, before and after intervention
multiple births).
or if condition changes:
5. Presence of contractions, cramps, or
A. SpO2.
discomfort.
B. Blood glucose level PRN.
6. Pertinent past medical history.
C. Pain scale PRN.
D. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Crowning.
1. Pregnant.
1. Spontaneous abortion.
2. Bleeding.
2. Eclampsia.
2. Complicated breech
3. Abdominal pain.
3. Pre-eclampsia.
delivery.
4. Contractions.
4. Multiple birth.
3. Braxton’s Hicks
Home Meds
contractions.
1. Pre-natal vitamins.
4. Premature ruptured
2. Magnesium Sulfate.
membranes.

Appearance
Pulse
Grimace
Activity
Respirations

APGAR Scale
0 Points
1 Point
Cyanotic/pale all over Peripheral cyanosis
only
0
<100
No response to
Weak cry or
stimulus
movement when
stimulated
Floppy
Some flexion
Apneic

Slow or irregular
respirations

2 Points
Pink
>100
Cry when stimulated
Well flexed and
resisting extension
Strong cry

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 100 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-01

Childbirth
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. IV, NS, TKO when possible.
Treatment #1- Normal Delivery:
1. For imminent delivery, assist mother with delivery, using clean preferably sterile
technique:
A. Control and guide delivery of head and shoulders.
B. Once delivered, wipe face with clean dry cloth, suction only if needed.
C. Assess APGAR.
D. Clamp and cut cord.
E. Dry and warm neonate.
2. If neonatal resuscitation is needed, see protocol PCAR-01.
3. Perform fundal massage and delivery placenta.
4. Continue to protocol AOBG-04, for further post-partum care.
Treatment #2- Nuchal Cord:
1. Attempt to gently slide cord over baby’s head.
2. If cord is tight, clamp and cut cord.
Treatment #3- Breech Delivery:
1. If breech is two feet or buttocks, attempt to deliver as normal delivery.
2. If unable to delivery or other breech types:
A. Place a gloved hand into the birthing canal to relive pressure on umbilical cord.
B. Transport.
C. Place mother in left lateral recumbent.
Treatment #4- Prolapsed Cord:
1. Place in Trendelenburg position.
2. Elevate hips with pillow.
3. If cord has a pulse, cover cord with saline soaked gauze.
4. If cord has no pulse, place a gloved hand into the birthing canal to relive pressure on cord.
Considerations:
1. If undeliverable breech, transport immediately.
2. If prolapsed cord has no pulse, transport immediately.
3. Always assess mother for signs of shock and treat accordingly to protocol AOBG-04.
4. First priority in childbirth is assisting mother with delivery of child.
5. The primary complication of the newborn is hypothermia which can occur in minutes.
6. Ensure newborn is warm and dry.
7. Ensure newborn has a clear airway. Suction with bulb syringe as needed.
8. Keep baby at or below the level of the mother’s heart until cord is clamped.
9. Do not pull on the umbilical cord.
10. Consider transport while waiting for placenta to deliver.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 101 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-02

Eclampsia & Preeclampsia (AOBG-02)
Preeclampsia and Eclampsia are diseases of pregnancy that involve the development or
worsening of high blood pressure during the second half of pregnancy. Pre-eclampsia may
develop into the more severe condition eclampsia. Eclampsia includes symptoms of
preeclampsia, along with seizures. These conditions typically occur after 20 weeks of
pregnancy. They also may develop shortly after delivery. In very rare situations, they occur
before 20 weeks of pregnancy.
Definitions:
1. Severe Preeclampsia- means pregnancy 20 weeks or greater with hypertension (SBP
>140, diastolic >90), WITHOUT change in mental status, visual disturbances, and/or
peripheral edema.
2. Eclampsia- means pregnancy 20 weeks or greater with seizures, change in mental
status, and/or coma, and typically but not always hypertension (SBP >140, diastolic >90).
3. Post-partum eclampsia- means within 6 weeks post-partum hypertension (SBP >140,
diastolic >90), WITH change in mental status, visual disturbances, peripheral edema,
seizures, and/or coma.
4. Gravid fundus- Is a pregnant uterus with obvious signs of anatomical changes related to
pregnancy.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Last menstrual period and possibility of
every 15 minutes for stable patients:
pregnancy.
A. BP.
4. Duration and amount of any bleeding.
B. Respirations.
5. Weeks of pregnancy, estimated due date,
C. Pulse.
any anticipated problems (e.g. preD. SpO2
eclampsia, lack of prenatal care,
2. If performed, before and after intervention
expected multiple births).
or if condition changes:
6. Presence of contractions, cramps, or
A. 12 lead ECG.
discomfort.
B. Blood glucose level.
7. Pertinent past medical history
C. Pain scale PRN.
8. Estimated blood loss.
D. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Spontaneous abortion or
1. Eclampsia.
1. Eclampsia.
passage of products of
2. Preeclampsia.
2. Preeclampsia.
conception.
3. Multiple Birth.
3. Placenta previa.
2. Headaches, blurred
4. Eclampsia or
4. Placenta abruption.
vision.
Preeclampsia with
5. Intra cranial hemorrhage.
3. Severe abdominal
previous pregnancies.
cramps or sharp
5. Gestational hypertension.
abdominal pain.
4. Crowning.
5. Painful vaginal bleeding.
Home Meds
6. Painless vaginal
1. Prenatal Vitamins.
bleeding.
2. Magnesium Sulfate.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 102 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-02

Eclampsia & Pre-eclampsia
1. Cardiac monitor.
2. Monitor SpO2, if <94%, 1-15 LPM O2 via NC or NRB, titrate to 94%.
3. IV, NS, TKO.
Treatment #1- Eclampsia:
1. Obtain blood glucose level, if <70 mg/dL, see protocol ANRO-03.
2. If seizing (regardless of BP), Magnesium Sulfate 2g IV in 250 ml NS, infusion over 10
minutes.
3. Initiate transport during infusion.
4. If seizure continues after Magnesium Sulfate, see base hospital order below.
5. If seizures continue after 10 minutes, see seizure protocol ANRO-05.
6. For ALOC or visual disturbances, make base hospital contact for Magnesium Sulfate.
Treatment #2- Preeclampsia:
1. Obtain blood glucose level, if <70 mg/dL, see protocol ANRO-03.
Considerations:
1. Transport pregnant patients with Eclampsia or Preeclampsia to closest OB receiving
facility.
2. If patient presents in the third trimester or is obviously pregnant, place in left lateral
recumbent position.
3. Do not visualize genital region except for known or suspected active bleeding, severe
trauma to region or active labor.
4. When possible, have a care giver of same gender as the patient perform evaluations of
the pelvis/genital area.

Base Hospital Orders
If ALOC and SBP >140:
1. Magnesium Sulfate 2-4g IV over 10 minutes.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
If seizure continues after initial 2 G
1. Additional 2 G IV over 10 minutes

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 103 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-03

Obstetrical Emergencies (AOBG-03)
The first principles of dealing with obstetric emergencies are the same as for any emergency
(see to the airway, breathing, and circulation), but remember that in obstetrics there are two
patients; the fetus is very vulnerable to maternal hypoxia.
Definitions:
1. High risk obstetrical- means a pregnancy in which some condition puts the mother, the
developing fetus, or both at higher than normal risk for complications during or after the
pregnancy and birth.
2. Placenta Previa- Bright red vaginal bleeding without pain during the second half of
pregnancy is the main sign of placenta previa. Some women also have contractions.
3. Placenta Abruptio- Bright red vaginal bleeding with complaints of back or abdominal
pain. Patient may also experience contractions or firmness and rigidity to abdomen.
4. Spontaneous abortion- Loss of a fetus before the 20th week of pregnancy. May have
vaginal bleeding or passage of fetal tissue, severe cramps, abdominal pain or bleeding
that progress from light to heavy.
5. Ectopic pregnancy- Implantation of a fertilized egg outside the uterus. May have severe
abdominal pain, abnormal vaginal bleeding, nausea and or vomiting.
6. Gravid fundus- Is a pregnant uterus with obvious signs of anatomical changes related to
pregnancy.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Last menstrual period and possibility of
every 15 minutes for stable patients:
pregnancy.
A. BP.
4. Duration and amount of any bleeding.
B. Respirations.
5. Weeks of pregnancy, estimated due date,
C. Pulse.
any anticipated problems (e.g. pre2. If performed, before and after intervention
eclampsia, lack of prenatal care,
or if condition changes:
expected multiple births).
A. 12 lead ECG.
6. Presence of contractions, cramps, or
B. SpO2.
discomfort.
C. Blood glucose level PRN.
7. Pertinent past medical history.
D. Pain scale PRN.
8. Estimated blood loss.
E. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Spontaneous abortion
1. Eclampsia.
1. Eclampsia.
has passage of products
2. Preeclampsia.
2. Preeclampsia.
of conception.
3. Multiple Birth.
3. Placenta Previa.
2. Headaches, blurred
4. Placenta abruptio.
vision.
3. Severe abdominal
Home Meds
cramps or sharp
1. Prenatal Vitamins.
abdominal pain.
2. Magnesium Sulfate.
4. Crowning.
5. Painful vaginal bleeding.
6. Painless vaginal
bleeding.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 104 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-03

Obstetrical Emergencies
1. Cardiac monitor.
2. Monitor SpO2
Treatment #1- Pregnant without shock:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. If in 3rd trimester and bleeding, establish IV.
IV, NS, TKO.
Treatment #2- Pregnant with shock:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. IV, NS, TKO.
3. If SBP <90 without evidence of fluid overload, give NS 500ml rapid IVF bolus, may repeat
to a max 2L.
4. If SBP <90 with fluid overload, give NS 250ml rapid IVF bolus, may repeat to a max 1L.
5. Consider 2nd IV for refractory hypotension.
Considerations:
1. If patient presents with gravid fundus, place in left lateral recumbent position.
2. Do not visualize genital region except for known or suspected active bleeding, severe
trauma to region or active labor.
3. For active bleeding, place bulky dressing externally to absorb blood flow.
4. Do not pack vagina with any material, use external dressings only.
5. When possible, have a care giver of same gender as the patient perform evaluations of
the pelvis/genital area.

Base Hospital Orders
Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 105 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-04

Postpartum Care (AOBG-04)
Postpartum emergencies can include headache, eclampsia, infection, heart failure, and
hypertension. Failure to recognize and treat these conditions can lead to disastrous
consequences for the patient, including stroke, permanent brain damage, or death.
Definitions:
1. Postpartum bleeding- Causes of postpartum bleeding include loss of tone in the uterine
muscles, a bleeding disorder, or the placenta failing to come out completely, or tearing.
Symptoms include vaginal bleeding that doesn't slow or stop.
2. Perineal trauma- Vaginal tears during childbirth, also called perineal lacerations or tears,
occur when the baby's head is coming through the vaginal opening and is either too large
for the vagina to stretch around or the head is a normal size but the vagina doesn't stretch
easily. These kinds of tears are relatively common and may or may not have significant
bleeding.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Last menstrual period and possibility of
every 15 minutes for stable patients:
pregnancy.
A. BP.
4. Duration and amount of any bleeding.
B. Respirations.
5. Weeks of pregnancy, estimated due date,
C. Pulse.
any anticipated problems (e.g. pre2. If performed, before and after intervention
eclampsia, lack of prenatal care,
or if condition changes:
expected multiple births).
A. 12 lead ECG.
6. Presence of contractions, cramps, or
B. SpO2.
discomfort.
C. Blood glucose level.
7. Pertinent past medical history.
D. Pain scale.
8. Estimated blood loss.
E. Physical assessment.

Objective Findings:
Signs & Symptoms
1. Spontaneous abortion
has passage of products
of conception.
2. Headaches, blurred
vision.
3. Severe abdominal
cramps or sharp
abdominal pain.
4. Crowning.
5. Painful vaginal bleeding.
6. Painless vaginal
bleeding.

Comorbidities
1. Eclampsia.
2. Preeclampsia.
3. Multiple Birth.

Differentials
1. Eclampsia.
2. Preeclampsia.
3. Placenta previa.
4. Placenta abruptio.

Home Meds
1. Prenatal Vitamins.
2. Magnesium Sulfate.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 106 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Obstetrical

AOBG-04

Post-partum Care
1. Cardiac monitor.
2. Monitor SpO2.
Treatment #1- Postpartum without shock:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Perform fundal massage if bleeding or cramping.
3. Control external bleeding with large bulky dressing.
4. Put infant to breast (as appropriate).
5. For seizure activity see Eclampsia protocol AOBG-02.
Treatment #2- Postpartum with shock:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Perform fundal massage If bleeding or cramping.
3. Put infant to breast (as appropriate).
4. Control external bleeding with large bulky dressing.
5. IV, NS, TKO.
6. If SBP <90 without fluid overload, NS 500ml rapid IVF bolus. May repeat to max 2L.
7. If SBP <90 with signs of fluid overload, NS 250ml rapid IVF bolus. May repeat to max 1L.
8. Consider 2nd IV.
9. For persistent hypotension, AVOID push dose epinephrine or dopamine infusion. Contact
base hospital.
10. For seizure activity see protocol ANRO-05.
Considerations:
1. Do not visualize genital region except for known or suspected active bleeding, or severe
trauma to region.
2. For active bleeding, place bulky dressing externally to absorb blood flow.
3. Do not pack vagina with any material, use external dressings only.
4. When possible, have a caregiver of same gender as the patient perform evaluations of the
pelvis/genital area.

Base Hospital Orders
1. If after 1L, NS if SBP <90, consult base hospital to discuss push dose epinephrine or
dopamine.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 107 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 108 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 109 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-01

Acute Dystonic Reactions (AODP-01)
Acute dystonic reactions are an extrapyramidal side effect of antipsychotic and certain other
medications such as Phenothiazines. Dystonia refers to sustained muscle contractions,
frequently causing twisting, repetitive movements, or abnormal postures. They may affect any
part of the body. Patients experiencing acute dystonic reactions are often frightened and
fearful, and may be in considerable pain.
Definitions:
1. Symptomatic/Mild Reaction- Intermittent spasms or sustained involuntary contractions
isolated to extremities, tongue or jaw.
2. Grossly Symptomatic/Severe Reaction- Intermittent spasms or sustained involuntary
contractions affecting back or entire body.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Name of medication.
every 15 minutes for stable patients:
4. Estimated number of pills or dose.
A. BP.
5. Route of administration.
B. Respirations.
6. Time of administration.
C. Pulse.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose level.
D. Pain scale.
E. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Inability to move eyes.
1. Abdominal pain.
1. Seizure.
2. Muscle spasms of face,
2. Nausea and vomiting.
neck, body, arms, or legs 3. Bipolar disorder.
causing unusual postures 4. Schizophrenia.
or unusual expressions
on face.
3. Rapid or worm-like
Common Med Names
movements of tongue.
1. Prochlorperazine
4. Sticking out of tongue.
(Compazine, Compro,
5. Tic-like or twitching
Procomp).
movements.
2. Chlorpromazine
6. Trouble in breathing,
(Promapar, Thorazine).
speaking, or swallowing.
3. Fluphenazine (Permitil,
7. Uncontrolled chewing
Prolixin).
movements.
4. Perphenazine.
8. Uncontrolled movements 5. Trifluoperazine
of arms or legs.
(Stelazine).
9. Uncontrolled twisting
6. Thioridazine (Mellaril).
movements of neck,
trunk, arms, or leg.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 110 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-01

Acute Dystonic Reactions
Treatment #1- Symptomatic/Mild Reaction:
1. Consider IV, NS, TKO.
2. If able to swallow safely, diphenhydramine 50 mg PO.
3. If UNABLE to swallow safely, diphenhydramine 1mg/kg IM/IV, max of 50mg.
Treatment #2- Grossly Symptomatic/Severe Reaction:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. IV, NS, TKO.
4. Diphenhydramine 1mg/kg IV/IO, max of 50mg.
Considerations:
1. If benzodiazepines have already been administered to treat seizures, DO NOT withhold
Diphenhydramine.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 111 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-02

Beta Blockers Overdose (AODP-02)
Beta blockers, also known as beta-adrenergic blocking agents, are medications that are
commonly used to reduce BP. Beta blockers work by blocking the effects of the adrenaline.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibility of beta blocker
overdose but patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals beta blocker overdose and patient
is showing signs and symptoms including bradycardia, hypotension, hypothermia,
hypoglycemia, seizures.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Name of medication.
every 15 minutes for stable patients:
4. Estimated number of pills or liquid.
A. BP.
5. Route of administration.
B. Respirations.
6. Time of administration.
C. Pulse.
D. SpO2
2. If performed, before and after intervention
or if condition changes:
A. 12 lead ECG.
B. Blood glucose level.
C. Pain scale.
D. Physical assessment.
E. Pupils.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Hypotension.
1. High BP.
1. Co-ingestion.
2. Bradycardia.
2. Irregular heart rhythm
2. Calcium channel blocker
3. AV block.
(arrhythmia).
OD.
4. Heart failure.
3. Heart failure.
3. Digoxin toxicity.
5. Bronchospasm.
4. Chest pain (angina).
4. Complete heart block.
6. Hypoglycaemia.
5. Heart attacks.
5. Renal failure.
7. Hyperkalaemia.
6. Migraine.
8. Stupor.
7. Certain types of tremors.
9. Coma.
10. Seizures.
Home Meds:
1. Acebutolol (Sectral).
2. Atenolol (Tenormin).
3. Bisoprolol (Zebeta).
4. Metoprolol (Lopressor,
Toprol-XL).
5. Nadolol (Corgard).
6. Nebivolol (Bystolic).
7. Propranolol (Inderal LA,
InnoPran XL).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 112 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-02

Beta Blockers Overdose
1. Cardiac monitor.
2. 12 lead ECG.
3. Monitor SpO2.
Treatment #1- Asymptomatic:
1. If SpO2 <94%, O2 1-6 LPM via NC, titrate to 94%.
2. Consider, IV, NS, TKO.
3. Blood glucose level every 30 minutes.
4. If blood glucose level <70 mg/dL, see Hypoglycemia protocol ANRO-03.
5. If SBP <90, NS 500ml IVF bolus, max 1L. Notify receiving hospital of hypotension.
Treatment #2- Symptomatic:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. IV, NS, TKO.
3. Blood glucose level every 15 minutes.
4. If blood glucose level <70 mg/dL, see hypoglycemia protocol ANRO-03.
5. SBP <90 without fluid overload or history of CHF/Dialysis, NS 500ml IVF bolus. May
repeat, max 2L.
6. SBP <90 and HR <50 with fluid overload or history of CHF/Dialysis, NS 250ml IVF bolus.
May repeat if no worsening fluid overload, max 1L.
7. For refractory hypotension with HR <50, epinephrine 10 mcg, 1:100,000, IV/IO, every 3-5
minutes, titrate to SBP >90.
8. If no response epinephrine & HR <50, initiate transcutaneous pacing.
9. For seizure activity, see protocol ANRO-05.
Considerations
1. Monitor QRS duration closely even in asymptomatic patients.
2. If patient is physically combative, consider involving law enforcement to assist in putting
patient in 4-point restraints.
To make epinephrine 1:100,000:
1. Mix 9ml NS with, 1ml of epinephrine 1:10,000.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 113 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-03

Calcium Channel Blocker Overdose (AODP-03)
Calcium channel blockers are used in the treatment of hypertension, angina pectoris, cardiac
arrhythmias, and other disorders. These medications are available in both immediate-release
and extended-release preparations. The potential toxicity of these agents is substantial, and
is often under appreciated by the public.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibility of calcium channel
blocker overdose but patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals calcium channel overdose and
patient is showing signs and symptoms including hypotension, bradycardia, or sudden
cardiac collapse.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Name of medication.
every 15 minutes for stable patients:
4. Estimated number of pills or liquid.
A. BP.
5. Route of administration.
B. Respirations.
6. Time of administration.
C. Pulse.
D. SpO2
2. If performed, before and after intervention
or if condition changes:
A. 12 lead ECG.
B. Blood glucose level.
C. Pain scale.
D. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Constipation.
1. Hypertension.
1. Co-ingestion.
2. Headache.
2. Angina pectoris.
2. Beta blocker OD.
3. Palpitations.
3. Cardiac arrhythmias.
3. Digoxin toxicity.
4. Dizziness.
4. Complete heart block.
5. Rash.
Home meds
5. Renal failure.
6. Drowsiness.
1. Amlodipine (Norvasc).
7. Flushing.
2. Diltiazem (Cardizem,
8. Nausea.
Tiazac, others).
9. Swelling in the feet and
3. Felodipine.
lower legs.
4. Isradipine.
10. Bradycardia.
5. Nicardipine.
11. Hypotension.
6. Nifedipine (Adalat CC,
12. Shortness of breath.
Afeditab CR, Procardia).
7. Nisoldipine (Sular).
8. Verapamil (Calan,
Verelan).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 114 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-03

Calcium Channel Blocker Overdose
1. Cardiac monitor.
2. 12 lead ECG.
3. Monitor SpO2.
Treatment #1- Asymptomatic:
1. If SpO2 <94%, O2 1-6 LPM via NC, titrate to 94%.
2. Consider IV, NS, TKO.
Treatment #2- Symptomatic:
1. if SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. IV/IO, NS, TKO.
3. If SBP <90 & HR <50, calcium chloride 20 mg/kg 10% IV/IO, max 2g .
4. If SBP remains <90 without fluid overload or history of CHF/Dialysis, NS 500ml IVF bolus.
May repeat, max 2L.
5. If SBP remains <90 and HR <50 with fluid overload or history of CHF/Dialysis, NS 250ml
bolus. May repeat if no worsening fluid overload, max 1L
6. After bolus if SBP <90 and HR <50, epinephrine 10 mcg 1:100,000 IV/IO, every 3-5
minutes, titrate to SBP >90.
7. If no response to epinephrine, initiate transcutaneous pacing.
Considerations:
1. Monitor QRS duration closely even in asymptomatic patients.
2. Cardiac monitor for presence of AV nodal blocks.
3. If patient is physically combative, consider involving law enforcement to assist in putting
patient in 4 point restraints.

To make epinephrine 1:100,000:
1. Mix 9ml NS, with 1ml of epinephrine 1:10,000.

Base Hospital Orders
1. Additional normal saline for hypotension.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 115 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-04

Actue Drug Intoxication (AODP-04)
Acute drug intoxication refers to the immediate and deleterious effects of drugs such as
cocaine, amphetamines, PCP or bath salts, on the body. Although acute drug intoxication and
drug dependence can be present in the same individual, these syndromes present with
different symptoms.
Definitions:
1. Intoxication- History reveals or patient is showing signs and symptoms of acute drug
intoxication however patient is cooperative.
2. Intoxication with serious agitation- History reveals or patient is showing signs and
symptoms of acute drug intoxication however, patient is not cooperative, is a safety risk to
crews or a safety risk to themselves. Safety risks include physically combative or erratic
dangerous behavior.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. 12 lead ECG.
B. Blood glucose level.
C. Physical assessment.
D. Pupils.
E. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Tachycardia.
1. Drug use.
1. Co-ingestion.
2. Hypertension.
2. Previous OD.
2. Stimulant induced MI.
3. Dilated pupils.
3. Encephalopathy.
4. Hyperthermia.
4. Drug induced psychosis.
5. Restlessness.
Home Meds
6. Anxiety, panic, paranoia.
1. Methadone.
7. Erratic behavior.
8. Tremors.
9. Psychosis.
10. Nausea.
11. Agitation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 116 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-04

Acute Drug Intoxication
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-6 LPM via NC, titrate to 94%.
Treatment #1- Intoxication:
1. If chest pain, obtain 12 lead ECG. If STEMI see chest pain protocol ACAR-03.
Treatment #2- Intoxication with serious agitation:
1. If chest pain, obtain 12 lead ECG, if STEMI see chest pain protocol ACAR-03.
2. If ALOC, obtain blood glucose level. If blood glucose level <70 mg/dL, see protocol
ANRO-03.
3. Consider IV, NS, TKO, ONLY IF SAFE TO DO SO.
4. IF age is between 18 and 55, and patient is PHYSICALLY COMBATIVE, midazolam 4mg
IM/IN. If outside these ages, make base hospital contact.
Considerations:
1. Safety is the highest priority. Consider law enforcement assistance if patient is agitated.
2. If patient is physically combative consider involving law enforcement to assist in putting
patient in 4 point restraints.

Base Hospital Orders
1. Midazolam 2-4mg IM, for patients older than 55 and younger than 18.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 117 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-05

Cyclic Antidepressants Overdose (AODP-05)
The clinical presentation of cyclic antidepressant overdose is extremely variable. Patients can
present alert with normal vital signs or comatose and hypotensive. In any case, rapid onset of
symptoms and rapid deterioration are characteristic of cyclic antidepressant overdose.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibly of cyclic antidepressants
overdose but patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals cyclic antidepressants overdose
and patient is showing signs and symptoms related to cyclic antidepressants or is having
dysrhythmias, VF/VT, widening QRS, prolonged QT, wide complex tachycardia that’s is
not VF/VT.
Documentation Standards:
1. Every 5 minutes for unstable patients,
7. Name of medication.
every 15 minutes for stable patients:
8. Estimated number of pills or liquid.
2. BP.
9. Route of administration.
3. Respirations.
10. Time of administration.
4. Pulse.
5. SpO2.
6. If performed, before and after
intervention or if condition changes:
a. ECG.
b. Blood glucose level.
c. Pain scale.
d. Physical assessment.
e. Pupils.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Blurred vision.
1. Depression.
1. Co-ingestion.
2. Dry mouth.
2. Previous OD.
3. Constipation.
3. Panic disorder.
4. Weight gain or loss.
4. Bulimia.
5. Rash.
5. Chronic pain.
6. Hives.
6. Migraine.
7. Increased heart rate.
7. Tension headaches.
8. Cardiac conduction
8. Diabetic neuropathy.
delays.
9. Phantom limb pain.
9. Dysrhythmias.
10. Chronic itching.
10. Hypotension.
11. Respiratory depression.
Home meds
12. Seizures.
1. Amitriptyline.
13. Coma.
2. Amoxapine.
3. Desipramine (Norpramin).
4. Doxepin.
5. Imipramine (Tofranil).
6. Nortriptyline (Pamelor).
7. Protriptyline (Vivactil).
8. Trimipramine (Surmontil).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 118 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-05

Cyclic Antidepressants Overdose
1. Cardiac monitor.
2. Monitor SpO2.
3. Obtain 12 lead ECG.
Treatment #1- Asymptomatic:
1. If SpO2 <94%, O2 1-6 LPM via NC, titrate to 94%.
2. Consider IV, NS, TKO.
Treatment #2- Symptomatic or dysrhythmias:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. IV/IO, NS, TKO.
3. Sodium bicarbonate 50 mEq IV/IO every 3 min to resolution of ECG changes, max 150
mEq. May make base hospital contact for additional doses.
4. For seizure activity see protocol ANRO-05.
5. If SBP <90 without fluid overload or history of CHF/Dialysis, NS 500ml IVF bolus. May
repeat, max 2L.
6. If SBP <90 with fluid overload or history of CHF/Dialysis, NS 250ml IVF bolus. May repeat
if no worsening fluid overload, max 1L
7. If SBP <90 after bolus, see protocol ACAR-06.
8. If patient requires assistance with ventilations, hyperventilate, to EtCO2 30-35.
Considerations:
1. Cardiac monitor closely even in asymptomatic patients as tricyclic antidepressant
overdose patients deteriorate suddenly and quickly.
2. If patient is on a hold or there is potential for intentional OD, consider 4-point restraints.
3. If patient is physically combative consider involving law enforcement to assist in putting
patient in 4 point restraints.

Base Hospital Orders
1. Additional sodium bicarbonate beyond 150mEq.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 119 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-06

Opiate Overdose (AODP-06)
Physical and mental symptoms that occur after taking too many opioids, a substance found in
certain prescription pain medications and illegal drugs like heroin.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibility of opiate overdose but
patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals opiate overdose and patient is
showing signs and symptoms related to opiate overdose, including respiratory depression
or apnea.
Documentation Standards:
1. Every 5 minutes for unstable patients,
every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
E. EtCO2
2. If performed, before and after
intervention or if condition changes:
A. ECG.
B. Blood glucose level, if diabetic history
or continues to have ALOC.
C. Physical assessment.
D. Pupils.
Objective Findings:
Signs & Symptoms
1. Lethargy.
2. ALOC.
3. Shortness of breath.
4. Pinpoint pupils.
5. Slow or absent
respirations.
6. Hypotension.

3.
4.
5.
6.

Name of medication or substance.
Estimated number of pills or liquid.
Route of administration.
Time of administration.

Comorbidities
1. Short-term pain
management.
2. Chronic pain
management.
3. Heroin use.

Differentials
1. Pontine bleed.

Home Meds
1. Hydrocodone (Vicodin®).
2. Oxycodone (OxyContin®,
Percocet®).
3. Oxymorphone (Opana®).
4. Morphine (Kadian®,
Avinza®).
5. Codeine.
6. Fentanyl.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 120 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-06

Opiate Overdose
1. Monitor SpO2.
2. Monitor EtCO2.
Treatment #1- Asymptomatic:
1. Consider cardiac monitor.
2. If EtCO2 is elevated, evaluate efficacy of respirations.
Treatment #2- Symptomatic with inadequate respiration:
1. Cardiac monitor.
2. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Support ventilations with BVM and O2 15-20 LPM as needed.
4. IV, NS, TKO or saline lock.
5. Naloxone 0.4mg IV/IO or 2mg IM/IN. Repeat for ineffective respirations or RR <10. Max
4mg. Contact base hospital for additional doses
DO NOT titrate to level of consciousness or pupil size.
Considerations:
1. Ventilate patient prior to administration of naloxone.
2. Preferred route is IV. However, if unable to start IV, IM/IO/IN are acceptable.
3. In patients with chronic opioid use, naloxone can induce SEVERE withdrawals including:
A. Pulmonary edema.
B. Seizures.
C. Arrhythmias.
D. Hypertension.
4. Always use the lowest dose possible to obtain an improvement in respirations.

Base Hospital Orders
1. Additional naloxone 2mg.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 121 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-07

Organophosphates Exposure (AODP-07)
Organophosphates are a group of chemicals that poison insects and mammals.
Organophosphates are the most widely used insecticides today. They are used in agriculture,
the home, gardens, and veterinary practice. Organophosphate work by damaging an enzyme
acetylcholinesterase.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibility of organophosphates
exposure but patient is showing no signs or symptoms.
2. Symptomatic- Patient has admitted or history reveals organophosphates exposure and
patient is showing signs and symptoms related to organophosphates exposure, but is still
hemodynamically stable.
3. Grossly Symptomatic- Patient has admitted or history reveals organophosphates
exposure and patient is showing signs and symptoms related to organophosphates
exposure, but is NOT hemodynamically stable.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. If safe to identify:
every 15 minutes for stable patients:
A. Chemical labels.
A. BP.
B. Safety data sheet (SDS).
B. Respirations.
C. Placards.
C. Pulse.
D. Chemical type.
D. SpO2.
E. Chemical amount.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. Blood glucose level.
C. Pain scale.
D. Physical assessment.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Salivation.
1. Agricultural setting.
1. Nerve agent exposure.
2. Lacrimation.
2. Industrial setting.
3. Urination.
4. Defecation.
Common Names
5. Gastrointestinal distress.
1. Parathion.
6. Emesis.
2. Malathion.
3. Methyl parathion.
4. Chlorpyrifos
5. Diazinon.
6. Dichlorvos.
7. Phosmet.
8. Fenitrothion.
9. Tetrachlorvinphos.
10. Azamethiphos.
11. Azinphos-methyl.
12. Terbufos.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 122 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult Overdose Poisoning

AODP-07

Organophosphates Exposure or Ingestion
1. Avoid contamination.
2. Cardiac monitor.
3. Monitor SpO2.
4. Consider IV, NS, TKO.
Treatment #1- Mildly symptomatic:
1. if SpO2 <94%, O2 1-6 LPM via NC, titrate to 94%.
2. IV/IO NS, TKO.
3. If HR <100, atropine 2mg IV/IO every 10 minutes. Max 4mg.
Treatment #2- Grossly symptomatic:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. IV/IO, NS, TKO.
3. Atropine 2mg IV/IO every 5 minutes. Max of 4mg.
4. For seizure activity see protocol ANRO-05.
Considerations
1. Safety is top PRIORITY.
2. Patient must be grossly decontaminated prior to transport.
3. Patient must be fully decontaminated prior to entering ED.
Base Hospital Orders
1. Additional atropine beyond 4 mg.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
Nerve Agent Exposure and EMS Chempack use
If EMS Chempack is deployed and atropine auto injectors, pralidoxime (2-Pam) auto
injectors, and diazepam are available they may be used as follows:
1. Cardiac monitor.
2. Monitor SpO2.
3. Consider IV/IO, NS, TKO.
4. If SBP <90 without fluid overload or history of CHF/Dialysis, NS 500ml IVF bolus. May
repeat, max 2L.
5. If SBP <90 with fluid overload or history of CHF/Dialysis, NS 250ml IVF bolus. May repeat
if no worsening fluid overload, max 1L.
6. If seizing, diazepam 2.5-10mg slow IVP or 10mg IM. May repeat once, max of 20mg.
7. Atropine and 2-pam Auto injectors according to below chart.
Exposure level
Mild Liquid or Vapor
– (Dyspnea
Rhinorrhea,
Wheezing)
Moderate –
(SLUDGE )
Severe – (SLUDGE
and Seizure activity)

Atropine (2mg Auto Injector)
One (1) Auto injector IM (2Mg)
every 3-5 min.

2-Pam (600mg Auto Injector)
If symptomatic after atropine:
One (1) Auto Injector IM (600Mg)
No repeat.

Two (2) Auto injector IM (4Mg)
every 3-5 min.
Three (3) Auto injector IM (6Mg)
every 3-5 min.

One (1) Auto injector IM (600Mg)
may repeat once in 5-10 min.
Three (3) Auto injector IM
(1.8Gms) No repeat.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 123 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 124 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 125 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-01

Sepsis (AGEN-01)
Sepsis is the body's overwhelming and life-threatening response to infection. In sepsis, when
an infection occurs at any potential site in the body, the immune system's inflammatory
response can be overwhelmed leading to SIRS (Systemic Inflammatory Response
Syndrome) which causes tissue damage that can lead to organ dysfunction, failure and
death.
Definitions:
1. SIRS Criteria- possible infection (Abnormal WBC), fever, tachypnea, tachycardia or
hypotension.
2. Asymptomatic- DOES NOT meet TWO or MORE SIRS Criteria.
3. Symptomatic Sepsis- Meets TWO or MORE SIRS criteria, PLUS has source of infection
and is hemodynamically stable.
4. Septic Shock- Meets two or more SIRS criteria and is hemodynamically UNSTABLE.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. Blood glucose level, if diabetic.
C. Pain scale.
D. Physical assessment.
E. Temp.
F. Lung Sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. SIRS Criteria
1. Evidence of infection.
1. Pneumonia.
A. Temp: >38°C or
2. Clotting problems.
2. Abdominal infection.
<36°C.
3. Abnormal liver or kidney
3. Kidney infection / failure.
B. HR >90.
function.
4. Bloodstream infection
C. RR >20.
4. Impaired oxygen
(bacteremia).
2. Significantly decreased
availability.
5. Meningitis.
urine output.
5. Electrolyte imbalances.
6. Encephalitis.
3. Abrupt change in mental
6. Transplant patient.
7. Myocarditis.
status.
7. On active chemotherapy.
4. Difficulty breathing.
8. HIV/AIDs.
5. Abdominal pain.
9. Chronic steroid use.
6. Identifiable infection.
10. Indwelling Foley catheter.
11. Indwelling PIC line.
Home Meds:
1. Antibiotics.
2. Immunosuppressant
medications.
3. Immunomodulatory
medications.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 126 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-01

Sepsis
1. Cardiac monitor.
2. Monitor SpO2.
Treatment #1- Asymptomatic:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Consider 12 lead ECG.
3. Blood glucose level, if <70 mg/dL, see protocol ANRO-03.
4. If ALOC, perform stroke screen. If positive, see protocol ANRO-01.
Treatment #2- Symptomatic meeting TWO or MORE SIRS Criteria with identifiable infection:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Obtain 12 lead ECG.
3. Blood glucose level, if <70 mg/dL, see protocol ANRO-03.
4. If ALOC, perform stroke screen. If positive, see protocol ANRO-01.
5. IV, NS, TKO.
6. NS 500ml IVF bolus may repeat x1.
Treatment #3- Shock with TWO or MORE SIRS Criteria:
1. If SpO2 <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Monitor EtCO2 if using an advanced airway or BVM.
3. Obtain 12 lead ECG.
4. Blood glucose level, if <70 mg/dL, see protocol ANRO-03.
5. If ALOC, stroke screen. If positive, see protocol ANRO-01.
6. IV/IO, NS, TKO.
7. If SBP <90 without fluid overload or history of CHF/Dialysis, NS 500ml IVF bolus. May
repeat, max 2L.
8. If SBP <90 with fluid overload or history of CHF/Dialysis, NS 250ml IVF bolus. May
repeat if no worsening fluid overload, max 1L.
9. If hypotension persists after bolus, dopamine 10mcg/kg/min IV/IO, via dial-a-flow.
OR
10. Epinephrine 10mcg 1:100,000 IV/IO, every 3-5 minutes, titrate to SBP >90.
Considerations:
1. If patient is in shock and does not meet TWO or more SIRS Criteria see protocol ACAR06.
2. SIRS Criteria:
A. Temp: >100.4°F or <96°F.
B. HR >90.
C. RR >20.
3. Always have a high index of suspicion of infection in patients on chronic steroids,
immunomodulatory medications and immunosuppression medications.
To make epinephrine 1:100,000:
1. Mix 9ml NS with 1ml epinephrine 1:10,000

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 127 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-02

Patients From Out Patient Offices (AGEN-02)
This protocol is in place to allow paramedics on a 911 / pre hospital call (Not to include IFT) to
transport patients that may be currently under anesthesia or having an adverse reaction to
out of hospital anesthesia, such as at dental offices or outpatient care facilities.
Definitions:
1.

Local anesthesia- a type of pain prevention used during minor procedures to numb a
small site where the pain is likely to occur without changing the patient's awareness.
2. General anesthesia- a medically induced coma with loss of protective reflexes, resulting
from the administration of one or more general anesthetic agents.
3. Nerve and regional blocks- deliberate interruption of signals traveling along a nerve,
often for the purpose of pain relief.
4. Conscious sedation- is a combination of medicines to help you relax (a sedative) and to
block pain (an anesthetic) during a medical or dental procedure.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 3. Type of anesthetic used.
15 minutes for stable patients:
4. Procedure being performed:
A. BP.
A. Surgical.
B. Respirations.
B. Medical.
C. Pulse.
C. Dental.
2. If performed, before and after intervention
5. Reaction to anesthetic.
or if condition changes:
6. Treatments administered prior to arrival:
A. ECG.
A. Defibrillations.
B. SpO2.
B. Airway management.
C. Blood glucose.
C. Medication administration.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
G. EtCO2.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. ALOC.
1. Outpatient procedure.
1. CVA/TIA.
2. Unconscious.
2. Dental procedure.
2. Hypoglycemia.
3. Apneic.
3. Seizure.
4. Uncontrolled airway.
Possible Anesthetic drugs:
5. History of:
1. Nitrous oxide.
A. Procedural sedation.
2. Ativan.
B. Local anesthesia.
3. Barbiturates:
C. General anesthesia.
A. Amobarbital.
D. Conscious sedation.
B. Methohexital.
C. Thiamylal.
4. Benzodiazepines:
A. Diazepam.
B. Lorazepam.
C. Midazolam.
5. Etomidate.
6. Ketamine.
7. Propofol.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 128 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-02

Patients From Out Patient Offices
Treatment
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC, NRB or BVM, titrate to 94%.
3. Monitor EtCO2 if patient received any sedation or analgesic medications or if using an
advanced airway or BVM.
4. Consider IV/IO, NS, TKO.
5. Consider 12 lead, if STEMI see protocol ACAR-03.
6. Blood glucose level, if <70 mg/dL, see protocol ANRO-03.
7. If patient administered narcotics and RR <10, naloxone 0.4mg IV/IO or 2mg IM/IN, Max
4mg.
Titrate to respirations. DO NOT titrate to level of consciousness or pupil size.
8. If SBP <90 without fluid overload or history of CHF/Dialysis, NS 500ml IVF bolus. May
repeat, max 2L.
9. If SBP <90 with fluid overload or history of CHF/Dialysis, NS 250ml IVF bolus. May repeat
if no worsening fluid overload, max 1L
10. If hypotension persists after bolus, dopamine 10mcg/kg/min IV/IO, via dial-a-flow.
OR
11. Epinephrine 10 mcg 1:100,000 IV/IO, every 3-5 minutes, titrate to SBP >90.
Considerations:
1. Secure airway as appropriate.
2. Advise doctor on scene they may maintain care if they ride with you to ED and they do not
delay transport.
3. Only the base hospital physician can give field personnel orders.
4. Contact the base hospital for any questions or concerns.
To make epinephrine 1:100,000:
1. Mix 9ml NS with 1ml epinephrine 1:10,000.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 129 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-03

Pain Management (AGEN-03)
This protocol is intended for the treatment of pain associated with traumatic injuries, burns, or
medical conditions that cause significant ACUTE pain or SEVERE Exacerbation of chronic
pain.
Definitions:
1. Pain- is a significantly unpleasant sensation, occurring in varying degrees of severity,
which results because of injury, disease, or emotional disorder.
2. Max Single Dose (Max SD)- is maximum medication given in one administration.
3. Max Total Dose (Max TD)- is the most the patient can have overall without a base order.
4. Mild to moderate pain- Pain on movement, chronic pain, or pain that is managed with,
positioning, ice, stabilization, or immobilization.
5. Moderate to Severe Pain- patient pain is unable to be managed with, positioning, ice,
stabilization, or immobilization AND patient is showing outward signs of being
symptomatic secondary to pain. Symptoms may include guarding, grimacing at rest,
tachycardia, tachypnea, hypertension, and diaphoresis, etc.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
A. Pulse.
B. SpO2.
2. If performed, before and after intervention or if condition changes:
C. ECG.
D. Blood glucose.
E. Pain scale.
F. Physical assessment.
G. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Guarding.
1. Recent traumatic
1. Chronic pain exacerbation.
2. Grimacing.
event.
2. Complex Regional pain.
3. Deformity.
2. Chronic pain.
3. Compartment syndrome.
4. Swelling.
4. Nerve injury.
5. Diaphoresis.
6. Splinting.
Pain management medication guidelines:
Medication
Best use
Ketorolac
Mild to moderate pain

Acetaminophen
Ibuprofen
Morphine
Fentanyl

Visceral pain
Somatic pain, or
patients with
hypotension

Contraindications
>65Y/O, GI bleed, pregnancy,
asthma, Acute coronary syndrome,
Coagulation disorders, meets
trauma triage criteria,
anticoagulation medications.
Allergy, Liver failure, ETOH
Intoxication.
Currently taking ASA, or NSAID, GI
bleed, Blood thinner, Pregnant.
Hypotension.
GI obstruction.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 130 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-03

Pain Management
Treatment #1- Mild to Moderate:
1. Elevate as appropriate.
2. Ice as appropriate.
3. Position as appropriate.
4. Stabilize as appropriate.
5. 650mg acetaminophen PO OR 400mg ibuprofen PO (withhold if pregnant).
Treatment #2- Moderate to Severe:
1. Consider Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. IV/IO, NS, TKO.
4. If pain scale >5 & symptomatic from pain see dose chart below.
5. Monitor EtCO2.
Considerations:
1. Treatment should not be based on pain scale alone. Use objective signs to support
treatment.
2. If SBP<100 consider fentanyl for pain management.
3. IM fentanyl shall only be used for patients with difficult IV access (IN may be considered if
patient refuses IM injection).
4. An IO should not be established solely for the purpose of pain management. An IO may
be utilized for pain management where indicated, ONLY if IO was established for other
treatments.
Medication
Max SD
Max TD
Acetaminophen IV
A. 15mg/kg IV over 15 min,
15mg/kg
1,000mg
no repeat
Ketorolac
A. 15mg IV No repeat Or
15Mg
N/A
B. 30 mg IM no repeat
Morphine
A. 2mg slow IV/IO, every 5
2 mg IV
min, Or
20 mg
B. 5-10 mg IM, every 30 min.
10 mg IM
Fentanyl
A. 1 mcg/kg slow, IV/IM/IN/IO, 100 mcg
2 mcg/kg, For burns max TD is
every 5 minutes.
3mcg/kg
Base Hospital Orders
1. Medication dose above listed maximums
2. In the presence of any finding listed below
A. Allergy or sensitivity to the medication being administered.
B. SBP <90.
C. RR <12.
D. History of loss of consciousness.
E. Decreased mental status from patient baseline.
F. Pregnancy greater than 20 weeks.
3. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 131 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-04

Nausea (AGEN-04)
Nausea may be due to a viral illness (e.g. gastroenteritis), motion sickness, or medication
side effects. However, it is important to remember that serious medical conditions also
produce nausea or vomiting such as stroke, head injuries, toxic ingestions, bowel obstruction,
appendicitis, and acute coronary syndrome. Generally, benign causes of nausea or vomiting
do not have any associated pain complaints, or alterations in level of consciousness (LOC).
Definitions:
1. Contraindications- Known sensitivity to ondansetron or other 5-HT-3 antagonists e.g.:
Granisetron (Kytril), Dolasetron (Anzamet), Palonosetron (Aloxi).

Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose if history of diabetes.
D. Pain scale.
E. Physical assessment.
F. Abdominal exam.

Objective Findings:
Possible Signs and
Symptoms
1. Nausea.
2. Vomiting.
3. Abdominal pain.
4. Diarrhea.

Comorbidities
1. Gastritis.
2. Gastroenteritis.

Differentials
1.
2.
3.
4.
5.

AMI.
Appendicitis.
Gall stones.
Kidney stones.
Bowel obstruction.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 132 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Adult General

AGEN-04

Nausea
Treatment #1- Persistent Mild Nausea:
1. Ondansetron 4mg Oral Disintegrating Tablet (ODT).
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
Treatment #2- Persistent Moderate to Severe Nausea:
1. Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Consider 12 lead ECG if concerns for cardiac related complaint.
4. IV, NS, TKO.
5. Ondansetron 4mg IVP over 1 min. May repeat once in 15 minutes OR ondansetron 4mg
ODT, no repeat.
Ondansetron 4mg, may be given via IO, IF IO is established for other treatments. An IO
should not be established solely for the purpose of nausea treatment.
Considerations
1. For patients greater than 55 years of age, perform 12-lead ECG.
2. Rapid administration of ondansetron has been associated with syncope.
3. Rare side effects include headache, dizziness, tachycardia, sedation, or hypotension.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 133 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 134 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Airway Management

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 135 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Airway

PAIR-01

Pediatric Advanced Airway Management (PAIR-01)
Definitions:
1. Pediatric Patient- twelve (12) years of age or younger and is not taller than a weightbased assessment tape (146.5 cm.).

Documentation Standards:
Supraglottic Airway Confirmation:
1. Capnography value and waveform.
2. Bilateral lung sounds.
3. Minimal epigastric sounds.
4. Positive chest rise.
Every 5 minutes and on Gross Patient Movement:
5. Capnography value and waveform.
6. Bilateral lung sounds.
7. Minimal epigastric sounds.
8. Positive chest rise.
At Transfer of Care:
6. Capnography value and waveform.
7. Bilateral lung sounds.
8. Minimal epigastric sounds.
9. Positive chest rise.
10. Name of receiving paramedic or ED physician.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 136 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Airway

Pediatric Advanced Airway Management

PAIR-01

Indications for Supraglottic Airway:
1. Inability of the patient to protect their airway (coma, decreased level of consciousness
with non-intact gag reflex).
2. Inability to adequately ventilate or oxygenate the patient using an OPA and BVM device.
3. Cardiac arrest. Adhere to sequence as specified in EMS Protocol PCAR-03.
4. Failing respirations (irregular and shallow), respiratory arrest.
If patient meets any of above criteria, place supraglottic airway.
Oral Tracheal intubation is outside the paramedic scope of practice in PEDIATRIC
PATIENTS - twelve (12) years of age or younger and is not taller than a weight-based
assessment tape (146.5 cm.).
5. Remove and replace the I-Gel Airway if resistance is met upon initial insertion.
6. After two (2) unsuccessful attempts, place a BLS an airway and transport red lights and
sirens to the closest receiving hospital.
Only use pediatric supraglottic airway if unable to maintain airway with BVM and OPA
Considerations:
1. The approved airway management procedure for the unconscious pediatric patient
consists of the following: providing BLS airway management skills; correctly assessing
the need for an advanced airway; and successfully inserting or an I-Gel Airway ONLY IF
there is no compliance with BVM and OPA.
2. DO NOT delay transport to establish an advanced airway in trauma patients except in the
case of complete airway obstruction, as evidenced by a complete inability to ventilate the
patient using an OPA and BVM device.
3. If unable to establish an airway due to complete airway obstruction not relieved using an
OPA and BVM maneuvers, begin red lights and siren (RLS) transport to closest receiving
hospital. During transport, consider insertion of an I-Gel Airway.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 137 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Airway

PAIR-02

Pediatric Airway Obstruction (PAIR-02)
Definitions:
1. Partial Airway Obstruction- Difficulty breathing but still able to ventilate.
2. Severe Airway Obstruction- Poor air exchange increased breathing difficulty, silent
cough, cyanosis, and/or inability to speak or breathe.
3. Weight based assessment tape Pediatric Emergency Tape- Means a pediatric length
based resuscitation tape used to determine drug doses, fluid volumes, defibrillation
settings, and equipment sizes. The tape is designed to estimate a child’s weight based on
length (head to heel). The tape also includes information about abnormal vital signs.
4. Pediatric Patient- Means a patient that is twelve (12) years of age or younger and is not
taller than a weight-based assessment tape (146.5 cm.).
Documentation Standards:
1. Every 5 minutes for unstable patients, every 10 minutes for stable patients:
A. BP.
B. Respirations.
A. Pulse.
B. SpO2.
2. If performed, before and after intervention or if condition changes:
C. ECG.
D. Blood glucose.
E. Pain scale.
F. Physical assessment.
G. Lung sounds.
Objective Findings
Signs & Symptoms
1. Holding neck (universal
choke sign).
2. Silent cough.
3. Stridor.
4. Inability to speak.
5. Drooling.

Comorbidities
1. Nothing by mouth (NPO
orders).
2. CVA.
3. Brain injury.
4. Choking episode.
5. Coughing while eating.

Differentials
1. Epiglottitis.
2. Esophageal obstruction.
3. Supraglottic stenosis.
4. Vocal cord dysfunction.
5. Retropharyngeal
abscess.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 138 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Airway

PAIR-02

Pediatric Airway Obstruction
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM, NC or NRB, titrate to 94%.
Treatment- Partial Obstruction:
1. Encourage patient to cough.
2. Suction as needed.
Treatment- Complete Obstruction:
1. Initiate back blows and chest thrusts.
2. If conscious and foreign body can be seen when patient opens mouth, remove foreign
body with Magill forceps.
3. If unconscious, remove foreign body with direct laryngoscopy and Magill forceps.
4. Assist ventilations with BVM.
5. If unable to remove, attempt to insert supraglottic airway. Go to closest ED with early
notification to receiving facility.
Considerations
1. Needle Cricothyrotomy is contraindicated in pediatrics.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 139 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 140 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 141 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-01

Neonatal Resuscitation (PCAR-01)
The goal of neonatal resuscitation is to preserve cerebral and coronary function through
meticulous attention to procedure and achieving return of spontaneous circulation (ROSC).
Definitions:
1. High quality CPR - use TEAM approach:
A. 100-120 compressions per minute.
B. 3:1 ratio compression to ventilation ratio.
C. Compress 1/3 depth of chest.
D. Allow complete recoil.
E. Minimize interruptions.
F. Rotate compressors every 2 minutes.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
A. Pulse.
B. ECG.
C. SpO2.
2. If performed, before and after intervention or if condition changes:
D. Blood glucose.
E. Physical assessment.
Objective Findings:
Signs & Symptoms
1. No pulse.
2. Weak pulse.
3. No muscle tone.
4. No cry.
5. Meconium staining.

1.
2.
3.
4.

Comorbidities
Expected complications.
Prolonged delivery.
Delivery complications.
Mother with significant
medical history.

Differentials
1. Still born.
2. Meconium aspiration.
3. Fetal Hypoxia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 142 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-01

Neonatal Resuscitation
1. Cardiac monitor.
2. Monitor SpO2.
3. Wipe and dry nose and mouth.
Treatment #1- Heart Rate >100 :
1. Monitor SpO2.
2. If peripheral cyanosis is present place in sniffing position O2 5-10 LPM via blow by.
3. Reassess heart rate every 30-60 seconds.
Treatment #2- Heart Rate 80-100 BPM:
1. Oxygen 100% via mask or blow by.
2. Stimulate and suction mouth and nose.
If heart rate is <100 BPM, after 30 Seconds of stimulation:
3. Assist ventilations with BVM and 100% oxygen at 40-60 per min.
4. Reassess heart rate and respirations every 15-30 seconds.
Treatment #3- Heart Rate 60-80 BPM:
1. Assist ventilations with BVM and 100% oxygen at 40-60 per min.
If no improvement after 30 seconds of assisted ventilations:
2. Start CPR, 3:1, @120 compressions/min.
Treatment #4- Heart Rate <60 BPM:
1. Assist ventilations with BVM and 100% oxygen at 40-60 per min.
2. Start CPR, 3:1, @120 compressions/min.
If no improvement after 60 seconds:
3. IV/IO, NS, TKO.
4. Epinephrine 0.01mg/kg IV/IO, every 6 minutes.
If no improvement after 60 seconds:
5. Consider supraglottic airway only if unable to ventilate with BVM.
6. If heart rate is >80 BPM, stop chest compressions and continue assisting ventilations.
Considerations
1. Note APGAR Scores at: 1, 3, and 5 minutes.
2. Meconium stain amniotic fluid: suction the mouth and nose of only those patients with a
non-vigorous cry or inability to protect their own airway. If the patient has a strong cry
wipe and dry the mouth and nose. There is no need to aggressively suction.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
APGAR
0
1
2
Score
Appearance
Cyanotic/ Pale
Peripheral cyanosis only
Pink
Heart Rate
0
<100
100-140
Grimace
No response to
Grimace or weak cry
Strong cry
stimulation
Activity
Absent
Flexed arms or legs
Active
Respirations
Absent
Slow or irregular
Loud cry

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 143 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-02

Pediatric Bradycardia (PCAR-02)
Bradycardia is characterized by a decrease in the rate of atrial depolarization due to slowing
of the sinus node. It may be secondary to sinus node disease, increased parasympathetic
tone or drug effects (e.g., digitalis, propranolol or verapamil.) The rhythm is regular or slightly
irregular with the heart rate is below length based treatment tape low value.
Definitions:
1. Asymptomatic- Patient has no complaints related to heart rate.
2. Mildly symptomatic- Patient is symptomatic but hemodynamically stable.
3. Grossly symptomatic- Patient is symptomatic and NOT hemodynamically stable. (Must
have ALOC, chest pain or hypotension related to a slow heart rate).
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. 12 lead.
C. SpO2.
D. Blood glucose.
E. Pain scale.
F. Physical assessment.
G. Skin signs.
H. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Near fainting or fainting
1. Damage to heart tissues
1. High degree heart block.
(syncope).
from heart disease or
2. Decompensated shock.
2. Dizziness or
heart attack.
3. Increased vagal tone.
lightheadedness.
2. Heart disorder present at
4. Accidental OD.
3. Fatigue.
birth (congenital heart
5. Lyme disease.
4. Shortness of breath.
defect).
6. Intracranial hemorrhage.
5. Chest pains.
3. Infection of heart tissue
7. Increased ICP.
6. Confusion or memory
(myocarditis).
problems.
4. A complication of heart
7. Easily tiring during
surgery.
physical activity.
5. Imbalance of chemicals in
the blood, such as
potassium or calcium.
6. Medications, including
some drugs for other
heart rhythm disorders,
high blood pressure and
psychosis.
Home Meds:
1. Beta blockers.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 144 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-02

Pediatric Bradycardia
1. Cardiac monitor.
2. Monitor SpO2.
Treatment #1- Asymptomatic:
1. Consider 12 lead ECG.
DO NOT start IV/IO solely for low HR if patient is asymptomatic.
Treatment #2- Mildly Symptomatic:
1. If SpO2 <94%, O2 1-6 LPM via NC, titrate to 94%.
2. Obtain 12 lead ECG.
3. IV, NS, TKO.
4. If SBP is below length based treatment tape low value, NS 20 ml/kg IVF bolus. Bolus may
repeat twice at 20ml/kg.
Treatment #3- Grossly Symptomatic:
1. If SpO2 <94%, 1-15 LPM O2 via NC or NRB, titrate to 94%.
2. Obtain 12 lead ECG.
3. IV/IO, NS, TKO.
4. If SBP is below length based treatment tape low value, NS 20ml/kg IVF bolus. Bolus may
repeat twice at 20ml/kg.
5. If history or assessment reveals bradycardia is due to increased vagal tone, atropine 0.02
mg/kg IV/IO, max single dose of 1 mg. Repeat once if needed.
6. If SBP remains below length based treatment tape low value after fluids, DILUTED
epinephrine 1ml IV/IO, every 3-5 minutes, titrate to normal age-based SBP.
7. If HR remains <60 BPM after treatment or patient is deteriorating quickly:
8. Start CPR
Considerations:
1. Used approved length based treatment tape to determine heart rate.

To make DILUTED epinephrine:
1. Mix epinephrine 0.01 mg/kg 1:10,000 to a total volume of 10ml with NS.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 145 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-03

Pediatric Medical Cardiac Arrest (PCAR-03)
The goal of cardiac resuscitation is to preserve cerebral and coronary function through
meticulous attention to procedure and achieving return of spontaneous circulation (ROSC).
Definitions:
1. Ventricular Fibrillation (VF)- Bizarre, rapid, irregular, ineffective rhythm with electrical
waveforms varying in size and shape. There is no P wave. QRS complexes are absent.
2. Pulseless Ventricular Tachycardia (pVT)- Regular or slightly irregular rhythm. Heart rate
100 to 200, A-V disassociation, QRS complex distorted, wide (> 0.12 seconds) and bizarre.
No pulse.
3. Asystole- Asystole represents the absence of electrical activity in the heart. There is no
rhythm, although an occasional P wave may be seen. Heart rate is less than five ectopic
beats per minute.
4. Pulseless Electrical Activity (PEA)- The absence of a detectable pulse and the presence
of some type of electrical activity other than VF or pVT.
5. Contraindications for this protocol.
A. Traumatic arrest see protocol PTRA-02.
B. VAD see protocol PCAR-07.
Documentation Standards:
1. Every 5 minutes:
3. Circumstances surrounding the arrest:
A. BP.
A. Estimated down time.
B. Respirations.
B. Onset (witnessed or unwitnessed).
C. Pulse.
C. Preceding symptoms.
2. If performed, before and after intervention
D. Bystander CPR.
or if condition changes:
E. Medications.
A. ECG.
F. Environmental factors (hypothermia,
B. SpO2.
inhalation, and asphyxiation).
C. Capnography.
D. Blood glucose.
E. Physical assessment.
F. Pupils.
G. Lung sounds.
Objective Findings:
Possible Signs and
Possible Medical History
Differentials
Symptoms
1. Congenital heart defects. 1. Respiratory arrest leading
1. Quickly assess for obvious
2. Asthma.
cardiac arrest.
signs of death:
3. Food or insect allergies.
2. Drowning.
A. Decapitation.
3. Hypothermia.
B. Decomposition.
C. Burnt beyond
recognition.
D. Lividity.
E. Rigor mortis.
2. No pulse.
3. No respiration.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 146 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-03

Pediatric Medical Cardiac Arrest
Treatments
1. Begin High Quality CPR:
A. Compressions rate 100 to 120 per minute.
B. Compress 1/3 depth of chest.
C. Allow complete recoil.
D. Minimize interruptions.
2. OPA & BVM with O2,10-15LPM, 15:2 compressions to ventilations.
3. IO
4. NS 20 ml/kg IVF bolus. May repeat x2
5. Initiate epinephrine 0.01 mg/kg 1:10,000 IO as soon as possible and repeat every 6
minutes.
6. Pulse and rhythm check every 2 minutes.
A. Pre-charge defibrillator before every pulse check.
7. If ROSC achieved, initiate transport, see protocol PCAR-05.
Treatment #1- VF/VT:
1. Initial shock 2 Joules/kg, ALL subsequent shocks 4 J/kg. (or manufacturer’s
recommendation)
2. After 3 shocks, lidocaine 1mg/kg IO. Repeat once if after 5 minutes patient remains in
VF/VT.
3. Consider reversible causes.
4. Transport after 15 minutes.
Treatment #2- Asystole/PEA:
1. Continue compressions.
2. Consider reversible causes.
3. Transport after 15 minutes.
Considerations:
1. EARLY EPINEPHRINE.
2. Administer medications beginning of compression cycle.
3. Use i-Gel only if unable to maintain airway with OPA/BVM or if patient has a history of
drowning or respiratory arrest prior to cardiac arrest.
REVERSIBLE CAUSES
1. Hypovolemia- NS 20 ml/kg IVF bolus IO, max 1L.
2. Hypoxia- Maintain ventilations every 3-5 seconds at a ratio of 15:2 compressions to
ventilations.
3. Hydrogen Ion- sodium bicarbonate 1mEq/kg IO.
4. Hypoglycemia- dextrose 10% 5ml/kg or dextrose 50% 1ml/kg.
5. Hypocalcemia- calcium chloride 20mg/kg IO.
6. Hyperkalemia- sodium bicarbonate 1mEq/kg.
7. Hypothermia- Active rewarming with warm IO fluids, start IV if possible, hot packs to
neck and groin.
8. Tension Pneumothorax- Needle decompression.
9. Tamponade, Cardiac- NS 20ml/kg IVF bolus IO, max 1L.
10. Toxins- See protocol PODP-01 to 07.
11. Torsade’s de pointes- magnesium sulfate 25mg/kg IO, max 2g.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 147 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-04

Pediatric Non Traumatic Shock (PCAR-04)
Shock is a syndrome, which is characterized by inadequate tissue perfusion. Shock can have
a variety of underlying causes, including hypovolemia, sepsis, cardiogenic, and anaphylaxis.
Definitions:
1. Asymptomatic- Patient has no complaints.
2. Mildly Symptomatic- Patient has tachycardia, delayed capillary refill and may have low
blood pressure with normal level of consciousness.
3. Grossly Symptomatic- Patient is symptomatic and NOT hemodynamically stable. (Must
have ALOC, mottled skin or hypotension delayed capillary refill).
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Compensated shock:
1. GI bleeding.
1. Myocardial infarction.
Initial often missed stage
2. Vomiting.
2. Septic shock.
of shock characterized by 3. Diarrhea.
3. DKA.
normal to slightly
4. Allergic reaction.
4. Dehydration.
decreased BP and
5. Septicemia.
5. Myocarditis.
tachycardia.
6. Anti-hypertensive O.D.
6. Cardiomyopathy.
2. Decompensated shock:
hypotension and
tachycardia.
3. Irreversible shock:
hypotension and
bradycardia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 148 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-04

Pediatric Non Traumatic Shock
Treatment #1- Mildly Symptomatic:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-6 LPM, NC, titrate to 94%.
3. IV, NS, TKO.
4. If BP is below length based treatment tape low value, NS 20ml/kg IVF bolus. May repeat
bolus twice.
Treatment #3- Grossly Symptomatic:
1. Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. 12 Lead.
4. IV/IO, NS, TKO.
5. If SBP is below length based treatment tape low value, NS 20ml/kg IVF bolus.
May repeat bolus twice
6. If SBP remains below length based treatment tape low value, DILUTED epinephrine 1ml
IV/IO, every 3-5 minutes, titrate to normal age-based SBP.
Considerations:
1. Patients that appear to be mildly symptomatic can be in the compensatory stage of shock.
2. Delayed capillary refill is one of the earliest signs of shock. Fluids should be administered
for delayed capillary refill.
3. Strongly consider checking blood glucose level in these patients. If they are
hyperglycemic, only initial bolus should be given to avoid cerebral edema

To make DILUTED epinephrine:
1. Mix epinephrine 0.01mg/kg 1:10,000 to a total volume of 10ml with NS.

Base Hospital Orders
1. Additional NS 10ml/kg IVF bolus.
2. Dopamine 10mcg/kg/min, via dial-a-flow
3. DILUTED epinephrine 1ml IV/IO, every 2 minutes,
4. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
Dopamine
Suggested: Mix 400mg in 250ml, NS or D5W, using a 60ggts drip set, (60 drops/min = 60 ml/hr)

Weight (kg) Gtts/min=10mcg/kg/min
35-45
15 gtts/min
45-55
20 gtts/min
60-70
25 gtts/min
75-80
30 gtts/min

Weight (kg) Gtts/min=10mcg/kg/min
85-90
35 gtts/min
95-105
40 gtts/min
110 &up
45 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 149 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-05

Pediatric Return of Spontaneous Circulation

(PCAR-05)

The presence of a palpable pulse AND/OR BP for at least 30 seconds after cardiac arrest.
Definitions:
1. Medical Cardiac Arrest- Cardiac arrest with no trauma.
2. Traumatic Arrest- Cardiac arrest secondary to blunt or penetrating trauma.
3. STEMI Receiving Facility- Facility approved by SJCEMSA to receive patients with ST
elevation myocardial infarctions.
Documentation Standards:
1. Every THREE 3 minutes:
A. BP.
B. Respirations.
A. Pulse.
B. SpO2.
C. ECG.
2. If performed, before and after intervention or if condition changes:
D. 12 Lead.
E. Blood glucose.
F. Pain scale.
G. Physical assessment.
H. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Breathing.
1. Congenital heart defects. 1. Sepsis.
2. Coughing.
2. Metabolic disorder.
2. Hypoxia.
3. Movement.
3. Drowning.
4. Palpable pulse.
4. Arrhythmia.
5. Measurable BP.
5. Hyperkalemia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 150 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-05

Pediatric Return of Spontaneous Circulation
1.
2.
3.
4.
5.

Cardiac monitor.
Monitor SpO2, if <94%, O2 1-20 LPM NC, NRB, or BVM, titrate to 94%.
Monitor EtCO2 if using a supraglottic airway or BVM.
12 Lead ECG
IV/IO, NS, TKO.

Treatment #1- Arrest Rhythm VF/VT and SBP below length based treatment tape low value:
1. Lidocaine 1 mg/kg IV/IO if not already given during arrest.
2. NS 20 ml/kg IVF bolus. Do not repeat.
3. If SBP is below length based treatment tape low value after bolus, Dopamine
10mcg/kg/min via dial-a-flow.
OR
4. DILUTED epinephrine 1ml of IV/IO every 3-5 minutes. Titrate to length based treatment
tape SBP low value.
5. If V-Tach persists lidocaine 0.1 mg/kg IV/IO. Make base hospital contact for additional
doses, max total dose of 1 mg/kg.
Treatment #2- Arrest Rhythm Asystole/PEA and SBP below length based treatment tape low
value:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-20 LPM, NC, NRB, or BVM, titrate to 94%.
3. Monitor EtCO2 if using supraglottic airway or BVM.
4. 12 Lead.
5. IV/IO, NS, TKO.
6. NS 20 ml/kg IVF bolus.
7. If low HR, see Bradycardia protocol PCAR-02.
8. If SBP is below length based treatment tape low value after bolus, dopamine
10mcg/kg/min, via dial-a-flow.
OR
9. DILUTED epinephrine 1ml IV/IO, every 2 minutes, titrate to length based treatment tape
low value.
Considerations:
1. All movements should be done delicately.
To make DILUTED epinephrine:
1. Mix epinephrine 0.01mg/kg 1:10,000 to a total volume of 10ml with NS.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
Dopamine- Mix 400mg in 250ml,NS or D5W, using a 60ggts drip set, (60 drops/min = 60
ml/hr)
Weight (kg)
Gtts/min=10mcg/kg/min
Weight (kg)
Gtts/min=10mcg/kg/min
35-45
15 gtts/min
85-90
35 gtts/min
45-55
20 gtts/min
95-105
40 gtts/min
60-70
25 gtts/min
110 &up
45 gtts/min
75-80
30 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 151 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-06

Pediatric Supraventricular Tachycardia (PCAR-06)
Supraventricular tachycardia (SVT), also called paroxysmal supraventricular tachycardia, is
defined as an abnormally fast heartbeat.
Definitions:
1. Asymptomatic- Patient has no complaints related to heart rate.
2. Mildly symptomatic- Patient is symptomatic but hemodynamically stable.
3. Grossly Symptomatic- Patient is symptomatic and NOT hemodynamically stable. (Must
have ALOC, chest pain or hypotension related to a SVT).
4. All Joules- are in biphasic, use of equivalent monophasic dose if equipped to do so is
appropriate. Follow manufacturer’s recommendations for single shocks.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. 12 lead.
C. SpO2.
D. Blood glucose.
E. Pain scale.
F. Physical assessment.
G. Skin signs.
H. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. A fluttering in chest.
1. Congenital heart defect.
1. Atrial fibrillation.
2. Rapid heartbeat
2. Hemodialysis.
2. Atrial flutter.
(palpitations).
3. Dehydration.
3. Shortness of breath.
4. Sepsis.
4. Lightheadedness or
Home Meds:
5. Drug use.
dizziness.
1. Beta blockers.
5. Sweating.
2. Calcium channel
6. A pounding sensation in
blockers.
the neck.
3. Amiodarone.
7. Fainting (syncope) or
4. Sotalol.
near fainting.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 152 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-06

Pediatric Supraventricular Tachycardia
1. Cardiac monitor.
2. Monitor SpO2, if < 94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
3. 12 lead ECG.
Treatment #1- Asymptomatic:
1. DO NOT start IV solely for high HR if patient is asymptomatic.
Treatment #2- Mildly Symptomatic:
1. IV (AC or Higher), NS, TKO.
2. Perform Valsalva’s Maneuver.
3. If SBP is below length based treatment tape low value, NS 20 ml/kg rapid IVF bolus.
4. If no response after 2 minutes, adenosine 0.1 mg/kg rapid IVP followed with 10ml NS IV.
Max of 6mg. May repeat adenosine 0.2 mg/kg rapid IVP, followed with 10ml NS IV. Max
of 12mg.
Treatment #3- Grossly Symptomatic:
1. IV (AC or Higher), NS, TKO.
2. If SBP is below length based treatment tape low value NS 20 ml/kg rapid IVF bolus.
3. If no response after 2 minutes, adenosine 0.2 mg/kg rapid IVP, followed with 10ml NS IV.
4. If no response after 2 minutes to adenosine, synchronized cardioversion 1 J/kg. May
repeat at 2 J/kg.
5. Just prior to synchronized cardioversion, give midazolam 0.1 mg/kg IV/IM. Max TOTAL
dose of 2mg,
OR
6. Midazolam 0.2 mg/kg IN (Half in each nostril). Max TOTAL dose of 2mg.
Considerations:
1. Consider pediatric normal values for heart rate. Infants may have heart rates as high as
220/minute and children may have heart rates as high as 180/minute in the presence of
fever, anxiety, and/or pain.
2. Used approved length based treatment tape to determine heart rate.

Base Hospital Orders
1. Additional synchronized cardioversions.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 153 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-07

Pediatric Ventricular Assist Device (VAD) Failure

(PCAR-07)

The following are key points to remember from this American Heart Association Scientific
Statement about cardiopulmonary resuscitation (CPR) in adults and children with mechanical
circulatory support (MCS).
Definitions:
1. LVAD- Left Ventricular Assist Device.
2. RVAD- Right Ventricular Assist Device.
3. BiVAD- Biventricular Assist Device.
4. Pulsatile- Will have pulsing or rhythmic sound and possible radial pulse, EtCO2 will read
accurately.
5. Continuous flow- Most common, located in patient’s thorax, will have no peripheral
pulses. Utilize monitor generated MAP to assess perfusion EtCO2 will read accurately.
6. HeartMate II- The most commonly implanted device.
7. HeartWare- Older version but still common.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP and MAP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. EtCO2 if using and supraglottic airway or BVM.
D. Blood glucose level.
E. Pain scale.
F. Physical assessment.
G. Lung sounds.
H. Capillary refill

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 154 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-07

Pediatric Ventricular Assist Device (VAD) Failure
Treatment:
1. Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Monitor MAP.
4. Assess capillary refill.
5. Monitor EtCO2 if using and advanced airway or BVM.
6. 12 lead.
7. Blood glucose level, If >70 mg/dL, see protocol PNRO-02.
8. Assess the device to see if it is working:
A.
Gather Information regarding the type of device, the implantation hospital, and/or
the VAD Coordinator contact telephone number.
B.
Telephone number may be available by a tag on the device, on the refrigerator, or
on a medical alert bracelet.
C.
If a caregiver is present, utilize his/her knowledge. Listen to their directions
regarding VAD device management until you are able to contact the VAD
Coordinator. The VAD Coordinator can help you decide the best course of action
regarding assessment of the equipment. NOTE: Only the base hospital is
legally allowed to give orders regarding patient care.
9.
If the patient has a continuous flow VAD (non-pulsatile/pulseless), auscultate the left
upper quadrant of the patient’s abdomen for the “hum” of the VAD, which can help direct
the appropriate actions.
10. A pulsatile VAD will make an audible sound without auscultation. Pulsatile VADs are
usually older devices which pump blood via pulsatile mechanism, generating a
peripheral pulse.
11. Determine if the device has power.
A.
If the device has power, you will see a green light on the HeartMate II, the most
commonly implanted device
B.
On the HeartWare device, the display will clearly tell you the Liters per Minute
(LPM) of blood flow.
12. Check the VAD for secure connections and that the batteries are charged and
functional.
If a VAD is definitively confirmed by a trained person and there are no signs of life, no MAP
and no pulse, and EtCO2 <20mmHg
13. Start CPR see protocol PCAR-03.
Considerations
1. While pulse oximetry can be used in patients with a VAD, the results may not be accurate
because of the lack of pulsatile flow.
2. A EtCO2 <20mmHg in an unresponsive, correctly intubated, pulseless patient with a VAD
would seem to be a reasonable indicator of poor systemic perfusion and should prompt
rescuers to initiate chest compressions.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 155 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-08

Pediatric Sustained Ventricular Tachycardia with a Pulse

(PCAR-08)

A regular or slightly irregular rhythm, heart rate 100 to 200 and wide >0.12 seconds QRS
complex.
Definitions:
1. Sustained Ventricular Tachycardia- Runs of ventricular tachycardia lasting longer than
30 seconds.
2. Asymptomatic- Patient has no complaints related to heart rate.
3. Mildly Symptomatic- Patient is symptomatic but hemodynamically stable.
4. Grossly Symptomatic- Patient is symptomatic and NOT hemodynamically stable. (Must
have ALOC, chest pain or hypotension related to a VT).
5. All Joules- Are in monophasic, use of equivalent Biphasic dose if equipped to do so is
appropriate. Follow manufacturer’s recommendations for single shocks.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. 12 lead.
C. SpO2.
D. Blood glucose level.
E. Pain scale.
F. Physical assessment.
G. Skin signs.
H. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Dizziness.
1. Congenital heart defect.
1. Aberrancy.
2. Shortness of breath.
2. Hemodialysis.
2. Hyperkalemia.
3. Lightheadedness.
3. Tricyclic antidepressant
4. Feeling as if your heart is
overdose.
racing (palpitations).
Home Meds:
5. Chest pain (angina).
1. Beta Blockers.
6. Loss of consciousness or 2. Calcium Channel
fainting.
blockers.
3. Amiodarone.
4. Sotalol.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 156 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Cardiac

PCAR-08

Pediatric Sustained Ventricular Tachycardia with a Pulse
1.
2.
3.
4.

Cardiac monitor.
Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
12 lead ECG.
IV, NS, TKO.

Treatment #1- Asymptomatic:
1. Lidocaine 0.5mg/kg IV.
If V-Tach persists:
2. Lidocaine 0.5mg/kg IV, No repeat.
Treatment #2- Mildly Symptomatic:
1. Lidocaine 1mg/kg IV.
If V-Tach persists:
2. Lidocaine 0.5mg/kg IV, every 5 minutes, max total dose of 3mg/kg.
Treatment #3- Grossly Symptomatic:
1. midazolam 0.1mg/kg IV/IM, max total dose of 2mg,
OR
2. Midazolam 0.2mg/kg IN, (Half in each nostril), max total dose of 2mg.
3. Synchronized cardioversion 1 J/kg.
If no cardioversion:
4. Synchronized cardioversion 2 J/kg.
Considerations:
1. Do not delay synchronized cardioversion for IV access and premedication with
midazolam.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 157 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 158 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 159 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-01

Pediatric Bronchospasms (PRSP-01)
Bronchospasm occurs when the airways (bronchial tubes) go into spasm and contract. This
makes it hard to breathe and causes wheezing (a high-pitched whistling sound).
Bronchospasm can also cause frequent coughing without wheezing. Bronchospasm is often
due to irritation, inflammation, or allergic reaction of the airways. People with asthma get
bronchospasm. However, not everyone with bronchospasm has asthma.
Definitions:
1. Mild Respiratory Distress- means mild wheezing, shortness of breath and/or cough, and
ability to speak full sentences.
2. Moderate Respiratory Distress- means spontaneous breathing and adequate tidal
volume with significant wheezing/SOB accompanied by any of the following signs:
accessory muscle use, nasal flaring, grunting, and/or inability to speak full sentences.
3. Severe Respiratory Distress- means ineffective ventilations and/or inadequate tidal
volume, which may be accompanied by any of the following signs: accessory muscle use,
cyanosis, inability to speak, gasping respirations, and/or decreased level of
consciousness.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
A. Pulse.
B. SpO2.
2. If performed, before and after intervention or if condition changes:
C. ECG.
D. Blood glucose if history of diabetes.
E. Pain scale.
F. Physical assessment.
G. Lung sounds before and after treatment.
H. Capillary refill
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Respirations <10 or >30
1. Asthma.
1. Smoke inhalation.
per minute, rhythm
2. Allergic reaction.
(abnormal pattern,
Home Meds:
3. Anaphylaxis.
shallow), effort (labored). 1. Albuterol.
4. Respiratory distress
2. Lung sounds (wheezing,
2. Atrovent.
syndrome.
stridor), cough, fever,
5. Pulmonary hemorrhage.
spitting/coughing up
6. Pneumonia.
blood or pink froth,
barking.
3. Rash.
4. Urticaria.
5. Restlessness.
6. Fever.
7. Sputum production.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 160 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-01

Pediatric Bronchospasms
1. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Capillary refill.
Treatment #1- Mild Bronchospasm:
1. Albuterol 2.5mg/3ml NS, via nebulizer, repeat as needed.
Treatment #2- Moderate Bronchospasm:
1. Cardiac monitor.
2. Albuterol 2.5mg/3ml NS & atrovent 0.5mg/2.5ml NS via nebulizer, do not repeat atrovent
administration without BHO.
3. Repeat albuterol 2.5mg/3ml NS every 5 minutes as needed.
4. Consider IV, NS, TKO.
Treatment #3- Severe Bronchospasm:
1. Cardiac monitor.
2. Albuterol 2.5 mg/3ml NS & atrovent 0.5mg/2.5ml NS via nebulizer, do not repeat atrovent.
3. Repeat albuterol 2.5mg/3ml NS every 5 minutes as needed
4. 12 Lead ECG.
5. IV, NS, TKO.
If significant wheezes and SOB after albuterol 10mg:
6. Magnesium Sulfate 75 mg/kg, max single dose 2g, IV/IO, in 250ml NS, infusion over 20
minutes.
If patient DOES NOT show signs of improvement or is deteriorating rapidly:
7. Epinephrine 0.01 mg/kg 1:1,000 IM, Max dose of 0.5mg.
If necessary, assist ventilations with BVM 100% oxygen and initiate an inline nebulizer
treatment with albuterol 2.5mg/3ml.
Considerations:
1. Suction as needed.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
2. Additional Dose of atrovent, 0.5mg/2.5ml NS, via nebulizer.
3. Additional dose epinephrine 0.01 mg/kg 1:1000 IM, max dose of 0.5mg IM

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 161 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-02

Pediatric Croup (PRSP-02)
Croup refers to an infection of the upper airway, which obstructs breathing and causes a
characteristic barking cough.
Definitions:
1. Croup without stridor- Is characterized by a brassy or “barking” cough and hoarseness.
The focus of treatment should be on keeping the patient calm.
2. Croup with stridor- Stridor is a harsh, crowing, or vibratory sound of variable pitch that
results from turbulent airflow caused by partial obstruction of the respiratory passages.
Audible without a stethoscope, stridor always warrants immediate attention because it
may be the first sign of a serious or life-threatening process.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
A. Pulse.
B. SpO2.
2. If performed, before and after intervention or if condition changes:
C. ECG.
D. Blood glucose level.
E. Pain scale.
F. Physical assessment.
G. Lung sounds.
3. Vaccine history.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Barking cough.
1. Recent illness.
1. Epiglottitis.
2. Raspy voice.
2. Upper respiratory
2. Smoke inhalation.
3. Fever.
infection.
3. Allergic reaction.
4. Hoarse voice.
4. Anaphylaxis.
5. Tachypnea.
Home Meds:
5. Foreign body airway
6. Lethargy.
1. Steroids
obstruction.
(Dexamethasone,
Prednisone).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 162 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-02

Pediatric Croup
Treatment #1- Without Stridor:
1. Keep patient calm.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC, NRB or blow by, titrate to 94%.
Do not use humidified O2 or nebulized saline.
Treatment #2- With Stridor:
1. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB or blow by, titrate to 94%.
2. Consider cardiac monitor.
If HR <200 and no cardiac history:
3. 2.25% racemic epinephrine 0.5mL in 2.5 mL NS via nebulizer.
OR
4. Epinephrine 2.5 mg 1:1,000 via nebulizer.
Considerations:
1. Suction as needed.
2. Keep patient calm as symptoms can worsen with agitation.
3. If signs of allergic reaction, see protocol PENV-01.
4. If signs of foreign body airway obstruction, see protocol PAIR-02.
5. If wheezing, see protocol PRSP-01.

Base Hospital Orders
1. Racemic epinephrine or nebulized epinephrine if patient has a cardiac history.
2. Additional dose of racemic epinephrine or nebulized epinephrine
3. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 163 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-03

Pediatric Epiglottitis (PRSP-03)
Epiglottitis is a potentially life-threatening condition that occurs when the epiglottis swells,
blocking the flow of air into your lungs. A number of factors can cause the epiglottis to swell
such as burns from hot liquids, direct injury to your throat and various infections.
Definitions:
1. Epiglottitis without stridor- Potentially life-threatening condition that occurs when the
epiglottis swells, blocking the flow of air into your lungs. The primary goal for presentation
of epiglottis with no stridor is keeping patient calm and transporting smoothly. Patient may
present with a history of infection and may be drooling or have difficulty swallowing.
2. Epiglottitis with stridor - Patients at this stage have audible high pitched respirations
secondary swelling in the upper airway. Great care should be taken to avoid respiratory
failure. Keep patient calm and transport smoothly.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose level.
D. Pain scale.
E. Physical assessment.
F. Lung sounds before.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Fever.
1. Recent illness.
1. Smoke inhalation.
2. Severe sore throat.
2. Recent upper airway
2. Allergic reaction.
3. Abnormal, high-pitched
infection.
3. Anaphylaxis.
sound when breathing in
(stridor).
Home Meds:
4. Difficult and painful
1. Antibiotics (Cipro, PCN).
swallowing.
5. Drooling.
6. Anxious, restless
behavior.
7. Position of comfort may
be sitting up or leaning
forward.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 164 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-03

Pediatric Epiglottitis
Treatment #1- Without Stridor:
1. Keep patient calm.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
If can be done without increasing agitation or crying:
3. Consider nebulized NS or humidified O2.
Treatment #2- With Stridor:
1. Keep patient calm.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Consider cardiac monitor.
4. Epinephrine 1:1,000 2.5mg nebulized
OR
5. 2.25% racemic epinephrine 0.5 mL mix in 2.5 mL NS via nebulizer.
If respiratory failure:
6. Ventilate with BVM and oral airway
7. Administer racemic epinephrine or epinephrine 1:1,000 via inline nebulizer.
Do not attempt to visualize airway:
8. Place supraglottic airway ONLY IF UNABLE TO VENTILATE with BVM and oral airway.
Considerations:
1. Suction as needed.
2. Keep patient calm as symptoms can worsen with agitation.
3. If signs of allergic reaction, see protocol PENV-01.
4. If signs of foreign body airway obstruction, see protocol PAIR-02.
5. If wheezing, see protocol PRSP-01.
6. Supraglottic airway can cause additional inflammation and must be used sparingly.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 165 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-04

Pediatric Smoke Inhalation (PRSP-04)
Smoke inhalation is the leading cause of death due to fires. It produces injury through several
mechanisms, including thermal injury to the upper airway, irritation or chemical injury to the
airways from soot, asphyxiation, and toxicity from carbon monoxide (CO) and other gases
such as cyanide.
Definitions:
1. Asymptomatic- Known significant exposure to smoke with no complaints or symptoms.
2. Mildly Symptomatic- Known significant exposure to smoke, with signs and symptoms,
such as weakness or mild shortness of breath.
3. Grossly Symptomatic- Known significant exposure to smoke, with serious signs and
symptoms, such as ALOC, severe shortness of breath, unconscious.
4. Carbon Monoxide- Is a colorless, odorless, and tasteless poisonous gas that can be fatal
when inhaled. CO inhibits the blood’s capacity to carry oxygen. CO can be produced
when burning any fuel. CO is a byproduct of incomplete combustion.
5. Smoke Inhalation- Suspected in patients rescued from fires or exposed to smoke.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. Pain scale.
C. Physical assessment.
D. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Symptoms of CO poisoning: 1. Exposure closed space
1. Pulmonary edema.
A. Similar to flu with no
fires.
2. CO poising.
fever.
B. Dizziness.
C. Severe headaches.
D. Nausea.
E. Sleepiness.
F. Fatigue/weakness.
G. Disorientation/confusion.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 166 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Respiratory

PRSP-04

Pediatric Smoke Inhalation
Treatment #1- Asymptomatic:
1. Monitor SpO2, if <94% 1-6 LPM O2 via NC, titrate to 94%.
Treatment #2- Mildly Symptomatic:
1. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Cardiac monitor.
If suspected CO poisoning and SpO2 >94%:
3. Administer O2 at 15LPM via NRB.
4. IV, NS, TKO.
If wheezing:
5. See protocol PRSP-01.
If SBP is below length based treatment tape low value, and lung sounds are clear:
6. NS 20ml/kg IVF bolus, may repeat x2.
Treatment #3- Grossly Symptomatic:
1. Monitor SpO2, if <94% 1-15 LPM O2 via NC or NRB, titrate to 94%.
2. Cardiac monitor.
If suspected CO poisoning and SpO2 >94%:
3. O2 at 15LPM via NRB.
4. IV, NS, TKO.
If wheezing:
5. See protocol PRSP-01.
If SBP is below length based treatment tape low value, and lung sounds are clear:
6. NS 20ml/kg IVF bolus, may repeat twice.
If seizing:
7. See protocol PNRO-04.
If dysthymias occur:
8. See protocols PCAR-01 to 08.
Considerations:
1. Completely remove victim’s clothing prior to transport.
2. Evaluate patient for facial burns, hoarseness, black sputum, and soot in the nose or
mouth.
3. Pulse oximetry values may be unreliable in smoke inhalation patients.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 167 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 168 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurologic

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 169 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-01

Pediatric Hyperglycemia (PNRO-01)
An excess of glucose in the bloodstream, often associated with diabetes mellitus.
Definitions:
1. Asymptomatic- No symptoms or complaints related to blood glucose level.
2. Mildly Symptomatic Showing symptoms of hyperglycemia such as polyuria, polydipsia
and dehydration.
3. Grossly Symptomatic- ALOC, confusion.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
1. Frequent urination.
2. Increased thirst.
3. Blurred vision.
4. Fatigue.
5. Headache.
6. Fruity-smelling breath.
7. Nausea and vomiting.
8. Shortness of breath.
9. Dry mouth.
10. Weakness.
11. Confusion.
12. Coma.
13. Abdominal pain.

Comorbidities
1. Insulin dependent
diabetes.
2. Non-insulin dependent
diabetes.
Home Meds:
1. Insulin.
2. Glucophage.

1.
2.
3.
4.
5.
6.
7.

Differentials
CVA.
ETOH intoxication.
Overdose.
Sepsis.
Dehydration.
DKA.
Hyperosmolar
hyperglycemic nonketotic
state HHNK.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 170 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-01

Pediatric Hyperglycemia
Treatment #1- Asymptomatic:
1. Obtain blood glucose level.
If blood glucose level >180 mg/dL:
2. DO NOT initiate IV solely for high blood glucose.
3. Notify receiving nurse/physician.
Treatment #2- Mildly Symptomatic:
1. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
2. Obtain blood glucose level.
If blood glucose level >300 mg/dL
3. IV, NS, TKO.
If no fluid restriction exists and lungs are clear:
4. NS 10 ml/kg IVF bolus. Do not repeat.
Treatment #2- Grossly Symptomatic:
1. Cardiac monitor.
2. Monitor SpO2, if <94% 1-15 LPM O2 via NC or NRB, titrate to 94%.
3. Obtain blood glucose level.
If Blood glucose level >300 mg/dL:
4. IV, NS, TKO
If no fluid restriction exists and lungs are clear:
5. NS 10ml/kg IVF bolus. May repeat 10 ml/kg IVF bolus x 1 if capillary refill is delayed.
Considerations:
1. It is imperative to rule out other causes of ALOC.
2. In pediatric patients with hyperglycemia, aggressive fluid resuscitation can cause cerebral
edema.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 171 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-02

Pediatric Hypoglycemia (PNRO-02)
Hypoglycemia is a condition caused by a very low level of blood glucose, your body's main
energy source.
Definitions:
1. Asymptomatic- No symptoms or complaints related to blood glucose level.
2. Mildly Symptomatic- Showing symptoms of hypoglycemia such as confusion abnormal
behavior or poor skin signs.
3. Grossly Symptomatic- Loss of consciousness or unconscious, seizure activity.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. An irregular heart rhythm. 1. Insulin dependent
1. CVA.
2. Fatigue.
diabetes
2. ETOH intoxication.
3. Pale skin.
2. Non-insulin dependent
3. Overdose.
4. Shakiness.
diabetes.
4. Shock.
5. Anxiety.
3. Malnutrition.
5. Sepsis.
6. Sweating.
7. Hunger.
8. Irritability.
Home Meds:
9. Confusion.
1. Insulin.
10. Abnormal behavior.
2. Glucophage.
11. Visual disturbances.
12. Blurred vision.
13. Seizures.
14. Loss of consciousness.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 172 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-02

Pediatric Hypoglycemia
1. Obtain blood glucose.
Treatment #1- Asymptomatic:
1. If blood glucose <70 mg/dL with diabetes history: Administer oral glucose.
2. If patient has NO DIABETES HISTORY administer oral glucose and notify receiving
facility.
Treatment #2- Mildly Symptomatic:
1. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
If less than 70 mg/dL: IV, NS, TKO.
Child >2 years of age
2. Consider oral glucose.
3. Dextrose 50% 1ml/kg IV/IO, titrate to blood glucose level >70 mg/dL,
OR
4. Dextrose 10% 5ml/kg IV/IO, titrate to blood glucose level >70 mg/dL.
Child <2 years of age
5. Dextrose 10% 5ml/kg IV/IO, titrate to blood glucose level >70 mg/dL.
Treatment #3- Grossly Symptomatic:
1. Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Obtain blood glucose level.
If blood glucose level <70 mg/dL:
4. IV/IO, NS, TKO.
Child >2 years of age
5. Dextrose 50% 1ml/kg IV/IO, titrate to blood glucose level >70 mg/dl,
OR
6. Dextrose 10% 5ml/kg IV/IO, titrate to blood glucose level >70 mg/dl.
Child <2 years of age
7. Dextrose 10% 5ml/kg IV/IO, titrate blood glucose level >70 mg/dl.
Considerations:
1. Dextrose 10% is the preferred concentration in pediatric patients.
2. If ALOC continues after Dextrose, go to protocol PNRO-03.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 173 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-03

Pediatric New Onset A.L.O.C. Unknown Etiology

(PNR O-03)

A mildly depressed level of consciousness or alertness may be classed as lethargy. Someone
in this state can be aroused with little difficulty. People who are obtunded have a more
depressed level of consciousness and cannot be fully aroused. Those who are not able to be
aroused from a sleep-like state are said to be stuporous. Scales such as the Glasgow coma
scale have been designed to measure the level of consciousness.
Definitions:
1. New Onset- No medical history that would cause a chronic altered level a of conscious
or a decrease in patients normal level of consciousness.
2. CPSS- Cincinnati Prehospital Stroke Scale.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Stroke screen.
G. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Evidence of trauma.
1. Recent fall.
1. Alcohol intoxication.
2. Recent infections.
2. Epilepsy.
2. Fever.
3. Chang in medications.
3. Hypo/Hyperglycemia.
3. Cough.
4.
Stopped
medications
4. Over/Underdose.
4. Fatigue.
5.
Accidental
overdose.
5. Trauma.
5. Shakiness.
6.
ETOH
abuse.
6. Sepsis.
6. Skin color changes.
7.
Liver
disease.
7. Shock.
7. Snoring respirations.
8. Behavioral.
Home Meds
1. Lactulose.
2. Narcotics or pain meds.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 174 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-03

Pediatric New Onset A.L.O.C. Unknown Etiology
Treatment #11. Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via BVM, NC or NRB, titrate to 94%.
3. Monitor EtCO2 if using an supraglottic airway or BVM.
4. Obtain blood glucose level, if <70 mg/dL, see protocol PNRO-02. If blood glucose level
>200 mg/dL, see protocol PNRO-01.
5. 12 lead ECG.
If presenting with serious signs and symptoms that do not fit into any other protocol:
6. IV, NS, TKO.
Considerations
1. Alcohol - Maintain airway as needed. If SBP below length based treatment tape low value,
see protocol PCAR-04.
2. Epilepsy - If postictal, maintain airway as needed. If seizing, see protocol PNRO-04.
3. Insulin - If blood glucose level >70 mg/dL, see protocol PNRO-01. If blood glucose level
<70 mg/dL, see protocol PNRO-02.
4. Overdose/ Underdose - See protocols PODP-01 to 07. If no reversible causes and serious
signs and symptoms, consider IV/IO.
5. Trauma - See protocol PTRA-01.
6. Infection - See protocol PGEN-05.
7. Psychosis - This should be considered only after all other potential causes are ruled out.
8. Shock - See protocol PCAR-04.
9. Stroke/Intracranial hemorrhage - assess pupil equality, presence of headache, posturing,
abnormal neuro exam – alert receiving hospital of abnormal findings.

Verbal

4
3
2
1
6
5
4
3
2
1

Motor

Score
4
3
2
1
5

EYE

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Child 4-14
Spontaneous
To Speech
To Pain
None
Age appropriate
orientation
Confused or disoriented
Inappropriate Words
Incompressible speech
None
Follows Commands
Localizes
Withdraws
Decorticate Posture
Decerebrate poster
None

Glasgow Coma Scale
Child 1-3
Spontaneous
To Speech
To Pain
None
Speaks and Social

Infant <1 Year
Spontaneous
To Speech
To Pain
None
Coos and babbles

Disoriented, Consolable
Inappropriate Words, Inconsolable
Incompressible speech, agitated
None
Moves Spontaneously
Moves purposefully
Withdraws to Pain
Abnormal Flexion
Abnormal Extension
None

Irritable cry’s
Cry’s to pain
Moans to pain
None
Moves Spontaneously
Moves purposefully
Withdraws to Pain
Abnormal Flexion
Abnormal Extension
None

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 175 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-04

Pediatric Seizures (PNRO-04)
A seizure is a sudden, uncontrolled electrical disturbance in the brain. It can cause changes
in your behavior, movements, or feelings, and in levels of consciousness. In the prehospital
setting, our goal is the management of generalized seizure activity that may affect respiratory
drive or airway patency.
Definitions:
1. Tonic Seizures- Tonic seizures cause stiffening of your muscles. These seizures usually
affect muscles in your back, arms, and legs and may cause you to fall to the ground.
2. Clonic Seizures- Clonic seizures are associated with repeated or rhythmic, jerking
muscle movements. These seizures usually affect the neck, face, and arms.
3. Tonic-Clonic Seizures- Tonic-Clonic seizures, previously known as grand mal seizures,
are the most dramatic type of epileptic seizure and can cause an abrupt loss of
consciousness, body stiffening, and shaking, and sometimes loss of bladder control or
biting your tongue.
4. Recurrent Seizure- Seizure witnessed by prehospital personnel lasting >2 minutes OR
patient having two (2) or more seizures without regaining consciousness.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. Blood glucose.
C. Pain scale.
D. Physical assessment
E. Pupils.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Evidence of trauma.
1. CVA.
1. Recent infection.
2. High temperature
2. Tetany.
2. Fever.
(febrile state).
3. Meningitis.
3. Trauma.
3. Current seizure activity. 4. Environment (heat/cold).
4. Encephalitis.
4. Medical information
5. Hypertension.
5. Epilepsy.
tags, bracelets, or
6. Drug OD.
medallions.
Home Meds:
1.
2.
3.
4.
5.
6.
7.
8.

Acetazolamide(Acetazolam).
Carbamazepine (Tegretol).
Clobazam (Frisium).
Clonazepam (Rivotril).
Diazepam (Valium).
Ethosuximide (Zarontin).
Gabapentin (Neurontin).
Lamotrigine (Lamictal).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 176 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Neurological

PNRO-04

Pediatric Seizures
1. Cardiac monitor.
2. 2-15 LPM via NC or NRB, titrate to 94%.
Treatment #1- Recurrent Seizure Treatment:
3. Obtain blood glucose level, if <70 mg/dL, see protocol PNRO-02. If >200 mg/dL, AVOID
fluids and notify receiving facility
4. If febrile, start active cooling measures, avoid midazolam unless seizure is >5 minutes.
See protocol PGEN-05.
5. IV, NS, TKO.
6. Midazolam 0.1 mg/kg IV/IM/IO, max of 5 mg,
OR
7. Midazolam 0.2 mg/kg IN (half in each nostril), max of 5mg.
Treatment #2- Continued Seizure Activity:
If after 5 minutes, initial dose has NOT lessened or stopped seizure activity:
1. Midazolam 0.1 mg/kg IV/ IM/IO, max total dose of 10 mg,
OR
2. Midazolam 0.2 mg/kg IN (Half in each nostril), max total dose of 10 mg.
If patient is showing signs of respiratory compromise secondary to seizure activity:
3. Support ventilations with BVM and OPA.
4. Suction as needed.
Considerations:
1. Protect patient from further injury – move furniture and ensure safe area for treatment.
2. Spinal stabilization as indicated.
3. DO NOT forcibly restrain patient during seizure activity.
4. If narcotic overdose is suspected, refer to protocol PODP-06.

Base Hospital Orders
1. Make base contact for additional medication if seizures continue after maximum dose of
midazolam.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 177 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 178 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 179 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-01

Pediatric Allergic Reaction/Anaphylaxis

(PENV-01)

Allergic reactions occur when your immune system reacts to a foreign substance and can
range from mild to severe.
Anaphylaxis is a severe, potentially life-threatening allergic reaction. It can occur within
seconds or minutes of exposure.
Definitions:
1. Mild- Hives, rash to arms or legs, itching, anxiety.
2. Moderate- Hives, rash to torso, bronchospasm, wheezing, nausea, delayed capillary refill.
3. Severe- Respiratory distress, chest tightness, difficulty swallowing, altered mental status.
4. Anaphylactic shock- Signs of hemodynamic instability, tachycardia, ALOC, hypotension,
syncope.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
D. SpO2.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. Blood glucose level.
C. Pain Scale.
D. Physical assessment.
E. Skin assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Sneezing.
1. Known allergy.
1. Asthma.
2. Itching of the nose, eyes
2. Asthma.
2. Toxic exposure.
or roof of the mouth.
3. Runny, stuffy nose.
Home Meds:
4. Swelling of the lips,
1. Epi-pen.
tongue, face or throat.
2. Diphenhydramine.
5. Hives.
6. Edema at the sting site.
7. Cough, chest tightness,
wheezing or shortness of
breath.
8. Loss of consciousness.
9. A drop in BP.
10. Urticaria.
11. Lightheadedness.
12. A rapid, weak pulse.
13. Nausea and vomiting.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 180 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-01

Pediatric Allergic Reaction/Anaphylaxis
Treatment #1- Mild Reaction:
1. Age >2 years of age, diphenhydramine 1mg/kg PO, max of 50 mg.
Treatment #2- Moderate Reaction:
1. Consider IV, NS, TKO.
2. Diphenhydramine 1mg/kg PO/IV/IM, max 50mg.
3. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
4. If wheezing, albuterol 2.5 mg/3ml NS via nebulizer, repeat as needed.
Treatment #3- Severe Reaction:
1. Monitor SpO2, if <94%, 1-15 LPM O2 via NC or NRB, titrate to 94%.
2. Cardiac monitor.
3. IV/IO, NS, TKO.
4. Epinephrine 0.01 mg/kg 1:1,000 IM in lateral thigh, max 0.3mg.
5. Diphenhydramine 1 mg/kg IM/IV/IO, max dose of 50mg.
6. If wheezing, albuterol 2.5 mg/3ml NS via nebulizer, repeat as needed.
7. If stridor, 2.25% racemic epinephrine 0.5mL nebulized in 2.5mL NS.
Treatment #4- Anaphylactic Shock:
1. Monitor SpO2, if <94% 1-15 LPM O2 via NC or NRB, titrate to 94%.
2. Cardiac monitor.
3. IV/IO, NS, TKO.
4. Epinephrine 0.01 mg/kg 1:1,000 IM to lateral thigh, max 0.5mg.
5. If wheezing, albuterol 2.5 mg/3ml NS via nebulizer, repeat as needed.
6. Diphenhydramine 1 mg/kg IM/IV/IO, max dose of 50mg.
7. If stridor, 2.25% racemic epinephrine 0.5mL Nebulized in 2.5mL NS.
8. If SBP is below length based treatment tape low value, without evidence of fluid overload
NS 20ml/kg IVF bolus, may repeat x2.
9. If after 3 fluid boluses and SBP is below length based treatment tape low value, dopamine
10mcg/kg/min via dial-a-flow,
OR
10. DILUTED epinephrine 1ml IV/IO every 3-5 minutes as needed, titrate to length based
appropriate SBP, normal mental status or brisk capillary refill.
If patient becomes unresponsive with no pulses:
11. Epinephrine 0.01 mg/kg 1:10,000 IV/IO, max of 0.5mg then go to Pediatric cardiac arrest
protocol PCAR-03.
Considerations:
1. Attempt to identify allergen if it can be done SAFELY.
2. Remove allergen if possible.
3. If patient or Optional Skill EMT-B gives epi auto injector prior to arrival and patient is:
A. Asymptomatic: give diphenhydramine 1mg/kg PO, max dose 50mg.
B. Mildly symptomatic: give diphenhydramine 1 mg/kg IM/IV, max dose of 50mg.
To make DILUTED epinephrine:
1. Mix epinephrine 0.01mg/kg 1:10,000 to a total volume of 10ml with NS.
Base Hospital Orders
1. To increase diluted epinephrine pushes to every 2 minutes
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 181 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-02

Pediatric Bites & Envenomation (PENV-02)
Common poisonous spiders to the Central Valley are the brown widow (brown with orange
hourglass on belly) and black widow (black with red hourglass on body) spiders and the
brown recluse spider. The only indigenous poisonous snake in the Central Valley is the
rattlesnake.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
1. Abrasions.
2. Punctures.
3. Swelling and edema.
4. Pain to site.

Comorbidities
1. Working on or around
woodpiles or agriculture
storage.
2. Hiking.

1.
2.
3.
4.
5.
6.

Differentials
Abscess.
Cellulitus.
Necrosis.
Necrotizing fasciitis.
Allergic reaction.
Anaphylaxis.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 182 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-02

Pediatric Bites & Envenomation
Treatment #1- Animal Bite:
1. Ensure personal safety.
2. Clean and dress wound as appropriate.
3. For possible fracture, see protocol PTRA-01.
4. For complaint of pain, apply ice packs.
5. If pain continues, consider pain management see protocol PGEN-03.
Treatment #2- Insect Bite or Sting:
1. Ensure personal safety.
2. Scrape away stinger if appropriate; DO NOT squeeze venom sac.
3. If allergic reaction or anaphylaxis, see protocol PENV-01.
4. For complaint of pain apply ice packs.
5. If pain continues, consider pain management see protocol PGEN-03.
6. Consider cardiac monitoring if tachycardic or bradycardic heart rates per child age.
7. Consider monitoring SpO2, if <94%, O2 1-6 LPM, NC, titrate to 94%.
Treatment #3- Snake Bite:
1. Ensure personal safety.
2. Clean and dress wound as appropriate.
3. Remove rings, watches, or other constricting items.
4. AVOID excessive movement of extremity.
5. Circle erythema around puncture site with ink pen and note time.
6. Monitor distal pulses.
7. Monitor SpO2, if <94% 1-15 LPM O2 via NC or NRB, titrate to 94%.
8. For complaint of pain DO NOT apply ice packs.
9. Consider pain management see protocol PGEN-03.
10. Consider cardiac monitoring if tachycardic or bradycardic heart rates per child age.

Considerations:
1. Do not apply constricting band or tourniquet.
2. Do not incise snakebites.
3. If dead or captured, have animal control transport snake for identification.
4. If safe, package insect or spider for transport and positive identification.
5. All bites (dog, cat, human, etc.) need to be transported for further evaluation at a hospital
for further cleansing and potential antibiotic therapy.
6. Time since envenomation is important as anaphylaxis rarely occurs more than 60 minutes
after inoculation.
7. Chemical ice packs should never be in direct contact with patient’s skin. Ice pack should
be wrapped in towel or other fabric material.
Base Hospital Orders
1. For known and confirmed black widow bite:
A. Calcium chloride 8mg/kg, IV/IO, max 500mg.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 183 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-03

Pediatric Hyperthermia (PENV-03)
Hyperthermia is a condition caused by your body overheating, usually as a result of
prolonged exposure to or physical exertion in high temperatures. Heatstroke, the most
serious form of heat injury, can occur if your body temperature rises to 104°F (40°C) or
higher. The condition is most common in the summer months.
Definitions:
1. Mildly Symptomatic- Signs of heat cramps and heat exhaustion.
2. Grossly symptomatic- Heat stroke.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Temperature.
G. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Headache.
Note: Persons at greatest risk 1. Always rule out other
2. Chest pain.
of hyperthermia are:
causes of ALOC.
3. Cramps.
1. The immune suppressed.
4. Nausea.
2. Athletes.
5. Weakness.
3. Persons on medications,
6. Abnormal temperature.
which impair the body’s
Heat cramps and heat
ability to regulate heat.
exhaustion:
1. Temperature normal to
slightly elevated.
2. Mental status alert to
slightly confused.
3. Skin signs diaphoresis,
warm or hot to touch.
4. Muscle cramps and
weakness.
Heat stroke:
1. High core temperature
usually above 104°F.
2. Altered mental status.
3. Skin hot to touch and
flushed.
4. Possible seizure activity.
5. Low BP.
6. Tachycardia.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 184 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-03

Pediatric Hyperthermia
Treatment #1- Mildly Symptomatic:
1. Move patient to cool environment.
2. Remove excess clothing.
3. Spray or sprinkle patient’s face with cool (not cold) water and use fan to evaporate.
4. Ice packs to palms of hands and soles of feet.
5. If able to swallow safely, cool water PO.
6. Consider IV, NS, TKO.
7. If no fluid restrictions exist and lungs are clear NS 20ml/kg IVF bolus IV, max 2,000 ml.
Treatment #2- Grossly Symptomatic:
1. Move patient to cool environment.
2. Remove excess clothing.
3. Cardiac monitor.
4. Monitor SpO2, if <94%, O2 1-15 LPM via NC or NRB, titrate to 94%.
5. Obtain blood glucose level.
6. Ice packs to palms of hands and soles of feet.
7. IV/IO, NS, TKO.
8. If no fluid restrictions exist and lungs are clear, NS 20ml/kg IVF bolus IV/IO, Max 2,000
ml.
9. If seizing, see seizure protocol PNRO-04.
Considerations:
1. Chemical ice packs should never be in direct contact with patient’s skin and should be
wrapped in towel or other fabric material.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 185 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-04

Pediatric Hypothermia (PENV-04)
Hypothermia is a medical emergency that occurs when your body loses heat faster than it can
produce heat, causing a dangerously low body temperature. Normal body temperature is
around 98.6°F (37°C). Hypothermia occurs as your body temperature falls below 95°F (35°C).
Definitions:
1. Mildly Symptomatic- Signs and symptoms of hypothermia.
2. Grossly symptomatic- Signs and symptoms of hypothermia with ALOC, loss of
consciousness or hypotension.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Length of exposure.
every 15 minutes for stable patients:
4. Air temperature, water temperature?
A. BP.
5. Was patient wet or dry?
B. Respirations.
6. Time of mental status changes?
C. Pulse.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
G. Patient’s body temperature.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Shivering.
1. Trauma.
1. Rule out other causes for
2. Slurred speech or
2. Alcohol consumption,
ALOC.
mumbling.
medications.
2. Severe sepsis.
3. Slow, shallow breathing.
3. Pre-existing medical
3. Environmental exposure.
4. Weak pulse.
problems.
4. Drug use.
5. Lack of coordination.
4. Recent illness.
6. Drowsiness.
7. Confusion or memory
loss.
8. Loss of consciousness.
9. Altered mental status.
10. Evidence of local cold
injury-blanching, red or
wax looking skin
especially ears, nose and
fingers, burning or
numbness in affected
areas.
11. Stuporous or comatose.
12. Dilated pupils.
13. Hypotensive or pulseless,
slowed or absent
respirations.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 186 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Environmental

PENV-04

Pediatric Hypothermia
Treatment #1- Mildly Symptomatic:
1. Move patient to warm environment.
2. Remove clothing if wet and cover with warm blankets.
3. Apply heat packs to groin and axillary.
4. Consider IV, NS, TKO.
5. If no fluid restrictions exist and lungs are clear, consider WARM NS 20 ml/kg IVF bolus,
no repeat.
Treatment #2- Grossly Symptomatic:
1. Move patient to warm environment.
2. Remove clothing if wet and cover with warm blankets.
3. Apply heats packs to groin and axillary.
4. Cardiac monitor.
5. Monitor SpO2, if <94% O2, 1-15 LPM via NC or NRB, titrate to 94%.
6. Obtain blood glucose level, if >70 mg/dL, see protocol PNRO-02. If >200 mg/dL see
protocol PNRO-01.
7. Consider 12 lead EKG.
8. IV/IO, NS, TKO.
9. If no fluid restrictions exist and lungs are clear WARM NS 20 ml/kg IVF bolus, may repeat
x2, max total dose 2,000 ml.
Considerations:
1. DO NOT attempt to thaw out frost bitten areas or apply heat packs to frostbite sites.
2. Chemical heat packs should never be in direct contact with patient’s skin. Heat pack should
be wrapped in towel or other fabric material.
3. Drive with caution and avoid bumps and hard shocks in all patient movements.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 187 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 188 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 189 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-01

Pediatric Trauma (PTRA-01)
Trauma can either be blunt or penetrating, open or closed, or any combination of all.
Definitions:
1. Blunt Trauma- Traumatic injury caused by a blunt object or surface.
2. Penetrating- Traumatic injury caused when an object enters the body.
3. Open- Traumatic injury with a break in the skin.
4. Closed- Traumatic injury without a break in the skin.
5. TBSA- Total burn surface area.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
G. Head to toe exam.
Objective Findings:
1. Mechanism of injury.
2. Medical history of cardiovascular problems, diabetes, or seizure disorder.
3. Check for DCAP-BTLS (Deformity, Contusion / Crepitus, Abrasion, Puncture, Bleeding,
Tenderness, Laceration, Swelling).
4. Glasgow coma score.
5. Neurological impairment or focal deficit – paralysis, weakness.
6. Eyes/vision – pupil inequality and reactivity, eye tracking, impaired vision – double vision,
stars.
7. Check for paradoxical chest wall movement (flail chest), rib cage, and sternal instability.
8. Check for pelvic instability, abdominal rigidity and guarding.
9. Check for range of motion, distal pulses, sensation, skin color, and associated injuries.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 190 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-01

Pediatric Trauma
Treatment #1 Asymptomatic:
1. If bleeding, see injury specific guidelines.
2. Place in spinal motion restriction if indicated.
3. See injury specific guidelines starting on PTRA-02.
Treatment #2- Symptomatic:
1. If bleeding, see injury specific guidelines.
2. Place in spinal motion restricting if indicated.
3. Monitor SpO2, if <94% 1-6 LPM O2 via NC, titrate to 94%.
4. See injury specific guidelines.
5. Consider treating for pain. See protocol PGEN-03.
6. If ALOC, loss of consciousness, obtain blood glucose level.
7. If chest pain Cardiac monitor.
8. Consider 12 lead ECG.
Treatment #3- Grossly Symptomatic or Signs of Shock:
1. If bleeding, see injury specific guidelines.
2. Place in spinal motion restricting if indicated.
3. Patients with ineffective respirations, support ventilations with BVM and airway adjunct.
4. Suction as needed.
5. TRANSPORT.
6. Cardiac monitor.
7. Monitor SpO2, if <94%, 1-15 LPM O2 via NC or NRB, titrate to 94%.
8. Consider treating for pain. See protocol PGEN-03.
9. If loss of consciousness or ALOC obtain blood glucose level, If <70 mg/dL, see protocol
PNRO-03.
10. If chest injury, consider 12 Lead.
11. 2 large bore IV, NS, TKO.
12. If SBP is below length based treatment tape low value, lung sounds are clear and no fluid
restrictions exist NS 20ml/kg IVF bolus, may repeat x1.
13. If SBP remains below length based treatment tape low value after fluids, DILUTED
epinephrine 1ml IV/IO, every 3-5 minutes, titrate to normal age-based SBP.
14. See injury specific guidelines.
15. If using BVM ventilate at 24/min.

Considerations:
1. Continually assess for signs of shock.
2. If brain injury is suspected, elevate the head of the patient as long as no signs of shock are
present.
3. Significant internal thoracic and abdominal trauma may occur without any signs of injury.
4. Transport patient in position of comfort if not in spinal precautions. Place pregnant patients
in left lateral recumbent position.
5. Avoid supraglottic airway unless no gag is present and unable to ventilate with BVM and
OPA.
Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 191 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-01

Injury Specific Guidelines

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 192 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-01

Trauma: Injury Specific Treatments
Treatment for Bleeding Control
1. Direct pressure.
2. If unable to control with direct pressure alone, use
hemostatic dressing on wound and pack wound if
applicable.
3. Elevate extremity
4. If bleeding still not controlled, apply tourniquet.
Treatment for Eye Injury
1. Apply dressing as appropriate.
2. Loosely cover affected and unaffected eye.
Treatment for Tooth Injury
1. Keep avulsed teeth in saline soaked gauze,
OR
2. Commercial tooth saver kit.
3. Transport tooth with patient.
Treatment for Mandible Fracture
1. Splint with cravat or bandage.
Treatment for Impaled Object
1. Stabilize with large bulky dressings.
2. Leave in place.

Treatment for Flail Chest
1. Stabilize chest with large bulky dressing.
Treatment for Open Chest Wound
1. Cover wound with loose dressing, do not seal.
Sucking chest wounds:
2. Immediately cover with gloved hand.
3. Cover with occlusive dressing taped on three sides,
OR
4. Use commercially available chest seal.
Treatment for Tension Pneumothorax
1. Perform needle decompression:
A. 2nd or 3rd intercostal space mid clavicular.

Treatment Considerations
1. Secure tourniquets as high on
arm or leg as possible.
2. Note time of placement.

Treatment Considerations
1. DO NOT attempt to re insert
eye.
Treatment Considerations
1. DO NOT attempt to re-insert
teeth.
2. DO NOT attempt to remove
partially avulsed teeth.
Treatment Considerations
1. Monitor airway compromise or
difficulty breathing.
Treatment Considerations
1. Removal of impaled objects
should only be considered if
object interferes with CPR or
airway cannot be managed.
2. Consider base contact for
consult.
Treatment Considerations
Treatment Considerations
1. Continuously monitor patient
for tension pneumothorax.
2. Attempt to “burp” the wound
by removing occlusive
dressing, allowing air to
escape and then recovering
the wound, prior to needle
decompression.
Treatment Considerations
1. Tension pneumothorax occurs
when a patient has:
A. Absent or decreased lung
sounds.
B. Difficulty breathing.
C. Hypotension.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 193 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-01

Trauma: Injury Specific Treatments
Treatment for Cardiac Tamponade
1. Cardiac monitor.
2. 12 Lead ECG.

Treatment Considerations

If SBP is below length based treatment tape low value, lung
sounds are clear and no fluid restrictions exist:
3. 20ml/kg NS Bolus, titrate to length based treatment
tape low value, may repeat x1.
Treatment for Cardiac Contusion
1. Cardiac monitor for dysrhythmias:
A. V-Tach- see protocol PCAR-08.
Treatment for Evisceration of Organs
1. Cover eviscerated organs with normal saline soaked
gauze.

Treatment for Genital Injuries
1. Cover genitalia with saline soaked gauze.

Treatment for Extremity Injuries
1. Check for range of motion, distal pulses, sensation, skin
color, and associated injuries.
2. Elevate extremity.
3. Apply cold packs to reduce pain and decrease soft
tissue swelling.
4. Splint injured extremity in position found unless
precluded by extrication consideration, no palpable
pulses, or patient discomfort.
Treatment for Mid Shaft Femur Fracture
1. Apply traction splint.
Treatment for Extremity Amputation
1. Place/cover amputated part in/with dry sterile dressing.
2. Place in sealed plastic bag or wrap with plastic.
3. Place dressed and wrapped part on top of ice or cold
pack.

Treatment for Soft Tissue Injuries
1. Cover open wounds with sterile dressings.

Treatment Considerations
1. Consider 12 lead with blunt
chest trauma.
Treatment Considerations
1. Frequently assess gauze
for dryness and add
additional normal saline if
needed.
2. DO NOT attempt to reinsert
organs.
Treatment Considerations
1. If necessary, apply direct
pressure to control
bleeding.
2. Treat amputation as
extremity amputation.
Treatment Considerations
1. Pad all splinted extremities
and recheck distal pulses
and neurological function
every 5 minutes.
2. DO NOT apply traction or
attempt to reduce an open
extremity fracture.
Treatment Considerations
Treatment Considerations
1. If patient condition allows,
transport amputated part
with patient. Chemical ice
packs should never be in
direct contact with patient’s
skin. Ice pack should be
wrapped in towel or other
fabric material.
Treatment Considerations

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 194 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-01

Trauma: Injury Specific Treatments
Treatment for Burns
1. Remove clothing from burned area if possible without
removing skin.
2. Patients with respiratory distress see protocol PRSP-01
to 04.
If <20% TBSA:
3. Estimate depth of burn (full thickness, partial thickness,
surface burn).
4. Calculate TBSA using rule of nines, see chart below.
5. Cover with sterile dressing soaked with sterile water.
If >20% TBSA:
6. Cover with dry sterile burn sheet or cleanest dry sheet.
7. Place patient on dry sterile burn sheet for transport.
8. IV, NS, titrate fluids to Parkland Formula.
9. Transport to trauma center. If AIRWAY is
compromised, or LOW SPO2, go to NEAREST ED.
Chemical
1. Follow appropriate decontamination or hazmat
procedures.
2. Brush off dry powders.
3. Remove contaminated clothing.
4. Irrigate with copious amounts of water.
Thermal and Electrical
1. Stop the burning process.
2. Cool with water for up to 30 minutes.
3. Remove jewelry and non-adhered clothing.
4. Cover burn.

Treatment Considerations
1. Always attempt to identify
type and source of burn:
A. Chemical.
B. Electrical.
C. Steam.
D. Smoke.
E. Open flame.
Parkland Formula
2. 4 ml x %TBSA x body
weight (kg) = Total for 24
hours.
3. 50% given in first 8 hours;
50% given in next 16
hours.
Chemical
4. DO NOT attempt to remove
tar or other adhered
material.
5. If possible, bring chemical
Safety Data Sheet (SDS)
with patient to hospital.
Thermal and electrical
6. Avoid prolonged cool water
usage due to risk for
hypothermia and local cold
injury.
7. DO NOT use ice water or
apply ice or ice packs to
patient.
8. DO NOT break blisters.

Rule of Nines Burn Chart

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 195 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-02

Pediatric Traumatic Arrest (PTRA-02)
Loss of cardiac and pulmonary function due to traumatic event.
Definitions:
1. High Quality CPR- Use TEAM approach:
A. 100 to 120 compressions per minute.
B. 15:2 ratio compression to ventilation ratio.
C. Compress at least 1/3 the depth of the chest.
D. Allow complete recoil.
E. Minimize interruptions.
F. Rotate compressors every 2 minutes.
G. Pre-charge monitor for defibrillation while CPR is in progress.
Documentation Standards:
1. Every 5 minutes:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Capnography.
D. Blood glucose.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
1. Obtain patient history and document the following:
A. Estimated down time.
B. Quickly assess for obvious signs of death:
i.
Decapitation.
ii.
Decomposition.
iii.
Burnt beyond recognition.
iv.
Lividity.
v.
Rigor mortis.
C. Circumstances surrounding the arrest:
i.
Onset (witnessed or unwitnessed).
ii.
Preceding symptoms.
iii.
Bystander CPR.
iv.
Medications.
v.
Environmental factors (hypothermia, inhalation, and asphyxiation).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 196 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-02

Pediatric Trauma Arrest
Treatment- Treat reversible causes upon identification.
Reversible Causes
1. Hypovolemia- (history suggesting volume depletion)
Start 2nd IV, NS 20ml/kg bolus IV/IO, repeat x2.
2. Hypoxia- (SpO2 <94%)
Maintain ventilations at 24 a minute, with 100% O2, BVM & OPA.
If unable to ventilate, insert supraglottic airway.
3. Hydrogen Ion- (acidosis, long down time, dialysis patient)
Sodium bicarbonate 1mEq/kg IV/IO. Max 50mEq.
4. Hypoglycemia- (Blood glucose level <70 mg/dL)
dextrose 10% 5 ml/kg IV/IO,
OR
dextrose 50% 1 ml/kg IV/IO.
5. Hypocalcemia- (long down time, dialysis patient)
Calcium chloride 10%, 10mg/kg IV/IO, max 1 gm.
6. Hyperkalemia- (long down time, dialysis patient)
sodium bicarbonate 1mEq/kg IV/IO, max 50mEq.
7. Hypothermia- (body temp <34°C)
Active rewarming with warm IV/IO fluids, hot packs to neck and groin.
8. Tension Pneumothorax- (absent lung sounds on affected side)
Needle decompression.
9. Tamponade, CardiacIf SBP is below length based tape low level:
NS 20 ml/kg IVF bolus IV/IO, may repeat x2.
10. ToxinsSee protocol PODP-01 to 07.
11. Torsade’s De pointesMagnesium sulfate 25mg/kg IV/IO, max 2g.
Considerations:
1. The goal is high quality CPR.
2. DO NOT delay vascular access with IV attempts. Go directly to IO.
3. Monitor capnography with BVM & OPA.
4. Transport immediately. After spinal motion restriction, perform all treatment enroute.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 197 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Trauma

PTRA-02

Pediatric Trauma Arrest
Treatment

2 Min.

To approved Trauma Center
perform ALL treatment enroute

2Min

Transport

1. 200 compressions
2. OPA & BVM at 24/min
3. Bilateral needle decompression
4. NS 20ml/kg IO/IV bolus, may repeat
x2.
5. Consider advanced airway

Rhythm check #2
Asystole / PEA

Shock 2
Joules/kg

1. 200 compressions
2. Epi 0.01 mg/kg, IO,
Once.

ROSC

See ROSC
protocol
PCAR-05.

2 Min.

V-Fib / pV-Tach

Rhythm check #1
V-Fib/V-Tach

1. 200 compressions

ROSC

See ROSC
protocol
PCAR-05.

2 Min.

Shock 4
Joules/kg

Asystole/PEA

1. 200 compressions
2. Lidocaine 1mg/kg
IV/IO, max 3mg/kg,
No Repeat

Return to Rhythm check #1
Always consider
reversible causes
and treat when
identified

2 Min.

All Joules- are in Biphasic, use of equivalent Monophasic
dose if equipped to do so is appropriate. Follow
manufacturer’s recommendations for single shocks.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 198 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 199 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-01
Pediatric Acute Dystonic Reactions (PODP-01)

Acute dystonic reactions are an extrapyramidal side effect of antipsychotic and certain other
medications such as phenothiazines. Dystonia refers to sustained muscle contractions,
frequently causing twisting, repetitive movements, or abnormal postures. They may affect any
part of the body. Patients experiencing acute dystonic reactions are often frightened and
fearful, and may be in considerable pain.
Definitions:
1. Symptomatic/Mild Reaction- Intermittent spasms or sustained involuntary contractions
isolated to extremities, tongue or jaw.
2. Grossly Symptomatic/Severe Reaction- Intermittent spasms or sustained involuntary
contractions affecting back or entire body.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Name of medication.
every 15 minutes for stable patients:
4. Estimated number of pills or dose.
A. BP.
5. Route of administration.
B. Respirations.
6. Time of administration.
C. Pulse.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Inability to move eyes.
1. Abdominal pain.
1. Seizure.
2. Muscle spasms of face,
2. Nausea and vomiting.
neck, body, arms, or legs 3. Bipolar disorder.
causing unusual postures 4. Schizophrenia.
or unusual expressions
on face.
3. Rapid or worm-like
Common Med Names
movements of tongue.
1. Prochlorperazine
4. Sticking out of tongue.
(Compazine, Compro,
5. Tic-like or twitching
Procomp).
movements.
2. Chlorpromazine
6. Trouble breathing,
(Promapar, Thorazine).
speaking, or swallowing.
3. Fluphenazine (Permitil,
7. Uncontrolled chewing
Prolixin).
movements.
4. Perphenazine.
8. Uncontrolled movements 5. Trifluoperazine
of arms or legs.
(Stelazine).
9. Uncontrolled twisting
6. Thioridazine (Mellaril).
movements of neck,
trunk, arms, or leg.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 200 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-01

Pediatric Acute Dystonic Reactions
Treatment #1- Symptomatic/Mild Reaction:
1. Monitor SpO2, if <94%, O2 1-6 LPM via NC, titrate to 94%.
2. Diphenhydramine 1mg/kg PO, max of 50mg.
Treatment #2- Grossly Symptomatic/Severe Reaction:
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM NC or NRB, titrate to 94%.
3. IV, NS, TKO.
4. Diphenhydramine 1mg/kg IV, max of 50mg,
OR
5. Diphenhydramine 1mg/kg PO, max of 50mg.

Considerations:
1. If benzodiazepines have already been administered to treat seizures, DO NOT withhold
diphenhydramine.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 201 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-02

Pediatric Beta Blockers Overdose (PODP-02)
Beta blockers, also known as beta-adrenergic blocking agents, are medications that are
commonly used to reduce BP. Beta blockers work by blocking the effects of the adrenaline.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibly of beta blocker overdose
but patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals beta blocker overdose and patient
is showing signs and symptoms related to beta blockers.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Name of medication.
every 15 minutes for stable patients:
4. Estimated number of pills or amount of
A. BP.
liquid.
B. Respirations.
5. Route of administration.
C. Pulse.
6. Time of administration.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Pupils.
G. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Hypotension.
1. High BP.
1. Co-ingestion.
2. Bradycardia.
2. Irregular heart rhythm
2. Calcium channel OD.
3. AV block.
(arrhythmia).
3. Digoxin toxicity.
4. Heart failure.
3. Heart failure.
4. Complete heart block.
5. Bronchospasm.
4. Chest pain (angina).
5. Renal failure.
6. Hypoglycemia.
5. Heart attacks.
7. Hyperkalemia.
6. Migraine.
8. Stupor.
7. Certain types of tremors.
9. Coma.
10. Seizures.
Home Meds:
1. Acebutolol (Sectral).
2. Atenolol (Tenormin).
3. Bisoprolol (Zebeta)
4. Metoprolol (Lopressor,
Toprol-XL).
5. Nadolol (Corgard).
6. Nebivolol (Bystolic).
7. Propranolol (Inderal LA,
InnoPran XL).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 202 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-02

Pediatric Beta Blockers Overdose
1. Cardiac monitor.
2. 12 Lead ECG.
3. Monitor SpO2, if < 94% 1-15 LPM O2 via NC or NRB, titrate to 94%.
Treatment #1- Asymptomatic:
1. Consider, IV, NS, TKO.
2. Blood glucose level every 15 minutes.
3. If blood glucose level <70 mg/dL, administer oral glucose, titrate to blood glucose level
>70 mg/dL,
OR
4. Dextrose 10% 5 ml/kg IV, titrate to blood glucose level >70 mg/dL.
Treatment #2- Symptomatic:
1. IV, NS, TKO.
2. Blood glucose level every 15 minutes.
3. If blood glucose level <70 mg/dL, dextrose 10% 5 ml/kg IV/IO, titrate to blood glucose
level >70 mg/dL,
4. If SBP is below length based treatment tape low value without evidence of fluid overload,
NS 20 ml/kg IVF bolus, may repeat x2.
5. If SBP remains below length based treatment tape low value, see base hospital order
below.
6. For seizure activity, see protocol PNRO-04.
Considerations:
1. Monitor QRS duration closely even in asymptomatic patients.
2. If patient is on a hold or there is potential for intentional OD consider 4 point restraints.
3. If patient is physically combative, consider involving law enforcement to assist in putting
patient in 4 point restraints.

To make DILUTED epinephrine:
1. Mix epinephrine 0.01 mg/kg 1:10,000 to a total volume of 10ml with NS.
Base Hospital Orders
1. Additional 10ml/kg, NS, IV/IO.
2. Dopamine 10mcg/kg/mi, via dial-a-flow or,
3. DILUTED epinephrine 1 ml IV/IO every 3-5 minutes.
4. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
Dopamine
Suggested: Mix 400mg in 250ml,NS or D5W, using a 60gtts drip set, (60 drops/min = 60
ml/hr)
Weight (kg)
gtts/min=10mcg/kg/min
Weight (kg)
gtts/min=10mcg/kg/min
35-45
15 gtts/min
85-90
35 gtts/min
45-55
20 gtts/min
95-105
40 gtts/min
60-70
25 gtts/min
110 &up
45 gtts/min
75-80
30 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 203 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-03

Pediatric Calcium Channel Blocker Overdose (PODP-03)
Calcium channel blockers are used in the treatment of hypertension, angina pectoris, cardiac
arrhythmias, and other disorders. These medications are available in both immediate-release
and extended-release preparations. The potential toxicity of these agents is substantial, and
is often under appreciated by the public.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibly of calcium channel
blocker overdose but patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals calcium channel overdose and
patient is showing signs and symptoms related to calcium channel.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Name of medication.
every 15 minutes for stable patients:
4. Estimated number of pills or amount of
A. BP.
liquid.
B. Respirations.
5. Route of administration.
C. Pulse.
6. Time of administration.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose level.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Constipation.
1. Hypertension.
1. Co- ingestion.
2. Headache.
2. Angina pectoris.
2. Beta blocker OD.
3. Palpitations.
3. Cardiac arrhythmias.
3. Digoxin toxicity.
4. Dizziness.
4. Complete heart block.
5. Rash.
Home Meds:
5. Renal failure.
6. Drowsiness.
1. Amlodipine (Norvasc).
7. Flushing.
2. Diltiazem (Cardizem,
8. Nausea.
Tiazac, others).
9. Swelling in the feet and
3. Felodipine.
lower legs.
4. Isradipine.
10. Bradycardia.
5. Nicardipine.
11. Hypotension.
6. Nifedipine (Adalat CC,
12. Shortness of breath.
Afeditab CR, Procardia).
7. Nisoldipine (Sular).
8. Verapamil (Calan,
Verelan).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 204 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-03

Pediatric Calcium Channel Blocker Overdose
1. Cardiac monitor.
2. 12 lead ECG.
3. Monitor SpO2 if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
Treatment #1- Asymptomatic:
1. Consider, IV, NS, TKO.
Treatment #2- Symptomatic:
1. IV/IO, NS, TKO
2. Calcium chloride 10% 20 mg/kg IV/IO over 3-5 minutes max 2g.
3. If SBP is below length based treatment tape low value, lung sounds are clear, NS 20ml/kg
IVF bolus, may repeat x2.
4. If SBP remains below length based treatment tape low value, lung sounds are clear and
no fluid restrictions exist, see base order below.

Considerations:
1. Monitor QRS duration closely even in asymptomatic patients.
2. Monitor ECG for presence of AV nodal blocks.
3. If patient is on a hold or there is potential for intentional OD, consider 4 point restraints.
4. If patient is physically combative consider involving law enforcement to assist in putting
patient in 4 point restraints.

To make DILUTED epinephrine:
1. Mix epinephrine 0.01mg/kg 1:10,000 to a total volume of 10ml with NS.
Base Hospital Orders
1. Additional NS 10ml/kg IVF bolus.
2. Dopamine 10mcg/kg/min via dial-a-flow.
3. DILUTED epinephrine 1ml IV/IO every 3-5 minutes, titrate to length based treatment tape
SBP low value.
4. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
Dopamine
Suggested: Mix 400mg in 250ml,NS or D5W, using a 60ggts drip set, (60 drops/min = 60
ml/hr)
Weight (kg)
gtts/min=10mcg/kg/min
Weight (kg)
gtts/min=10mcg/kg/min
35-45
15 gtts/min
85-90
35 gtts/min
45-55
20 gtts/min
95-105
40 gtts/min
60-70
25 gtts/min
110 &up
45 gtts/min
75-80
30 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 205 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-04

Pediatric Acute Drug Intoxication

(PODP-04)

Acute drug intoxication refers to the immediate and deleterious effects of drugs such as
cocaine, amphetamines, PCP or bath salts, on the body. Although acute drug intoxication and
drug dependence can be present in the same individual, these syndromes present with
different symptoms.
Definitions:
1. Intoxication- History reveals or patient is showing signs and symptoms of acute drug
intoxication however patient is cooperative.
2. Intoxication with serious agitation- History reveals or patient is showing signs and
symptoms of acute drug intoxication however, patient is not cooperative, is a safety risk to
crews or a safety risk to themselves. Safety risks include physically combative or erratic
dangerous behavior.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose level.
D. Physical assessment.
E. Pupils.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Tachycardia.
1. Drug use.
1. Co-ingestion.
2. Hypertension.
2. Previous OD.
2. Stimulant induced MI.
3. Dilated pupils.
3. Encephalopathy.
4. Hyperthermia.
4. Drug induced psychosis.
5. Restlessness.
Home Meds:
6. Anxiety, panic, paranoia.
1. Methadone.
7. Erratic behavior.
8. Tremors.
9. Psychosis.
10. Nausea.
11. Agitation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 206 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-04

Pediatric Acute Drug Intoxication
Treatment #1- Intoxication:
1. Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. If chest pain obtain 12 lead EKG.
4. If ALOC blood glucose level, if <70 mg/dL, see protocol PNRO-02.

Considerations:
1. Safety is the highest priority. Consider law enforcement assistance if the patient is
agitated.
2. If patient is physically combative consider involving law enforcement to assist in putting
the patient in 4 point restraints.

Base Hospital Orders
1. Midazolam 0.05 mg/kg IM/IN, max of 2mg for serious agitation.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 207 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-05

Pediatric Cyclic Antidepressants Overdose (PODP-05)
The clinical presentation of cyclic antidepressant overdose is extremely variable. Patients can
present alert with normal vital signs or comatose and hypotensive. In any case, rapid onset of
symptoms and rapid deterioration are characteristic of cyclic antidepressant overdose.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibly of cyclic antidepressants
overdose but patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals cyclic antidepressants overdose and
patient is showing signs and symptoms related to cyclic antidepressants or is having
dysrhythmias.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Name of medication.
every 15 minutes for stable patients:
4. Estimated number of pills or amount of
A. BP.
liquid.
B. Respirations.
5. Route of administration.
C. Pulse.
6. Time of administration.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose level.
D. Pain scale.
E. Physical assessment.
F. Pupils.
G. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Blurred vision.
1. Depression.
1. Co-ingestion.
2. Dry mouth.
2. Previous OD.
3. Constipation.
3. Panic disorder.
4. Weight gain or loss.
4. Bulimia.
5. Rash.
5. Chronic pain.
6. Hives.
6. Migraine.
7. Increased heart rate.
7. Tension headaches.
8. Cardiac conduction
8. Diabetic neuropathy.
delays.
9. Phantom limb pain.
9. Dysrhythmias.
10. Chronic itching.
10. Hypotension.
11. Respiratory depression.
Home Meds:
12. Seizures.
1. Amitriptyline.
13. Coma.
2. Amoxapine.
3. Desipramine (Norpramin).
4. Doxepin.
5. Imipramine (Tofranil).
6. Nortriptyline (Pamelor).
7. Protriptyline (Vivactil).
8. Trimipramine (Surmontil).

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 208 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-05

Pediatric Cyclic Antidepressants Overdose
1. Cardiac monitor.
2. Monitor SpO2, if <94%, 1-15 LPM O2 via NC or NRB, titrate to 94%.
3. 12 lead ECG.
Treatment #1- Asymptomatic:
1. Consider IV, NS, TKO.
Treatment #2- Symptomatic or has Dysrhythmias:
1. IV/IO, NS, TKO.
2. If QRS complex is greater than 0.10 ms, sodium bicarbonate 1mEq/kg IV/IO, max single
dose 50 mEq. Repeat until QRS <0.10ms
3. For seizure activity, see protocol PNRO-04.
4. If SBP is below length based treatment tape low value, and lung sounds are clear, NS
20ml/kg IVF bolus, may repeat x2.
5. If SBP remains below length based treatment tape low value, see base hospital order
below.
6. If assisting ventilations hyperventilate.
7. Monitor EtCO2 if using a supraglottic airway or BVM.
Considerations:
1. Monitor ECG closely even in asymptomatic patients as TCA overdose patients deteriorate
suddenly and quickly.
2. If patient is on a hold or there is potential for intentional OD consider 4 point restraints.
3. If patient is physically combative consider involving law enforcement to assist in putting
patient in 4 point restraints.

To make DILUTED epinephrine:
1. Mix epinephrine 0.01mg/kg 1:10,000 to a total volume of 10ml with NS.
Base Hospital Orders
1. Additional NS 10ml/kg IVF bolus.
2. Dopamine 10mcg/kg/min, via dial-a-flow.
3. DILUTED epinephrine 1ml IV/IO every 3-5 minutes, titrate to length based treatment tape
SBP low value.
4. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
Dopamine
Suggested: Mix 400mg in 250ml,NS or D5W, using a 60ggts drip set, (60 drops/min = 60
ml/hr)
Weight (kg)
gtts/min=10mcg/kg/min
Weight (kg)
gtts/min=10mcg/kg/min
35-45
15 gtts/min
85-90
35 gtts/min
45-55
20 gtts/min
95-105
40 gtts/min
60-70
25 gtts/min
110 &up
45 gtts/min
75-80
30 gtts/min

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 209 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-06

Pediatric Opiate Overdose (PODP-06)
Physical and mental symptoms that occur after taking too many opioids, a substance found in
certain prescription pain medications and illegal drugs like heroin.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibility of opiate overdose but
patient is showing no signs or symptoms of overdose.
2. Symptomatic- Patient has admitted or history reveals opiate overdose and patient is
showing signs and symptoms related to opiate overdose, including respiratory depression
or apnea.
Documentation Standards:
1. Every 5 minutes for unstable patients,
every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose if diabetic history or
continues to have ALOC.
D. Physical assessment.
E. Pupils.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
1. Lethargy.
2. ALOC.
3. Shortness of breath.
4. Pinpoint pupils.
5. Slow or absent
respirations.
6. Hypotension.

3. Name of medication.
4. Estimated number of pills or amount of
liquid.
5. Route of administration.
6. Time of administration.

Comorbidities
1. Short-term pain
management.
2. Chronic pain
management.
3. Heroin use.

1.
2.
3.
4.
5.

Differentials
Pontine stroke.
Co-ingestion.
Hypoxia.
Hypothermia.
Seizure.

Home Meds:
1. Hydrocodone (Vicodin®).
2. Oxycodone (OxyContin®,
Percocet®).
3. Oxymorphone (Opana®).
4. Morphine (Kadian®,
Avinza®).
5. Codeine.
6. Fentanyl.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 210 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-06

Pediatric Opiate Overdose
1. Cardiac monitor.
2. Monitor EtCO2.
3. Monitor SpO2.
Treatment #1- Symptomatic with Inadequate Respiration:
1. If SpO2 <94%, 1-15 LPM via NC, NRB or BVM, titrate to 94%.
2. Ventilate with BVM and OPA for bradypnea or ineffective respirations.
3. IV/IO, NS, TKO or saline lock.
4. Naloxone 0.4-2mg IV/IO, max 2mg,
OR
5. Naloxone 0.1 mg/kg IM / IN (half in each nostril), max 4 mg.
Titrate to normal respiration rate based on length based tape,
DO NOT titrate to level of consciousness or pupil size.
Considerations:
1. Ventilate patient prior to administration of Naloxone.
2. USE LOWEST DOSE OF NALOXONE AVAILABLE TO PREVENT WITHDRAWAL.
3. Preferred route is IV. However, if unable to start IV, IN is acceptable.

Base Hospital Orders
1. Additional naloxone 2mg.
2. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.
Naloxone Pediatric Dose Chart
Weight KG/lbs.
5kg / 11lbs.
10kg / 22 lbs.
15kg / 33 lbs.
20kg / 44 lbs.

Dose
0.5mg
1.0mg
1.5.mg
2.0mg DO NOT EXCEED 2MG

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 211 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-07

Pediatric Organophosphates Exposure (PODP-07)
Organophosphates are a group of chemicals that poison insects and mammals.
Organophosphates are the most widely used insecticides today. They are used in agriculture,
the home, gardens, and veterinary practice. Organophosphate work by damaging an enzyme
acetylcholinesterase.
Definitions:
1. Asymptomatic- Patient has admitted or history reveals possibility of organophosphates
Exposure but patient is showing no signs or symptoms.
2. Symptomatic- Patient has admitted or history reveals organophosphates exposure and
patient is showing signs and symptoms related to organophosphates exposure, but is still
hemodynamically stable.
3. Grossly Symptomatic- Patient has admitted or history reveals organophosphates
Exposure and patient is showing signs and symptoms related to organophosphates
Exposure, but is NOT hemodynamically stable.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. If safe to identify:
every 15 minutes for stable patients:
A. Chemical labels.
A. BP.
B. Safety data sheet.
B. Respirations.
C. Placards.
C. Pulse.
D. Chemical type.
2. If performed, before and after intervention
E. Chemical amount.
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain Scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. Salivation.
1. Agricultural setting.
1. Nerve agent exposure.
2. Lacrimation.
2. Industrial setting.
3. Urination.
4. Defecation.
Common Names
5. Gastrointestinal distress.
1. Parathion.
6. Emesis.
2. Malathion.
3. Methyl parathion.
4. Chlorpyrifos.
5. Diazinon.
6. Dichlorvos.
7. Phosmet.
8. Fenitrothion.
9. Tetrachlorvinphos.
10. Azamethiphos.
11. Azinphos-methyl.
12. Terbufos.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 212 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric Overdose & Poisoning

PODP-07

Pediatric Organophosphates Exposure or Ingestion
1. Avoid contamination.
2. Cardiac monitor.
3. Monitor SpO2, O2 if <94%, 1-15 LPM via NC or NRB, titrate to 94%.
Treatment #1- Asymptomatic:
1. Consider IV, NS, TKO.
Treatment #2- Mildly Symptomatic:
1. IV/IO NS, TKO.
2. If HR <100 bpm, atropine 0.05 mg/kg IV/IO every 5 minutes, max 4 mg.
Treatment # 3- Grossly Symptomatic:
1. IV/IO NS, TKO.
Atropine 0.05 mg/kg, every 5 minutes, max of 4 mg. Base hospital contact for further atropine.
Considerations:
1. Safety is top PRIORITY.
2. Patient must be grossly decontaminated prior to transport.
3. Patient must be fully decontaminated prior to entering ED.
Base Hospital Orders
1. Additional atropine beyond 4 mg Max dose.
2. Consult Base Hospital if additional orders are needed or patient has atypical presentation.
Nerve Agent Exposure
If EMS Chempack is deployed and atropine auto injectors, pralidoxime (2-Pam) auto
Iinjectors, and are available they MAY NOT BE USED on pediatrics, diazepam can be used
as outlined below:
1. Cardiac monitor.
2. Monitor SpO2, if <94% 1-15 LPM O2 via NC or NRB, titrate to 94%.
3. Consider IV/IO, NS, TKO.
If SBP is below length based treatment tape low value, lung sounds are clear and no fluid
restrictions exist:
4. NS 20 ml/kg IVF bolus, may repeat x2. Titrate treatment tape low value.
Seizure activity:
5. Diazepam 0.1 mg/kg IV/IM, max total dose of 5mg.
OR
6. Diazepam 0.2 mg/kg IN (half in each nostril), max total dose of 5mg.
7. Atropine 0.05 mg/kg every 5 minutes, max of 4mg.
8. Do not administer 2-Pam auto injector.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 213 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 214 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 215 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-01

Pediatric Brief, Resolved, Unexplained, Event (PGEN-01)
Brief, Resolved, Unexplained Event (BRUE) indicates an episode that is frightening to the
observer (may think the infant has died). Occurs in a child younger than 1 year of age and
lasts less than 1 minute. These events usually occur in infants less than 12 months old;
however, any child less <2 years old who exhibits the symptoms listed below should still be
evaluated for BRUE.
Definitions:
1. Must have resolved and patient back to baseline and has one or more of the following:
A. Central cyanosis or pallor (discoloration of face, gums and/or trunk).
B. Absent, decreased or irregular breathing.
C. Marked change in tone (hypertonia or hypotonia).
D. Altered level of responsiveness.
Documentation Standards:
1. Every 5 minutes for unstable patients,
every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention
or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Lung sounds.
F. Complete physical exam.
Objective Findings:
Signs & Symptoms
1. Cyanosis or pallor.
2. Absent, decreased or
irregular breathing.
3. Marked change in tone
(hyper- or hypotonia).
4. Altered responsiveness
5. No explanation for the
event after full history and
exam.

3.
4.
5.
6.
7.

The general appearance of the child.
Skin color.
Extent of interaction with environment.
Evidence of trauma.
Medical history if any.

Comorbidities
1. Family history of sudden
death.
2. Family history of infant
death.
3. Born ≥32 weeks gestation
4. Post-conception age ≥45
weeks.

1.
2.
3.
4.
5.
6.
7.

Differentials
Hypoglycemia.
Seizure.
Poisoning.
Overdose.
Choking.
Arrhythmia.
Sepsis.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 216 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-01

Pediatric Brief, Resolved, Unexplained, Event
Treatment
1. Consider Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. Assess capillary refill.
Consider and treat any identifiable causes:
4. Blood glucose level, if >70 mg/dL, see protocol PNRO-02.
5. For seizure activity see protocol PNRO-04.
6. For signs of shock see protocol PCAR-04.
Considerations:
1. Must have resolved and patient back to baseline
2. Assume the history given is accurate.
3. Consider and treat any identifiable causes.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 217 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-02

Pediatric Nausea (PGEN-02)
Nausea may be due to a viral illness (such as gastroenteritis), motion sickness, or medication
side effects. It is important to remember that serious medical conditions also produce nausea
or vomiting such as stroke, head injuries, toxic ingestions, bowel obstruction, appendicitis,
and acute coronary syndrome. Generally, benign causes of nausea or vomiting do not have
any associated pain complaints, or alterations in level of consciousness (LOC).
Definitions:
1. Contraindications- Known sensitivity to ondansetron or other 5-HT-3 antagonists e.g.:
Granisetron (Kytril), Dolasetron (Anzamet), Palonosetron (Aloxi).

Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose if history of diabetes.
D. Pain scale.
E. Physical assessment.
F. Abdominal exam.
G. Lung sounds.
Objective Findings:
Possible Signs & Symptoms
Comorbidities
Differentials
1. Nausea.
1. Gastritis.
1. Appendicitis.
2. Vomiting.
2. Gastroenteritis.
2. Bowel obstruction.
3. Abdominal pain.
4. Diarrhea.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 218 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-02

Pediatric Nausea
Treatment #1- Persistent Mild Nausea:
1. Weight of 8-15 kg ondansetron 2 mg oral disintegrating tablet (ODT).
2. Weight >15 kg ondansetron 4 mg ODT.
3. Obtain blood glucose level.
Treatment #2- Persistent Moderate to Severe Nausea:
1. Cardiac monitor.
2. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
3. IV, NS, TKO.
4. Obtain blood glucose level.
5. Weight of 8-15kg ondansetron 2 mg IV over 1 minute.
OR
6. Weight >15kg ondansetron 4 mg IV over 1 minute.
Ondansetron 4mg, may be given via IO, IF IO is established for other treatments. An IO
should not be established solely for the purpose of nausea treatment.
Considerations:
1. Rapid administration of ondansetron has been associated with syncope.
2. Rare side effects include headache, dizziness, tachycardia, sedation, or hypotension.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 219 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-03

Pediatric Pain Management (PGEN-03)
This protocol is intended for the treatment of pain associated with traumatic injuries, burns, or
medical conditions that cause significant ACUTE pain or SEVERE exacerbation of chronic
pain.
Definitions:
1. Pain- is a significantly unpleasant sensation, occurring in varying degrees of severity, due
to injury, disease, or emotional distress.
2. Max Single Dose (Max SD)- is maximum medication given in one administration.
3. Max total Dose (Max TD)- is the most the patient can have overall without a base order
4. Mild to Moderate pain- Pain on movement, chronic pain, or pain that is managed with,
positioning, ice, stabilization, or immobilization.
5. Moderate to Severe Pain- patient pain is unable to be managed with, positioning, ice,
stabilization, or immobilization and patient is showing outward signs of being symptomatic
secondary to pain. Symptoms may include guarding, grimacing at rest, tachycardia,
tachypnea, hypertension, and diaphoresis, etc.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Possible signs and symptoms
Comorbidities
Differentials
1. Guarding.
1. Recent traumatic event. 1. Chronic pain
2. Grimacing.
2. Chronic pain.
exacerbation.
3. Deformity.
2. Complex regional pain.
4. Swelling.
3. Compartment syndrome.
5. Diaphoresis.
4. Arterial occlusion.
6. Splinting.
5. Nerve injury.
Pain management medication guidelines:
Medication
Best use
Acetaminophen
Mild to moderate pain due
Ibuprofen
Morphine

Visceral pain

Fentanyl

Somatic pain, patients with
hypotension

Contraindications
Allergy, Liver failure, ETOH
intoxication
Currently taking ASA, or
NSAID, GI Bleed, on blood
thinners
Hypotension

GI obstruction,

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 220 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-03

Pediatric Pain Management
Treatment #1- Mild to Moderate:
1. Consider SpO2, if <94%, O2 1-6 LPM via NC, titrate to 94%.
2. Elevate as appropriate.
3. Ice as appropriate.
4. Position as appropriate.
5. Stabilize as appropriate.
6. Acetaminophen 15 mg/kg, PO, max 650 mg (withhold if had in last 4 hours).
OR
7. Ibuprofen 10mg/kg PO, max 400mg, do not give to children age <6 months old (withhold if
had in last 6 hours).
Treatment #2- Moderate to Severe Pain:
1. Monitor SpO2, if <94% O2 1-15 LPM via NC or NRB, titrate to 94%.
2. IV/IO, NS, TKO.
3. Consider monitoring EtCO2.
4. If pain scale greater than 5 and symptomatic from pain, see dose chart below.
Considerations:
1. Treatment should not be based on pain scale alone, use objective signs to support
2. If SBP is low, consider fentanyl for pain management.
3. If pain scale greater than 5 and symptomatic from pain. An IO SHOULD NOT be
established solely for the purpose of pain management. An IO may be utilized for pain
management where indicated, only if IO was established for other treatments. (For
example, a burn patient’s IO that was established for fluid replacement may be also used
for pain medications).
Morphine
Burns, Trauma & Other
Max SD
Max TD
1. 0.1 mg/kg slow push IV/IO, every 5 minutes,
OR
2 mg
10 mg
2. 0.1 mg/kg IM, every 30 minutes.
Fentanyl
Trauma & Other
Max SD
Max TD
1. 1 mcg/kg slow push IV/IO, every 5 minutes,
OR
50 mcg
2 mcg/kg
2. 1 mcg/kg IN (half per nostril), every 5 minutes.
Burn
Max SD
Max TD
1. 1 mcg/kg slow push IV/IO, every 5 minutes,
OR
50 mcg
3 mcg/kg
2. 1 mcg/kg IN (half per nostril), every 5 minutes.
Base Hospital Orders
1. Medication dose above listed maximums.
2. In the presence of any finding listed below.
A. Allergy or sensitivity to the medication being administered.
B. SBP below length based treatment tape low value.
C. Respirations less than 12.
D. History of loss of consciousness.
E. Decreased mental status.
F. Pregnancy greater than 20 weeks.
3. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 221 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-04

Pediatric Patients from Out Patient Offices (PGEN-04)
This protocol is in place to allow paramedics on a 911/pre hospital call (Not to include IFT) to
transport patients that may be currently under anesthesia or having an adverse reaction to
out of hospital anesthesia, such as at dental offices or outpatient care facilities.
Definitions:
1. Local anesthesia - a type of pain prevention used during minor procedures to numb a
small site where the pain is likely to occur without changing the patient's awareness.
2. General anesthesia - a medically induced coma with loss of protective reflexes, resulting
from the administration of one or more general anesthetic agents.
3. Nerve and regional blocks - deliberate interruption of signals traveling along a nerve,
often for the purpose of pain relief.
4. Conscious sedation- is a combination of medicines to help you relax (a sedative) and to
block pain (an anesthetic) during a medical or dental procedure.
Documentation Standards:
1. Every 5 minutes for unstable patients,
3. Type of anesthetic used.
every 15 minutes for stable patients:
4. Procedure being performed.
A. BP.
5. Reaction to anesthetic.
B. Respirations.
6. Treatments administered prior to arrival.
C. Pulse.
A. Shock.
2. If performed, before and after intervention
B. Airway management.
or if condition changes:
A. ECG.
B. SpO2.
C. Blood Glucose.
D. Pain Scale.
E. Physical assessment.
F. Lung sounds.
Objective Findings:
Signs & Symptoms
Comorbidities
Differentials
1. ALOC.
1. Outpatient procedure.
1. CVA/TIA.
2. Unconscious.
2. Dental procedure.
2. Hypoglycemia.
3. Apneic.
3. Seizure.
4. Uncontrolled airway.
Possible Anesthetic Drugs:
5. Patients that have
1. Nitrous oxide.
received:
2. Ativan.
A. Procedural sedation.
3. Barbiturates:
B. Local anesthesia.
A. Amobarbital.
C. General anesthesia.
B. Methohexital.
C. Thiamylal.
4. Benzodiazepines:
A. Diazepam.
B. Lorazepam.
C. Midazolam.
5. Etomidate.
6. Ketamine.
7. Propofol.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 222 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-04

Pediatric Patients from Out Patient Offices
Treatment
1. Cardiac monitor.
2. Monitor SpO2, if <94%, O2 1-15 LPM via NC/NRB/BVM, titrate to 94%.
3. Monitor EtCO2 if patient received any sedation or analgesic medications or if using an
advanced airway or BVM.
4. Consider IV/IO, NS, TKO.
5. 12 lead ECG.
6. Obtain blood glucose level, if <70 mg/dL, see protocol PNRO-02.
7. If SBP is less than length based tape, lung sounds are clear and no fluid restrictions exist,
see protocol PCAR-04.
8. If patient was administered narcotics and respirations are depressed, naloxone 0.4- 2mg
IV/IN/IM/SL max 4 mg. Titrate to respiration of 12-20 per minute. DO NOT titrate to level
of consciousness.
Considerations:
1. Secure airway as appropriate.
2. As soon as feasible, advise doctor on scene they may maintain care if they ride with you
to ED and they do not delay transport.
3. Only the Base Hospital Physician can give field personal orders.
4. Contact the base hospital for any questions or concerns.

Base Hospital Orders
1. Consult Base Hospital if additional orders are needed or patient has atypical
presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 223 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-05

Sepsis (PGEN-05)
Sepsis is the body's overwhelming and life-threatening response to infection. When an
infection occurs at any potential site in the body, the immune system's inflammatory response
can be overwhelmed leading to SIRS (Systemic Inflammatory Response Syndrome) which
causes tissue damage that can lead to organ dysfunction, failure and death.
Definitions:
1. SIRS Criteria-possible infection (abnormal WBC), fever, tachypnea, tachycardia or
hypotension.
2. Asymptomatic- DOES NOT meet TWO or MORE SIRS criteria.
3. Symptomatic- Meets TWO or MORE SIRS criteria, hemodynamically stable and ALOC.
4. Septic Shock- Meets TWO or MORE SIRS criteria and is hemodynamically UNSTABLE.
Documentation Standards:
1. Every 5 minutes for unstable patients, every 15 minutes for stable patients:
A. BP.
B. Respirations.
C. Pulse.
2. If performed, before and after intervention or if condition changes:
A. ECG.
B. SpO2.
C. Blood glucose.
D. Pain scale.
E. Physical assessment.
F. Temp.
G. Lung sounds.
Objective Findings:
Signs & Symptoms
1. SIRS Criteria:
A. Temp: >100.4 F. or
<96F.
B. Tachycardia.
C. Tachypnea.
2. Significantly decreased
urine output.
3. Abrupt change in mental
status.
4. Difficulty breathing.
5. Abdominal pain.
6. Identifiable infection.

Comorbidities
1. Evidence of infection.
2. Clotting problems.
3. Abnormal liver or kidney
function.
4. Impaired oxygen
availability.
5. Electrolyte imbalances.

1.
2.
3.
4.

Differentials
Pneumonia.
Abdominal infection.
Kidney infection.
Bloodstream infection
(bacteremia).

Home Meds:
1. Antibiotics.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 224 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Pediatric General

PGEN-05

Sepsis
1. Monitor SpO2, if <94%, O2 1-15 LPM via NC/NRB, titrate to 94%.
Treatment #1- Asymptomatic (fever only):
1. Consider cardiac monitor.
2. Acetaminophen 15 mg/kg PO, max dose 650 mg. (Withhold if had in last 4 hours)
Treatment #2- Symptomatic Meets TWO or more SIRS Criteria:
1. Cardiac monitor.
2. Consider 12 lead ECG.
3. Obtain blood glucose level, if >70 mg/dL, see protocol PNRO-02. If >200 mg/dL, see
protocol PNRO-01.
4. If ALOC, see protocol PNRO-03.
5. IV, NS, TKO.
6. NS 20ml/kg IVF bolus. May repeat once for delayed capillary refill.
7. If fever and able to swallow acetaminophen 15 mg/kg PO, max single dose 650 mg.
(Withhold if had in last 4 hours)
OR
8. If greater than 6 months old, Ibuprofen 10mg/kg PO, max dose 400 mg. (Withhold if had
in last 6 hours)
Treatment #3- Shock meets two or more SIRS Criteria and Hemodynamically UNSTABLE:
1. Cardiac monitor.
2. Monitor EtCO2 if using a supraglottic airway or BVM.
3. Obtain blood glucose level, if >70mg/dL, see protocol PNRO-02. If >200 mg/dL, see
protocol PNRO-01.
4. If ALOC, perform CPSS if positive, see protocol PNRO-03.
5. If fever and able to swallow acetaminophen 15 mg/kg, PO, max single dose 500mg.
(Withhold if had in last 4 hours)
6. IV/IO, NS, TKO.
7. If SBP is below length based treatment tape low value, lung sounds are clear and no fluid
restrictions exist NS 20ml/kg IVF bolus, may repeat twice if blood glucose level <200
mg/dL without base hospital order. Titrate to mental status, capillary refill and SBP.
Considerations:
1. If patient is in shock and does not meet TWO or more SIRS Criteria, see protocol PCAR04.
2. SIRS Criteria:
a. Temp: >100.4F or <96F.
b. Tachycardia.
c. Tachypnea.
To make DILUTED epinephrine:
1. Mix epinephrine 0.01mg/kg 1:10,000 to a total volume of 10ml with NS.
Base Hospital Orders
1. Additional NS 10ml/kg IVF bolus.
2. Dopamine 10mcg/kg/min, via dial-a-flow.
3. DILUTED epinephrine 1mL IV/IO, every 3-5 minutes.
4. Consult Base Hospital if additional orders are needed or patient has atypical presentation.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 225 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

This page intentionally left blank

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 226 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Interfacility Transport

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 227 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

IFT-01

Monitoring Mechanical Ventilators – ALS (IFT-01))
PURPOSE: The purpose of this protocol is to authorize paramedics to use and monitor
preset mechanical ventilators during interfacility transport.
POLICY:
I.
ALS Ambulance providers must apply to and be approved by the San Joaquin
County EMS Agency (SJCEMSA) prior to initiating service to perform monitoring
of preset mechanical ventilators during interfacility transports.
II.

The monitoring of preset mechanical ventilators is restricted to San Joaquin
County accredited paramedics that have successfully completed a training
program approved by the SJCEMSA for the monitoring of preset mechanical
ventilators during interfacility transports.

III.

Patients that are candidates for paramedic transport will have preexisting
mechanical ventilation established. Prehospital personnel may not initiate
mechanical ventilator use.

IV.

Preset Mechanical Ventilators
In accordance with the provisions of this policy, a paramedic may transport a
patient who is on mechanical ventilation only when following these parameters:
A.
A completed interfacility transfer form signed by the transferring physician
must be obtained prior to transport.
B.
The transferring physician must provide orders for maintaining mechanical
ventilation during transport and certify that the patient is stable for transfer
or that the benefits of transport outweigh the risks of transport.
C.
Patient is placed on capnography, cardiac and pulse oximetry monitors
and monitored continuously during transport.
D.
Vital signs will be monitored and documented no less than every 10
minutes during patient transport.
E.
Paramedics shall not make mechanical ventilator setting changes unless
parameters of changes are outlined in the sending physician’s orders.
F.
If any complications related to mechanical ventilation arise during
transport mechanical ventilation is to be discontinued and patient is to be
ventilated with a bag valve mask.
G.
If complications arise during transport and mechanical ventilation is
stopped, transport shall be diverted to nearest emergency department.

V.

Continuous Quality Improvement
All calls involving the transfer of patients with preexisting mechanical ventilation
shall be reviewed through the ambulance provider’s CQI program to determine
compliance with policy and transferring physician orders. Findings and data will
be submitted to the SJCEMSA quarterly.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 228 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

IFT-02

Monitoring Potassium Chloride Infusions – ALS (IFT-02)
PURPOSE: The purpose of this protocol is to authorize paramedics to monitor and
adjust infusions of potassium chloride during interfacility transfers.
POLICY:
I.
ALS Ambulance providers must apply to and be approved by the San Joaquin
County EMS Agency (SJCEMSA) prior to initiating service to perform monitoring
potassium chloride infusions during interfacility transports.
II.

The monitoring of potassium chloride infusions is restricted to San Joaquin
County accredited paramedics that have successfully completed a training
program approved by the SJCEMSA for the monitoring of potassium chloride
infusions during interfacility transports.

III.

Patients that are candidates for paramedic transport will have preexisting
potassium chloride infusions. Prehospital personnel may not initiate potassium
chloride infusions.

IV.

Potassium Chloride Infusions
In accordance with the provisions of this policy, a paramedic may transport a
patient who has a preexisting intravenous (IV) solution containing potassium
chloride only when following these parameters:
A.
A completed interfacility transfer form signed by the transferring physician
must be obtained prior to transport. The transferring physician must
provide orders for maintaining the potassium chloride infusion during
transport and certify that the patient is stable for transfer or that the
benefits of transport outweigh the risks of transport.
B.
Patient is placed on cardiac and pulse oximetry monitors and monitored
continuously during transport.
C.
Infusion rates shall be maintained as ordered by the transferring physician
not to exceed 10mEq/hr max concentration of 40mEq/liter.
D.
Fluid boluses and medications shall not be administered using the IV line
infusing potassium chloride.
E.
Vital signs will be monitored and documented no less than every 10
minutes during patient transport.
F.
Monitor patient for adverse effects during transport including:
1.
Cardiovascular: dysrhythmias, cardiac arrest.
2.
Respiratory: depression, arrest.
3.
Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain.
4.
Neurological: paresthesia of extremities, muscular paralysis,
confusion.
5.
IV infiltration: monitor IV site as infiltration may cause necrosis. If
patient complains of burning or irritation at the insertion site, the I.V.
should be checked for patency and the infusion rate slowed or

Version 1.9 EMS Policy No. 5700 ALS Treatment Protocols Effective July 1, 2025
Page 229 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

Potassium Chloride cont.

IFT-02

discontinued.
V.

Continuous Quality Improvement
All calls involving the transfer of patients with preexisting potassium chloride
infusions shall be reviewed through the ambulance provider’s CQI program to
determine compliance with policy and transferring physician orders. Findings
and data will be submitted to the SJCEMSA quarterly.

VI.

General Information on Potassium Chloride
A.
Potassium is an essential macromineral in human nutrition with a wide
range of biochemical and physiological roles. Among other things, it is
important in the transmission of nerve impulses, the contraction of cardiac,
skeletal and smooth muscle, the production of energy, the synthesis of
nucleic acids, the maintenance of intracellular tonicity and the
maintenance of normal blood pressure.
B.
Indications for the use of potassium chloride
1.
The treatment of potassium depletion in patients with hypokalemia
when oral replacement is not feasible.
2.
Treatment of digitalis intoxication.
C.
Contraindications:
1.
Renal impairment with oliguria or azotemia.
2.
Untreated Addison's disease.
3.
Hyperadrenalism associated with adrenogenital syndrome.
4.
Extensive tissue breakdown as in severe burns.
5.
Adynamia episodica hereditaria.
6.
Hyperkalemia of any etiology.
D.
Precautions:
1.
Pregnancy.
2.
Chronic renal disease.
3.
Adrenal insufficiency.
4.
Any other condition which impairs potassium excretion.
5.
Potassium should be used with caution in diseases associated with
heart blocks.
E.
Adverse Effects:
1.
Fever.
2.
Venous thrombosis, infection at injection site.
3.
Extravasation, phlebitis, pain at injection site.
4.
Hypervolemia.
5.
Hyperkalemia.
6.
Abdominal pain.
7.
Nausea/Vomiting.
8.
Paresthesias of the extremities.
9.
ECG abnormalities.
10.
Mental confusion.
11.
Hypotension.
F.
Interactions:

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 230 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

Potassium Chloride cont.

IFT-02

1.

G.

Cardiac arrest can occur with high potassium conditions, such as
chronic renal failure, burns, acidosis, dehydration, and potassium
sparing diuretic usage.
2.
Drug interactions causing elevation of potassium can occur with
ACE inhibitors (used to treat high blood pressure) and certain
diuretics (aldactone and triamterene).
Standard Dosages for potassium chloride infusions:
1.
For serum potassium level >2.5mEq/L an IV infusion is
administered continuously at 10mEq/hr in a concentration up to
40mEq/L. With maximum dose of 200mEq per day.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 231 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

IFT-03

ALS Interfacility Transfers

Monitoring Heparin Infusions – ALS (IFT-03)
PURPOSE: The purpose of this protocol is to authorize paramedics to monitor
intravenous heparin infusions during interfacility transport.
POLICY:
I.

ALS Ambulance providers must apply to and be approved by the San Joaquin
County EMS Agency (SJCEMSA) prior to monitoring heparin infusions during
interfacility transports.

II.

The monitoring of heparin infusions is restricted to San Joaquin County
accredited paramedics that have successfully completed a training program for
monitoring heparin infusions and the use of infusion pumps.

III.

Patients that are candidates for paramedic transport are limited to those with
preexisting heparin infusions. Prehospital personnel may not initiate heparin
infusions.

IV.

Paramedics may restart heparin infusions if the heparin infusion is interrupted
due to infiltration, accidental disconnection of the intravenous (IV) line,
malfunctioning pump, etc. All lines must be restarted in accordance with the
transferring physician’s orders. Paramedics will ensure new IV line is patent prior
to re-starting the infusion.

V.

Heparin Infusions
The following parameters shall apply in all cases where paramedics transport
patients with preexisting heparin drips:
A.
Patient shall be placed on cardiac, blood pressure and pulse oximetry
monitors and monitored continuously during transport.
B.
A completed interfacility transfer form signed by the transferring physician
must be obtained prior to transport. The transferring physician must
provide orders for maintaining the heparin infusion during transport and
certify that the patient is stable for transfer or that the benefits of transport
outweigh the risks of transport.
C.
Infusion fluid must be D5W, NS or ½ NS.
D.
Medication concentration shall not exceed 100 units/ml of IV fluid or
50,000 units (e.g. 25,000 units/250ml or 50,000 units/500ml).
E.
Infusion rates must remain constant during transport except for the
discontinuation the infusion.
F.
Infusion rates shall be maintained as ordered by transferring physician.
Vital signs shall be monitored and documented every 15-20 minutes
during transport.

VI.

Continuous Quality Improvement

Version 1.9 EMS Policy No. 5700 ALS Treatment Protocols Effective July 1, 2025
Page 232 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

Heparin cont.

IFT-03

All calls involving the transfer of patients with preexisting heparin infusions shall
be reviewed through the ambulance provider’s CQI program to determine
compliance with policy and transferring physician orders. Findings and data will
be submitted to the SJCEMSA quarterly.
VII.

General Information on Heparin
A.
Heparin is an anticoagulant which acts to: prevent the conversion of
fibrinogen to fibrin, prevent the conversion of prothrombin to thrombin,
inactivate Factor X and enhance the inhibitory effects of antithrombin III.
B.
Pharmacokinetics:
1.
SC: Onset 20-60 minutes; duration 8-12 hours.
2.
IV: Onset immediate; peak 5 minutes; duration 2-6 hours.
3.
Metabolized in the liver and the spleen.
4.
Excreted in urine.
5.
Half-life of 1.5 hours.
C.
Indications for the use of heparin:
1.
In preventing additional clot formation or growth in DVT, MI,
pulmonary embolism, DIC, stroke or arterial thrombosis.
2.
Prophylactically to keep IV lines open (e.g. heparin flushes and
locks).
3.
Prophylactically before open heart surgery.
4.
Prophylactically post DVT, PE and MI to prevent clotting.
5.
Atrial fibrillation to prevent embolization.
6.
As an anticoagulant in transfusion and dialysis.
D.
Contraindications:
1.
Allergy to heparin.
2.
Bleeding disorders: hemophilia, etc.
3.
Blood dyscrasias such as leukemia with bleeding.
4.
Peptic ulcer disease.
5.
Severe hypertension.
6.
Severe hepatic disease.
7.
Severe renal disease.
8.
Subacute bacterial endocarditis.
9.
Active bleeding from any site.
E.
Precautions:
1.
Pregnancy (class C).
2.
Alcoholism (due to decreased liver function).
3.
Elderly (due to decrease liver and renal function and increased
injury capability).
F.
Adverse Effects:

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 233 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

Heparin cont.

IFT-03

1.

G.

H.

I.

Hemorrhage from any site. May manifest as easy bruising,
petechiae, epistaxis, bleeding gums, hemoptysis, hematuria,
melena.
2.
Fever and or chills (due to allergy).
3.
Abdominal cramps, nausea, vomiting, diarrhea (due to allergy).
4.
Anorexia (secondary to above).
5.
Rash and or uticaria (due to allergy).
Interactions:
1.
Oral anticoagulants (coumadin, warfarin) increase the actions of
heparin.
2.
Salicylates (aspirin) increase the actions of heparin.
3.
Corticosteriods increase the actions of heparin.
4.
Corticosteriods actions are decreased.
5.
Dextran increases the action of heparin.
6.
Nonsteriodal anti-inflammatory drugs (ibuprofen, Aleve, Midol,
naprosyn, toradol, voltaren, feldene, indocin, clinoril) increase the
actions of heparin.
7.
Diazepam: Action increase by heparin.
Standard Dosages and Routes:
1.
DVT/PE prophylaxis: 5,000 units subcutaneous every 8-12 hours.
2.
Active Clot Suppression:
a.
Loading dose:
i.
Adult: 5000-7000 units IVP.
ii.
Child: 50-100 units/kg IVP.
b.
Maintenance:
i.
Adult: 1000-1600 units per hour IV titrated to
PTT/ACT/INR level.
ii.
Child: 15-25 units per hour IV titrated to PTT/ACT/INR
level.
Special Considerations:
1.
Avoid IM injections or other procedures which may cause bleeding.
2.
Overdoses are treated in hospital with protamine sulfate 1:1
solution (protamine is not authorized for paramedic use.)

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 234 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

IFT-03

ALS Interfacility Transfers

Monitoring Nitroglycerin Infusions – ALS (IFT-04)
PURPOSE: The purpose of this protocol is to authorize paramedics to monitor and
adjust intravenous nitroglycerin infusions in adult patients during interfacility transport.
POLICY:
I.

ALS Ambulance providers must apply to and be approved by the San Joaquin
County EMS Agency (SJCEMSA) prior to monitoring nitroglycerin infusions
during interfacility transports.

II.

The monitoring of nitroglycerin infusions is restricted to San Joaquin County
accredited paramedics that have successfully completed a training program
approved by the SJCEMSA for monitoring nitroglycerin and the use of infusion
pumps.

III.

Patients that are candidates for paramedic transport are limited to those with
preexisting nitroglycerin infusions. Prehospital personnel may not initiate
nitroglycerin infusions.

IV.

Paramedics may restart nitroglycerin infusions if the nitroglycerin infusion is
interrupted due to infiltration, accidental disconnection of the intravenous (IV)
line, malfunctioning pump, etc. All IV lines must be restarted in accordance with
the transferring physician’s orders. Paramedics will ensure new IV line is patent
prior to restarting the infusion.

V.

Nitroglycerin Infusions
The following parameters shall apply in all cases where paramedics transport
patients with preexisting nitroglycerin drips:
A.
Patient shall be placed on cardiac, blood pressure and pulse oximetry
monitors and monitored continuously during transport.
B.
A completed interfacility transfer form signed by the transferring physician
must be obtained prior to transport. The transferring physician must
provide orders for maintaining the nitroglycerin infusion during transport
and certify that the patient is stable for transfer or that the benefits of
transport outweigh the risks of transport.
C.
Nitroglycerin infusions must be regulated by a mechanical intravenous
infusion pump. If pump failure occurs and cannot be corrected, the
paramedic will stop the nitroglycerin infusion and notify the transferring
hospital.
D.
Infusion fluid shall be D5W or NS.
E.
Nitroglycerin infusion concentration shall be 25 mg/250ml or 50 mg/250ml.

Version 1.9 EMS Policy No. 5700 ALS Treatment Protocols Effective July 1, 2025
Page 235 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

F.
G.
H.
I.

Nitroglycerin cont.

IFT-04

Regulation of the drip rate will be within parameters as defined by the
transferring physician, but in no case will changes be in greater than 5
mcg/minute increments every 10 minutes.
In cases of hypotension (SBP <90), the medication drip will be
discontinued and the transferring hospital and base hospital will be
notified.
Infusion rates shall be maintained as ordered by the transferring
physician.
Vital signs shall be monitored and documented every 10 minutes during
transport or every 5 minutes if an increase in the drip rate is ordered by
the base physician.

VI.

Continuous Quality Improvement
All calls involving the transfer of patients with preexisting nitroglycerin
infusions shall be reviewed through the ambulance provider’s CQI program to
determine compliance with policy and transferring physician orders. Findings
and data will be submitted to the SJCEMSA quarterly.

VII.

General Information on Nitroglycerin
A.

Nitroglycerin is a vasodilating agent that belongs to a group of drugs
referred to as nitrates. Nitroglycerin acts to: relax vascular smooth
muscle; vasodilate both arteries and veins (especially veins); increase
venous pooling; decrease venous return to the heart; increase arterial
relaxation; decrease systemic vascular resistance; decrease cardiac
workload; decrease cardiac oxygen consumption; dilate the large coronary
arteries; and lower diastolic more than systolic blood pressure.

B.

Pharmacokinetics:
1.
SL: Onset 1-3 minutes; duration 30 minutes.
2.
Transdermal (patch): Onset 0.5 - 1 hour; duration 12-24 hours.
3.
Transdermal (ointment): Onset 0.5-1 hour; duration 2-12 hours.
4.
PO (sustained release): Onset 20-40 minutes; duration 3-8 hours.
5.
IV: Onset usually immediate; duration is variable.
6.
Metabolized by the liver.
7.
Excreted in urine.
8.
Half-life of 1-4 minutes.
Indications for the use of Nitroglycerin
1.
Sublingual:
a.
Relief of acute anginal pain or related ischemic symptoms.
b.
Congestive Heart Failure (CHF) to decrease myocardial
workload.
2.
Intravenous:
a.
Diagnosed MI or unstable angina pectoris, even in the
absence of chest pain, to decrease myocardial workload.

C.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 236 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers
b.
c.

Nitroglycerin cont.

IFT-04

Relief of persistent ischemic chest pain that does not
respond to other medications.
Hypertension when associated with diagnosed MI or
unstable angina pectoris (not used solely for blood pressure
control).

D.

Contraindications:
1.
Allergy to nitrates.
2.
Increased intracerebral pressure such as in cases of stroke, head
trauma or intracerebral bleeding.
3.
Hypotension.
4.
Hypovolemia.
5.
Treatment of hypertension without progressively worsening signs of
organ damage, ischemia or neurologic deficit.

E.

Precautions:
1.
Pregnancy.
2.
Glaucoma patients (can increase intraocular pressure).
3.
Lactation (fetal effects in animal studies).
4.
May require decreased dosing in patients with liver disease.

F.

Adverse Effects:
1.
Hypotension.
2.
Headache (from vasodilation).
3.
Dizziness and syncope (from hypotension).
4.
Nausea/Vomiting.
5.
Tachycardia (in response to hypotension).
6.
Paradoxical bradycardia (in rare instances).
7.
Pallor, sweating (from hypotension).
8.
Flushing, sweating (from vasodilation).
9.
Rash, if allergic to nitrates.

G.

Interactions:
1.
Alcohol combined with nitroglycerin can worsen hypotension.
2.
Aspirin can increase serum nitrate concentrations.
3.
Calcium channel blockers combined with nitroglycerin can worsen
orthostatic hypotension.
4.
ß-blockers, diuretics (anti-hypertensives) can increase actions of
nitroglycerin.

H.

Standard Dosages for Nitroglycerin drips:
1.
For diagnosed patients with ischemic symptoms:
a.
Continuous IV Infusion: starting at 10-20 mcg/min and
increased by 5 or 10 mcg every 5-10 minutes until the
desired hemodynamic or clinical response is achieved. Most
patients respond to 50-200 mcg/min and the lowest possible

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 237 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

Nitroglycerin cont.

IFT-04

dose should be used. When indicated, rates should be
decreased in 10 minute intervals.
I.

Special Considerations:
1.
Glass infusion bottles and non-polyvinyl tubing must be used as
plastics will absorb nitroglycerin and alter the dose administered.
2.
Do not use in-line filters.
3.
Attach drip to port closest to catheter insertion.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 238 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

IFT-05

Sedation of Intubated Patients during ALS Interfacility
Transfer (IFT-05)
PURPOSE: The purpose of this protocol is to authorize paramedics to use midazolam
for sedation of intubated patients during interfacility transfers.
POLICY:
I.

ALS Ambulance providers must apply to and be approved by the San Joaquin
County EMS Agency (SJCEMSA) prior to initiating service to use midazolam for
sedation of intubated patients during interfacility transports.

II.

The use of midazolam for sedation of intubated patients is restricted to San
Joaquin County accredited paramedics that have successfully completed a
training program approved by the SJCEMSA for the use of midazolam for
sedation of intubated patients during interfacility transports.

III.

Patients that are candidates for paramedic transport will have preexisting
sedation. Prehospital personnel may not initiate midazolam for sedation of
intubated patients.

IV.

Procedure:
A.
Inclusion Criteria:
1.
Patient with advanced airway, 20 minutes or longer after RSI.
B.
Exclusion Criteria:
1.
Unstable Patients
a.
Pulse <50 or >100 bpm
b.
SBP <100 or >200
c.
DBP <50 or >100
d.
Patient sedation unable to be managed with only midazolam.
2.
Place patient in soft restraints.
3.
Monitor and document:
a.
ECG.
b.
Pulse Oximetry.
c.
Capnography.
d.
Blood pressure every 5 minutes.
e.
Heart Rate every 5-10 minutes.
C.
Max allowable dose 0.01mg/kg IV/IO Every 10 minutes.

VI.

Continuous Quality Improvement
All calls involving the transfer of patients with midazolam use for sedation of
intubated patients during interfacility transports, shall be reviewed through the
ambulance provider’s CQI program to determine compliance with policy and
transferring physician orders. Findings and data will be submitted to the
SJCEMSA quarterly.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 239 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

IFT-03

ALS Interfacility Transfers

Monitoring Magnesium Sulfate Infusions – ALS (IFT-06)
PURPOSE: The purpose of this protocol is to authorize paramedics to monitor
magnesium sulfate Infusions during interfacility transfers.
POLICY:
I.

ALS Ambulance providers must apply to and be approved by the San Joaquin
County EMS Agency (SJCEMSA) prior to initiating service to monitor magnesium
sulfate during interfacility transports.

II.

Monitoring magnesium sulfate infusions is restricted to San Joaquin County
accredited paramedics that have successfully completed a training program
approved by the SJCEMSA to monitor magnesium sulfate during interfacility
transports.

III.

Patients that are candidates for paramedic transport will have preexisting
sedation. Prehospital personnel may not initiate magnesium sulfate infusion.

IV.

Procedure:
A.
Patient shall be placed on cardiac, blood pressure and pulse oximetry
monitors and monitored continuously during transport.
B.
A completed interfacility transfer form signed by the transferring physician
must be obtained prior to transport. The transferring physician must
provide orders for maintaining magnesium sulfate infusions during
transport and certify that the patient is stable for transfer or that the
benefits of transport outweigh the risks of transport.
C.
Magnesium sulfate infusions must be regulated by a mechanical
intravenous infusion pump. If pump failure occurs and cannot be
corrected, the paramedic will stop the magnesium sulfate infusions
infusion and notify the transferring hospital.
D.
Regulation of the drip rate will be within parameters as defined by the
transferring physician, with a max of 2g per hour.
E.
Infusion rates shall be maintained as ordered by the transferring
physician.
F.
Vital signs shall be monitored and documented every 10 minutes during
transport.

VII.

General information on magnesium sulfate Infusions
A.
Mechanism of Action
1.
Depresses CNS, blocks peripheral neuromuscular transmission,
produces anticonvulsant effects; decreases amount of acetylcholine
released at end-plate by motor nerve impulse.
2.
Slows rate of SA node impulse formation in myocardium and
prolongs conduction time.
3.
Promotes movement of calcium, potassium, and sodium in and out

Version 1.9 EMS Policy No. 5700 ALS Treatment Protocols Effective July 1, 2025
Page 240 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ALS Interfacility Transfers

B.
C.

D.

VIII.

Magnesium Sulfate cont.

IFT-06

of cells and stabilizes excitable membranes.
4.
Promotes osmotic retention of fluid in colon, causing distention and
increased peristaltic activity, which subsequently results in bowel
evacuation.
Absorption:
1.
Onset (anticonvulsant): IV, immediate; IM, 1 hr.
2.
Duration (anticonvulsant): IV, 30 min; IM, 3-4 hr.
Contraindications:
1.
Hypersensitivity.
2.
Myocardial damage, diabetic coma, heart block.
3.
Hypermagnesemia.
4.
Hypercalcemia.
Cautions:
1.
Fetal skeletal demineralization, hypocalcemia, and
hypermagnesemia abnormalities reported with continuous longterm use (e.g. longer than 5-7 days) for off-label treatment of
preterm labor in pregnant women; the effect on the developing
fetus may result in neonates with skeletal abnormalities.
2.
In patients with renal impairment, ensure that renal excretory
capacity is not exceeded.
3.
Use with caution in digitalized patients.
4.
Use with extreme caution in patients with myasthenia gravis or
other neuromuscular disease.
5.
Hypomagnesemia is usually associated with hypokalemia
(potassium levels must be normalized).

Continuous Quality Improvement
All calls involving the transfer of patients with magnesium sulfate during
interfacility transports, shall be reviewed through the ambulance provider’s CQI
program to determine compliance with policy and transferring physician orders.
Findings and data will be submitted to the SJCEMSA quarterly.

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 241 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

Abbreviations Glossary

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 242 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

A
AC – Antecubital
ALOC- Altered level of consciousness
AMA- Against medical advice
AMI- Acute myocardial infarction
ASA- Acetylsalicylic Acid

B
BP- Blood pressure
BRUE – Brief resolved unexplained event
BVM- Bag valve mask

C
CHF- Congestive heart failure
CL- Cormack Lehane
COPD- Chronic obstructive pulmonary disease
CPAP- Continuous positive airway pressure
CPSS- Cincinnati pre hospital stroke scale
CVA- Cerebral vascular accident

D
DKA- Diabetic ketone acidosis
DVT- Deep vein thrombosis

E
Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 243 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

ECG- Electrocardiogram
ED- Erectile dysfunction
EJ- External jugular
ECG- Electrocardiogram
ESRD- End stage renal disease
ETCO2- End tidal carbon dioxide
ETOH- Alcohol

F
G
GCS- Glasgow coma scale

H
HD- Hemodialysis
HR- Heart rate
HTN- Hypertension
HHNK- Hyperosmolar hyperglycemic nonketotic

I
ICP- Intra cranial pressure
IFT- Inter facility transfer
IM -Intramuscular
IN- Intranasal
IV- Intravenous
IVF- Intravenous Fluid
IO- Intraosseous

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 244 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

J
JVD- Jugular venous distention

K
KG- Kilogram 2.2 pounds = 1KG

L
LKWT- Last known well time
LPM- Liters per minute

M
MAP- Mean arterial pressure
MS- Morphine sulfate
MSDS- Material safety data sheet

N
NC- Nasal cannula
NRB- Non-rebreather mask
NS- Normal saline
NTG- Nitroglycerine

O
O2- Oxygen
OD- Overdose
ODT- Orally dissolving tablet
OPA- Oropharyngeal airway

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 245 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

P
PCN- Penicillin
PEA- Pulseless electrical activity
PO- Administered orally
PPV- Positive pressure ventilation
PSC- Primary stroke center
PTA- Prior to arrival

Q
QRS- is a name for the combination of three of the graphical deflections seen on a typical
electrocardiogram

R
RACE- Rapid arterial occlusion evaluation
RLS- Red lights and sirens
ROSC- Return of spontaneous circulation
RR- Respirations
RVR- Rapid ventricular response

S
SIRS- Systemic inflammatory response syndrome
SL- Sub lingual
SOB- Shortness of breath
SpO2- Pulse oximetry
SRC- STEMI receiving center
SVT- Supraventricular tachycardia

T
Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 246 of 247

Docusign Envelope ID: CFA45146-D99F-4326-BC3F-462499B23DA5

TBSA- Total body surface area
TCA- Tricyclic antidepressants
TIA- Transient ischemic attack
TKO- To keep open

U
V
VAD- Ventricular Assist device
VT- Ventricular tachycardia

W
WBC- White blood cell
WO- Wide open

X
Y
Z

Version 1.9.1 EMS Policy No. 5700 ALS Treatment Protocols Effective August 22, 2025
Page 247 of 247

